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SUMMARY
ABSTRACTIn Chagas disease, caused by Trypanosoma cruzi, inflammation plays an important role in the pathophysiology. Lipid mediators derived from arachidonic acid (AA), as prostaglandins 
and leukotrienes, are considered regulators of homeostasis and inflammation. These molecules are produced by a biosynthetic pathway controlled by enzymes as cyclooxygenases 
and lipoxygenases. The role of cyclooxygenase-2 (COX-2) in immunosuppression during the acute phase of T. cruzi infection has been described using non-steroidal anti-inflammatory 
drugs, which are inhibitors of this enzyme. In this study, we first investigated the expression of enzymes involved in AA metabolism during T. cruzi infection. Susceptible and non-susceptible models of infection were used to further analyze the role of lipid mediators in 
T. cruzi infection. Our results confirm the expression of several of these enzymes in T. cruzi 
infected heart, in particular COX-2. CD68+ heart-infiltrating macrophages were the major 
cell type expressing COX-2. CD11b+ heart-infiltrating myeloid cells were purified and produced prostaglandins PGE2 and PGF2α.  In contrast, no AA metabolite was produced by the 
parasite itself. Studies using gene-deficient animal models indicate that regulation of COX-2 and PGE2 (through Prostaglandin E receptor 2 signaling) is in part responsible of cardiac 
inflammation in T. cruzi infected mice. We also describe the indirect participation of COX-2 in immunosuppression in the acute phase of infection by increasing inducible nitric oxide 
synthase expression. The key role of lipid mediators in Chagas disease inflammation and the availability of drugs which inhibit their synthesis and their receptors could be useful for the treatment of this neglected disease.
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SUMMARY
RESUMENEn la Enfermedad de Chagas, causada por Trypanosoma cruzi, la inflamación juega 
un papel muy importante en la fisiopatología. Los mediadores lipídicos derivados del ácido araquidónico (AA), como prostaglandinas y leucotrienos, son considerados reguladores de 
la homeostasis y de la inflamación. Estas moléculas son producidas por una ruta biosintética controlada por las enzimas ciclooxigenasas y las lipoxigenasas. El papel de la ciclooxigenasa-2 
(COX-2) en la inmunosupresión que ocurre durante la fase aguda de la infección con T. cruzi 
ha sido descrito usando antinflamatorios no esteroideos, los cuales son inhibidores de la 
enzima. En este trabajo hemos investigado la expresión de enzimas relacionadas con el metabolismo del AA en la infección por T. cruzi.  Modelos susceptibles y no susceptibles fueron utilizados para profundizar el análisis del papel de los mediadores lipídicos en la infección por T. cruzi. Nuestros resultados confirman la expresión de algunas de estas enzimas en el corazón infectado por T. cruzi, siendo COX-2 una de ellas. Los macrófagos CD68+ son 
el principal tipo celular de los que infiltra el corazón que expresa COX-2. Células mieloides CD11b+del corazón infectado fueron purificadas y produjeron prostaglandinas PGE2 y PGF2α. 
Por el contrario, el parásito no produjo mediadores lipídicos por sí solo. El uso de modelos 
animales genéticamente deficientes nos lleva a concluir que la regulación por COX-2 y PGE2 
(a través del receptor 2 de prostaglandina E) son en parte responsables de la inflamación cardiaca en ratones infectados por T. cruzi. También describimos la participación indirecta de 
COX-2 en la inmunosupresión que ocurre durante la fase aguda incrementando la expresión de la enzima óxido nítrico sintasa inducible. El papel clave de estos mediadores lipídicos 
en la inflamación de la Enfermedad de Chagas, junto con la disponibilidad de drogas que inhiben las enzimas productoras y los receptores, podrían ser de utilidad en tratamientos futuros para esta enfermedad olvidada.
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INTRODUCTION
Chagas diseaseChagas disease is a multisystemic disorder that due to the scarcity of preventive and therapeutic tools and population at risk is considered as a neglected tropical disease (Hotez et al., 2007; Morillo, 2013). Carlos Chagas 
described for the first time the disease and its causative agent Trypanosoma cruzi in 1909 (Chagas, 1909). The burden of Chagas disease in Latin America has decreased over recent years but the number of infected people is still over 8 million. More than 40.000 new infected people and 12.550 deaths per year are estimated. The high rate of migration towards non-endemic countries has spread the boundaries of the infection. Non-vectorial transmission is possible through blood transfusion, organ transplantation and from infected mother to child. The risk is related to the country of origin of the migrants and the rate of prevalence in a given region (Moncayo and Silveira, 2009). Spain is the second non-endemic country with more infected immigrants. In 2009 the estimation was between 47.000 and 67.000 infected people (Gascon et al., 2009). 
Trypanosoma cruzi is a kinetoplastid protozoan of the Tripanosomatidae family. Its life cycle involves stages in invertebrate and vertebrate hosts including domestic and wild vertebrates (Fig. 1). The insect vectors that transmit the parasite are blood sucking bugs of the Reduviidae family. Parasites replicate in the insect proximal gut in the form of epimastigote. In the distal part of the intestine it transforms into metacyclic trypomastigote. When the insect feeds on blood, it releases the infective parasite with the faeces. Due to scratching close to the site of the bite, the parasite can enter the bloodstream. Another route of entry is the intact mucosa. The metacyclic trypomastigote scapes from the parasitophorous vacuole and localizes 
in the cytoplasm of the infected cell, where it converts to the amastigote form. As obligate intracellular parasites, T. cruzi amastigotes use the nutrient pool present in the host cell cytoplasm for replication and transform into blood trypomastigotes. Parasites released from the host cell disseminate throughout the body via lymph and blood system and infect other cells. Although any nucleated mammalian cell can be parasitized by these organisms, cells of the reticulo-endothelial, nervous and muscle systems, including the heart, are usually targets of infection. Once the bug feeds on and infected host the cycle is completed. (Teixeira et al., 2012; Tyler and Engman, 2001).
Pathology of Chagas diseaseClinically T. cruzi infection progress can be divided in two phases, acute and chronic. In the 
acute phase, after infection, a local inflammatory lesion can appear at the site of the bite. Then, parasite dissemination through the body occurs, and circulating blood trypomastigotes can be observed. Death occurs occasionally in the acute phase (<5–10% of symptomatic cases) as a result of severe myocarditis or meningoencephalitis, or both. But frequently 
this phase shows very mild and unspecific symptoms and the infection can pass easily unnoticed. About 60–70% of the infected people will never develop clinically apparent disease. These patients have the indeterminate form of chronic Chagas disease, which is characterized by positivity for antibodies against T. cruzi in serum, normal electrocardiogram, and normal radiological examination of the chest, esophagus, and colon. The remaining 30–40% of patients develops the most severe pathology of the disease that appears between one and three decades after infection with T. cruzi. During this phase, circulating parasites cannot be detected in blood, but progressive damage 
24
INTRODUCTION
Figure I1│Schematic representation of the life cycle of Trypanosoma cruzi. When hemiptera (Fam. Reduviidae) bites an infected vertebrate (1), trypomastigotes in the blood are taken by the bug (2) and turn into epimastigotes (3) in the gut where they reproduce (4). In the distal intestine epimastigotes differentiate back to metacyclic trypomastigotes (5). T. cruzi infected hemiptera during blood sucking (6) releases metacyclic trypomastigotes with the faeces that penetrate the host (7), infect cells (8), multiply as amastigotes (11) and break out the cell to the bloodstream in the form of trypomastigotes (13). These parasites can infect new host cells (15) or can be taken up by invertebrate vectors to complete the cycle (1). Adapted from Teixeira et al. PLOS NtD (2012)
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occurs in tissues. Disease can evolve into different pathologies: cardiac (cardiomegaly), digestive (megaoesophagus and megacolon), or cardiodigestive affections have been described. In the chronic phase, the heart is the most commonly affected organ; cardiomyopathy frequently develops in congestive heart failure, the most common cause of death in these patients (Machado et al., 2012; Rassi et al., 2012; Rassi et al., 2010) (Fig. 2). Two main mechanisms have been proposed 
for the origin of chronic pathology. The first one states that the pathology is directly linked to parasite persistence and destruction of the infected tissues, resulting in chronic 
inflammation (Kierszenbaum, 2005; Tarleton, 2001; Viotti et al., 1994). The second one postulates an autoimmune etiology, and it is 
Figure I2│Chagas disease phases in humans. Trypanosoma cruzi infection generates different pathologies in humans. Adapted from Rassi et al. Lancet (2010)
based in the scarcity of parasites in affected organs during the chronic phase. It claims that 
T. cruzi infection induces an immune response against self-tissues (Cunha-Neto et al., 2011). 
Indeed, some groups consider the inflammatory cardiomyopathy of Chagas disease a genetically driven autoimmune disease (Teixeira et al., 2011). But both events, autoimmunity and persistence, might not be mutually exclusive (Girones et al., 2005; Girones and Fresno, 2003; Levin, 1996; Soares et al., 2001). Besides, it has been proposed that the diversity in the clinical manifestations of Chagas disease depends on host genetic background (Andrade et al., 2002; del Puerto et al., 2012). Different studies have demonstrated that 
T. cruzi is genetically heterogeneous with a typical clonal population structure (Zingales 
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et al., 2012). In spite of seldom recombination events (Sturm and Campbell, 2010) DNA markers as ribosomal DNA and miniexon have generated a consensus about the existence of six main phylogenetic lineages (Lewis et al., 2009), with different geographical distribution. There is indirect evidence that genetic variability could generate the different clinical forms of the disease associated with different geographic areas (Zingales et al., 2012). However, a well characterized direct correlation between parasite genetic diversity and clinical outcome of the disease has not yet been established. 
Innate response to Trypanosoma cruzi 
infection
T. cruzi infection elicits a complex immune response. Different cell types can recognize 
T. cruzi and react on different ways for controlling infection. Detection and direct destruction of parasites by phagocytes, like macrophages and dendritic cells, which are activated to become APCs and initiate the adaptive immune response is fundamental. Also non-hematopoietic cells, as primary targets of invasion, can sense infection and can contribute to control the infection. (Truyens and Carlier, 2010)Parasite entry through the skin and mucosa barriers triggers the host immune response. The 
first cells of the immune system which interacts with the parasite are the phagocytes. These cells detect and respond to pathogen associated molecular patterns (PAMPs) through pathogen pattern recognition receptors (PRRs). PAMPs are repetitive molecular structures of proteic, lipidic, glycolipidic and nucleotidic nature not found in the host. The better characterized PRRs are the Toll-like receptors (TLRs). 
TLRs activate nuclear factor κB (NF-κB) and interferon regulatory factor (IRF)–dependent pathways via their interaction with adaptor molecules like MyD88, TRIF and TIRAP, leading 
to IL-1, IL-6, IL-10, IL-12, TNF-α, IFN-γ and COX-2 production (Trinchieri and Sher, 2007). TLR-2, TLR-4 and TLR-9 can recognize 
T. cruzi molecules. The use of TLR deletion murine models of infection as well as the adaptor molecules MyD88 and TRIF revealed the important role of this pathway in T. cruzi immune response (Kayama and Takeda, 2010; Oliveira et al., 2010; Tarleton, 2007). Other PRRs, such as cell surface mannose receptor and cytosolic receptors of the nucleotide-binding oligomerization domain (NOD)-like also activate immune cells after interaction with PAMPs. Nod1-dependent responses have been related to host resistance against T. cruzi infection (Silva et al., 2011).Upon T. cruzi infection macrophages secrete IL-12, which activates natural killer (NK) cells 
to produce IFN-γ (Aliberti et al., 1996; Antunez and Cardoni, 2000). IFN-γ plays a crucial role in activation of macrophages acting synergistically 
with TNF-α to express inducible nitric oxide synthase (iNOS) (Derouich-Guergour et al., 2001; Munoz-Fernandez et al., 1992) 
and Cyclooxygenase-2 (COX-2) (Fig. 3). In macrophages, nitric oxide (NO) is synthesized by iNOS from L-arginine (L-Arg) and oxygen. iNOS can generate both NO and Superoxide (O-2) that interact to form the potent oxidant peroxynitrite (ONOO-) involved in killing intracellular parasites (Xia and Zweier, 1997). Susceptibility to T. cruzi infection has been demonstrated in 
mice defective in IFN-γ and IL-12 (Graefe et al., 2003; Torrico et al., 1991). IL-6 is produced during T. cruzi infection (Truyens et al., 1994) and is related to protective responses against the parasite (Gao and Pereira, 2002).
NO production of IFN-γ activated macrophages is reduced by IL-10 impairing its ability to kill intracellular Trypanosoma cruzi (Gazzinelli et al., 1992). But it has been found that 
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Figure I3│Macrophage activation in Trypanosoma cruzi infection. Upon T. cruzi infection macrophages secrete 
IL-12, which activates natural killer (NK) cells to produce IFN-γ. IFN-γ activates macrophages triggering, with TNF-α, the expression of inducible nitric oxide synthase (iNOS) and Cyclooxygenase-2 (COX-2). TNF-α and IL-6 are produced by 
activated macrophages and cooperate in the initiation of inflammation acting in other immune and non-immune cells. 
It has been described that IL-4, IL-13, IL-10 and TGF-β inactive inflammatory macrophages to prevent an excessive and damaging response. In macrophages, nitric oxide (NO) synthesized by iNOS is involved in killing intracellular parasites but also generates immunosuppression inhibiting T cell proliferation.
28
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IL-10 is required to prevent an excessive pro-
inflammatory response during T. cruzi infection (Hunter et al., 1997) and something similar 
occurs with tumor growth factor beta (TGF-β) (Silva et al., 1991). It has been proposed that 
IL-4 down-regulates IFN-γ and inflammation acting cooperatively with IL-10 (Abrahamsohn et al., 2000). IL-13 might also be involved in the 
down-regulation of IFN-γ release (Antunez and Cardoni, 2001)(Fig. 3).However, NO produced by macrophages also mediates the immunosuppression in the acute phase of T. cruzi infection and can also cause oxidative stress, which is especially harmful for the host causing tissue damage (Abrahamsohn and Coffman, 1995; Gutierrez et al., 2009). There are other mechanisms proposed to participate in the immunosuppression, like IL-2 receptor down-regulation (Majumder and Kierszenbaum, 1996), NO production by CD11b+Gr-1+ myeloid suppressor cells (Goni et al., 2002) and prostaglandin E2 (PGE2) production (Michelin et al., 2005). The enzyme arginase-1 (Arg-1) is involved in the urea cycle and the polyamines synthesis pathway, which are needed for proliferation of all eukaryotic cells including parasites. Arg-1 is mainly induced by Th2 cytokines (IL-4, IL-10) and PGE2 (Corraliza et al., 1995). Due to substrate sharing with iNOS, both enzymes have been involved in regulation of the Th1/Th2 balance during immune processes, and have been used as markers for M1 and M2 macrophage activation (Mills et al., 2000). In addition, it has been shown that iNOS and Arg-1 expressing CD11b+Ly6C+Ly6G- monocytic myeloid-derived suppressor cells (MDSCs) 
infiltrate cardiac tissue during T. cruzi infection can suppress the effector response (Cuervo et al., 2011; Cuervo et al., 2008).During the acute phase of infection when 
parasitism is high, there is a burst of chemokine synthesis in the myocardium (Machado et al., 2008; Teixeira et al., 2002). It appears that chemokine synthesis and myocarditis occur mainly in response to parasite molecules. CCL2 is highly expressed in infected cardiac tissue and plays a key role in leukocyte recruitment and parasite resistance (Paiva et al., 2009) . Also 
CCL3, CCL5 and CXCL9 have been described to play a protective role in experimental models of infections (Hardison et al., 2006; Roffe et al., 2010). Endothelial cells also collaborate in defense against T. cruzi infection by secreting molecules as Endothelin-1 (ET-1), the most potent endogenous vasoconstrictor (Mukherjee et al., 2004). ET-1 has been implied in the vasculature damage generated during T. cruzi infection (Machado and Camargos, 2008; Petkova et al., 2001). ET-1 receptor antagonist has a protective role in heart tissue (Rachid et al., 2006) and central nervous system (Rachid et al., 2010) in the rat model of infection. In contrast, a minor effect was found when infected mice were treated with the endothelin receptor antagonist (Roffe et al., 2010).
Adaptive response to Trypanosoma cruzi 
infectionParasites that do not escape the parasitophorous vacuole or soluble parasite antigens are presented to helper CD4+ T cells by professional APCs through MHC-II, despite the fact that MHC-II expression is down-regulated during T. cruzi infection (Alba Soto et al., 2003). T helper cells are very important to orchestrate the immune response and when became activated converts into different Th subsets 
with distinct cytokine expression profiles and functions. In addition, due to the ability of 
T. cruzi to invade a high variety of mammalian cell types, non-professional APCs are also able 
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to present parasite peptides to cytotoxic CD8+ lymphocytes through MHC-I, thus participating 
in the inflammatory and immune responses (Fig. 4). (Garg et al., 1997). B cell activation is not a generalized response and depends on host susceptibility. (Bryan et al., 2010). Nevertheless, antibody response is 
necessary because B cell-deficient mice succumb to T. cruzi infection (Kumar and Tarleton, 1998). 
Although it was initially published that perforin/granzyme mediated killing was not necessary for resistance to infection (Kumar and Tarleton, 1998), subsequent studies reported that cytotoxic CD8+ T lymphocytes are important to control intracellular infection through perforin/granzyme mediated killing of infected cells and/or FAS-mediated apoptosis (Martin and Tarleton, 2004; Muller et al., 2003). About the control of the reaction against parasite 
Figure I4│Adaptative response to Trypanosoma cruzi infection. Following an antigenic challenge at a peripheral site, antigen-presenting cells (APCs) migrate to draining lymph nodes in order to present parasite antigens to naïve T cells. This antigen presentation process is mediated by interaction of the TCR (T cell receptor) in CD8+ T cells with major histocompatibility complex class (MHC)-I, or in CD4+ T cells with MHC-II. Antigen presentation leads to T cell activation and proliferation. This is followed by the differentiation of naïve CD4+ T cells to distinct T helper subtypes that secrete different 
cytokines: T helper (Th)1 cells (IFN-γ), regulatory T (Treg) cells (TGF-β,IL-10), Th17 (IL-217, IL-22) and Th2 (IL-4, IL-13). T helper cells through their TCR and CD40L play a key role in B cell proliferation and differentiation to plasma cell in order to produce antibodies. Naïve CD8+ cells differentiate into CTL (Citotoxic T lymphocytes) that eliminate infected cells through 
granzyme/perforin and Fas/FasL mechanisms, also secrete IFN-γ to activate macrophages and promote differentiation of Th1 cells.  
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infection, cytokines are important regulators in the induction and type of immune response. But no clear Th1 or Th2 polarization was observed when mice susceptible or resistant to T. cruzi infection were analyzed (Zhang and Tarleton, 1996).Nevertheless, we should keep in mind that T. cruzi immune evasion mechanisms are important to understand the outcome of the disease. They interfere with innate and adaptive responses at several levels. Evasion 
of complement, cell surface modification, suppression of T cell proliferation and production of phospholipase A2 are a few of them (reviewed in (Osorio et al., 2012). 
CyclooxygenasesDerivatives of arachidonic acid (AA) belong to the eicosanoid family, which includes prostanoids (prostaglandins, thromboxanes and prostacyclins), leukotrienes and lipoxins. These mediators act at nanomolar concentration in an autocrine/paracrine manner and have been considered regulators of homeostasis and 
inflammation. AA is released from the plasma membrane by the action of phospholipase A2 and is further processed by cyclooxygenase 
(COX) (Harris et al., 2002; Smith et al., 1996). 
COX is a bifunctional enzyme that performs a complex reaction by acting successively as a bis-dioxygenase and peroxidase. It begins by catalyzing the oxygenation and cyclation of AA to form the hydroperoxy arachidonate metabolite. Thereupon, the peroxidase activity of the enzyme reduces the carbon 15 position hydroperoxide to its corresponding alcohol to form prostaglandin H2 (PGH2) (Nugteren and Hazelhof, 1973). There are two main isoforms 
involved in the metabolism of AA, COX-1 and 
COX-2. While COX-1 is constitutively expressed 
in most cells and tissues COX-2 is usually undetectable, being rapidly induced when cells 
are activated by inflammatory stimuli (Dubois et al., 1998). Although not exclusive, it is generally 
accepted that COX-1 is involved in cellular and 
tissue homeostasis whereas COX-2 is expressed 
primarily at inflammatory sites. Formation of prostanoids from PGH2 occurs through the activities of a group of synthases that are expressed in a tissue and cell type-selective manner. These terminal synthases include prostaglandin E synthase (PGES) (Tanaka et al., 1987), prostaglandin D synthase (PGDS) (Shimizu et al., 1982), prostaglandin F synthase (PGFS) (Hayashi et al., 1989), 
thromboxane A synthase (TXAS) (Ullrich and Haurand, 1983) and prostaglandin I synthase (PGIS) (DeWitt and Smith, 1983), which form PGE2, PGD2, PGF2α, TXA2 and PGI2 respectively. Differential expression of these cyclooxygenases and terminal synthases determines the 
profile of prostanoid production. Different, but not incompatible mechanisms have been 
proposed to explain this biosynthetic profile. Firstly, it has been suggested that physical 
compartmentalization of COX-1 and COX-2 
with specific terminal synthases could link the activity of these enzymes with the synthesis of 
specific prostaglandin (Naraba et al., 1998). One of these compartments are cytoplasmic lipid-rich organelles, named lipid bodies, consisting of a hydrophobic core containing neutral lipids surrounded by a phospholid monolayer, with a particular fatty acid composition and proteins (Bozza et al., 2011). In addition, nuclear distribution of cyclooxygenases has been reported (Parfenova et al., 2001). Secondly, some of the terminal synthases are inducible and their expression may be regulated by external signals (Kudo and Murakami, 2005; Shimura et al., 2010) (Fig. 5). Eventually, it has been 
proposed that differences in substrate affinity and kinetics of terminal synthases account for 
different production profiles of resting and 
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activated cells (Penglis et al., 2000; Shimura et al., 2010). There is also evidence that the two 
COX isoforms may differentially contribute to the synthesis of distinct prostanoids. For instance, in primary peritoneal macrophages 
COX-1 produces a balance of prostanoids, while 
COX-2 preferentially generates only PGE2 and PGI2 (Brock et al., 1999).
ProstanoidsProstanoids are generated in most tissues and cells, modulating many biological processes such as smooth muscle tone, vascular permeability, fever and platelet aggregation. Indeed, the clinical importance of prostanoids is emphasized by the fact that their biosynthesis 
is the target of non-steroidal anti-inflammatory drugs (NSAIDs), one of the most widely group 
Figure I5│Arachidonic acid metabolism in inflammation. The precursor arachidonic acid (AA) is derived from membranes phospholipids by the action of the enzyme Phospholipase A2. This free fatty acid is then metabolize by lipoxygenases 
(12/15 LO, 5-LO with collaboration of FLAP) to produce derivatives as 15-HETE, LXA4 or LTB4. Cyclooxygenase enzymes can convert AA into PGH2 which is further modified by terminal synthase into molecules like PGF2α, PGD2, TXA2 or PGE2. These molecules are secreted and act in an autocrine or paracrine manner by binding to G protein coupled receptor like EP-2 for PGE2. Converting enzymes are mainly distributed in perinuclear area bound to endoplasmic reticulum membrane or nuclear envelop. They have been detected also in lipid bodies, organelle that has a lipid monolayer, neutral lipids and 
proteins. Presence of COX-2 and 5-LO have been also reported in the nucleus. Eicosanoids synthesis can also occur through transcellular byosinthesis (see text). 
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of drugs used for the treatment of chronic 
inflammatory diseases (Stables and Gilroy, 2011). Prostanoids have also been implied in cardiovascular diseases (Alfranca et al., 2006; Grosser et al., 2006) and cancer (Greenhough et al., 2009). The maintenance of cardiovascular health is dependent on a balance between vasodilator PGI2 and pro-thrombotic TXA2 (Grosser et al., 2006).PGE2 and PGI2 are the predominant pro-
inflammatory prostanoids. Both enhance vasodilation and vascular permeability and oedema generation (Funk, 2001; Schror, 1992). PGE2 exerts pro-inflammatory properties (Krause et al., 2009) but also has immunosuppressive effects through up-regulation of intracellular cAMP (van der Pouw Kraan et al., 1995). PGE2 binds to four G-protein coupled Prostaglandin E receptors, termed EP-1, EP-2, EP-3 and EP-4, whereas PGI2 binds to only one receptor (IP) (Cheng et al., 2002). PGE2 receptors, both EP2 and EP4 are coupled to G-proteins, leading to increased production of cAMP and activation of protein kinase A (PKA) (Narumiya et al., 1999). PGE2 and PGI2 also reduce the ability of macrophages to phagocytize and kill microorganisms (Aronoff et al., 2004; Weinberg et al., 1985), and inhibit the production of downstream pro-
inflammatory mediators (Aronoff et al., 2007; Dorris and Peebles, 2012; Kunkel et al., 1988) yet enhance IL-10 production (Harizi et al., 2002). PGE2 has a multitude of functions in cell activation and differentiation and these effects vary depending on the micro-environment, maturation and activation state of the cell, type of EP receptor involved and local concentration of prostaglandin. (Chemnitz et al., 2006; Loffler et al., 2008; Napolitani et al., 2009; Yao et al., 2009). 
PGD2 can elicit anti-inflammatory response via ligation to DP1 and PD2 receptors. It can also act through its non-enzymatically dehydrated 
product 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2). This metabolite acts via ligation to the nuclear 
receptor PPAR-γ, decreasing pro-inflammatory cytokine release and inhibiting the actions 
of IκB kinase and NF-κB transcription factor (Scher and Pillinger, 2009). However, PGD2 acts as an important mediator in allergic asthma 
increasing eosinophilic infiltration, IL-4 secretion with subsequent Th2 activation (Arima and Fukuda, 2011). Dual actions of prostanoids are frequently seen in immune and allergic reactions, where different type of prostanoids and their receptors often exert opposite actions in a single process (Narumiya, 2009).
Both iNOS and COX-2 enzymes are induced 
upon inflammation stimuli. Crosstalk regulation of the expression and activity between both enzymes through its products PGE2 and NO has been described. Nitric oxide produced by 
iNOS increases the enzymatic activity of COX-2 activating the peroxidase activity (Salvemini et al., 2013; Salvemini et al., 1993). The mechanism 
of COX-2 activation seems to be mediated through peroxynitrite (Landino et al., 1996)(Cuzzocrea and Salvemini, 2007). Regulation of 
iNOS by COX-2 and its products has been scarcely 
studied. However, it seems that COX-2 activity is important for iNOS expression in macrophages of rat intestine (Hori et al., 2001) and Küpffer cells (Gaillard et al., 1992), and PGE2 signaling through EP4 is necessary for iNOS expression in murine breast cancer cell (Timoshenko et al., 2004).
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Lipoxygenases
Interestingly, the PGE2 generated during the 
onset phase of inflammation collaborates also in its termination by inducing the transcription of enzymes required for the generation of other classes of bioactive lipids that are pro-
resolutive mediators, such as lipoxins (LXs). These mediators inhibit granulocyte functional responses, modulate the expression of chemokines and cytokines, stimulate monocyte recruitment and enhance macrophage phagocytosis of apoptotic leukocytes. These events are critical in the control of self-limiting 
inflammatory responses (Levy et al., 2001). LXs have also been implicated in wound healing (Gronert et al., 2005) and regulation of fibrosis (Kronke et al., 2012). 
There are two major routes for LXs production. These routes can be distinguished by the type of lipoxygenase (LO) which begins AA oxygenation, which distribution depends on the cell type. One pathway involves the insertion of molecular oxygen at C-5 by 5-Lipoxygenase (5-LO) with its partner, 5-LO activating protein (FLAP), to produce 5-hydroperoxyeicosatetrenoic acid (5-HpETE). Which is further metabolized by 5-LO to generate leukotriene A4 (LTA4). This pathway is conducted only by leukocytes, since the distribution of 5-LO is largely restricted to these cell types. LTA4 is 
readily transferred to adjacent platelets, usually leading to its processing to other leukotrienes (Sala et al., 2010). Although, adherent platelets, 
via 12-LO could also convert LTA4, donated by 
leukocytes, to LXA4 and LXB4 (Folco and Murphy, 2006). The other major route of LX biosynthesis involves the initial conversion of AA to 15(S)-HpETE by 12/15-Lipoxygenase (12/15-LO). This enzyme is abundant in epithelial cells of the respiratory or gastrointestinal tracts, as well as in diverse leukocytes, including 
macrophages, monocytes and eosinophils. Following secretion, 15(S)-HpETE is taken up by neutrophils or monocytes and converted through a 5-LO/FLAP dependent mechanism to 
LXA4 and LXB4 (Levy et al., 1993). In addition, 
epimers of LXA4 and LXB4 can be produced following aspirin treatment. Aspirin irreversibly 
acetylates COX-2, inhibiting its ability to produce 
prostanoids. Nonetheless, acetylated COX-2 can metabolize AA to 15(R)-HETE, which could then be processed into “aspirin-triggered” lypoxin by 5-LO (Chiang et al., 2005; Serhan, 1997).
Eicosanoids in infections
COX-2 expression is up regulated upon bacterial infection and PGE2 has been shown to play an immunosuppressive role in this process (Goldmann et al., 2010). A COX-2 
deficient (COX-2-/-) mouse (Dinchuk et al., 1995) was used in different infection models 
with apparently contradictorily results. COX-
2 deletion seems to be beneficial for the host in the case of bacterial septicemia (Ejima et al., 2003) and viral lung infection (Carey et al., 2005). Supporting this, PGE2 secretion after infection is associated to viral replication (Janelle et al., 2002). However COX-2+/- mice 
presented more inflammatory myocardial 
damage in viral myocarditis than COX-2+/+ with similar viral burden (Takahashi et al., 2005). In addition, mPGES-1-/- mice showed higher parasite burden upon Mycobaterium 
tuberculosis infection (Chen et al., 2008).
Pathogen generation of eicosanoidsAnalysis of pathogen eicosanoid production is a complex issue. Eicosanoid production has been documented in fungi, helminthes and protozoans that infect humans. The role of these products and its relation with infection is far to be completely understood. Eukaryotic microbes like Plasmodium falciparum, Toxoplasma gondii, 
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Candida albicans, Trypanosoma brucei and 
Trypanosoma cruzi express a phospholipase-like enzyme. This enzyme releases AA from phospholipid layer allowing its conversion in bioactive lipids. No cyclooxygenase related protein has been described in pathogen microbes 
and some COX-independent mechanisms of lipid mediators have been proposed (Noverr et al., 2003). Prostaglandin generation by T. cruzi and 
T. brucei has been analyzed. PGF synthase activity has been described and TbPGFS and TcPGFS have been cloned. These enzymes are also related with drug metabolism and activation (Kubata et al., 2007). Trypanosoma 
brucei extracts are able to metabolize AA into PGE2, PGD2 and PGF2α (Kubata et al., 2000). PGD2 production by T. brucei has been related with the control of parasite density inside the host, probably contributing to disease symptomatology (Figarella et al., 2005). 
Trypanosoma cruzi production of prostaglandin and thromboxane has been reported (Kubata et al., 2007; Machado et al., 2011). But only the role of T. cruzi- derived TXA2 has already been studied in vivo by Ashton el al. These authors proposed that T. cruzi- derived 
TXA2 is important to control host survival and modulates cell activation and vasoconstriction (Ashton et al., 2007).
Host eicosanoid production after T. cruzi 
infectionLittle is known about the role of eicosanoids in human chagasic pathology (de Barros-Mazon et al., 2004; Sousa et al., 2008). In addition, all the research regarding the role of eicosanoids in Trypanosoma cruzi infection was performed in the rodent models of acute infection. During the acute phase of infection in the murine model, plasma PGF
2α
, TXB2, 6-keto-
PGF
1α
 (Cardoni and Antunez, 2004) and PGE2 levels (Celentano et al., 1995) were increased. Macrophages from infected rats show an 
increased number of lipid bodies, where COX-2 produces PGE2 (D’Avila et al., 2011). Also CD8+ T lymphocytes from infected mice secrete PGE2 (Gorelik et al., 1990; Sterin-Borda et al., 1996). Due to the availability of inhibitors of 
both enzymes (COX-1 and COX-2) and COX-2-selective inhibitors (NSAIDs), different research groups have used them with experimental model of T.cruzi infection. Unfortunately, the use of distinct parasite isolates and mouse strains in those studies have generated a body of controversial data. In some cases pharmacological inhibition of one or both isoforms increases mortality, parasitemia and cardiac parasite nests regardless of mouse or parasite strain used (Celentano et al., 1995; Hideko Tatakihara et al., 2008; Pinge-Filho et al., 1999; Sterin-Borda et al., 1996). But others have found that inhibition of prostaglandin synthesis ablates parasitemia and increases survival in mice (Abdalla et al., 2008; Freire-de-Lima et al., 2000; Michelin et al., 2005). These differences cannot be easy explained, and the effects of NSAIDs on T. cruzi infection have been puzzling since the publication on the issue (Celentano et al., 1995). In addition, differences in the ability to produce PGE2 between mouse strains, as BALB/c and C57BL/6 mice, (Kuroda and Yamashita, 2003), in cytokine serum levels (Roggero et al., 2002) or cardiac cytokine expression profile (Cuervo et al., 2008) after infection could be responsible for the observed discrepancies.
The effects of anti-inflammatory PGD2 derivative 15dPGJ2 have been studied also in T. 
cruzi experimental infection. When added to infected cardiomyocytes in vitro, the expression 
of pro-inflammatory mediators is reduced and 
parasite burden increases. PPAR-γ and NF-κB 
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pathways have been implied in this process (Hovsepian et al., 2011). Treatment of infected mice with 15dPGJ2 leads to a decrease TNF-α cardiac expression meanwhile IL-10 plasma level increase. No changes were observed in survival of the infected mice compared with the 15dPGJ2 treated ones. However, cardiac parasite burden data differed depending on the study (Penas et al., 2013; Rodrigues et al., 2010).The role of 5-lipoxygenase in and its derivatives T. cruzi infection seems to be mouse and parasite strain-dependent (Borges et al., 
2009). Again, there is contradictory data in the literature regarding the infection of 5-LO 
deficient model or the treatment with inhibitors (Pavanelli et al., 2010; Panis et al., 2011). However, despite of divergences due to mouse strain and parasite inoculum, the 5-lipoxygenase and its metabolite LTB4 is always related to nitric oxide (NO), key mediator in parasite killing (Vespa et al., 1994) and immunosuppression (Abrahamsohn and Coffman, 1995). Thus, previous in vitro studies have demonstrated that LTB4 augment NO level in T. cruzi infected macrophages (Talvani et al., 2002).

OBJECTIVES
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Lipid mediators produced by cyclooxygenases and lipoxygenases have a wide range of functions in the immune response against infection. One of those functions is the 
regulation of the initiation and resolution of inflammation. On the other hand, acute phase of Trypanosoma cruzi infection is characterized by inflammation with high secretion of cytokines and chemokines. After this phase, usually, parasite burden is dramatically 
reduced and inflammation resolves. Our hypothesis sustains that lipid mediators produced by cyclooxygenases and lipoxygenases have a role in T. cruzi elicited inflammation and resolution.
The main objective of this work was therefore to study the role of these mediators in 
initiation and resolution of inflammation during the acute phase of Trypanosoma cruzi 
infection. Three specific objectives were proposed:       
1. To analyze the expression of cyclooxygenases and lipoxygenases in hearts of mice infected with Trypanosoma cruzi.
2. To study the effect of the inhibition and deletion of cyclooxygenase-2 and Prostaglandin E receptor 2  in the outcome of Trypanosoma cruzi infection. 
3. To determine the role of cyclooxygenases and Prostaglandin E receptor 2 in the immunosuppression observed in the acute phase of Trypanosoma cruzi infection. 
 

MATERIALS & 
METHODS
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1. Parasites and mice 
Murine modelsYoung adult (6 to 8-week-old) BALB/c and C57BL/6 mice were purchased from Harlan, Interfauna Iberica or CharlesRiver. IL-4 Receptor 
deficient BALB/c mice (Mohrs et al., 1999) 
were a gift from Dr. Beschin (Vrije Universiteit 
Brussel, Belgium). COX-2 deficient mice: B6;129S7-Ptgs2tm1Jed/J were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Mixed background C57BL/6-129 mice were 
used as control for the studies with COX-
2 deficient model. EP-2 deficient C57BL/6: Ptger2tm1Sna mice were a gift form Dr. Shu Narumiya, (Faculty of Medicine, University of 
Kyoto, Japan). Genotype of gene deficient mice 
was determined by PCR protocol. Due to COX-2 -/- and EP-2-/- female inability to reproduce we bred the animals using homozygous males and heterozygous females in both strains. All mice were maintained under pathogen-free conditions in the animal facility at the Centro de Biología Molecular, Universidad Autónoma de Madrid (Spain) in compliance with local and European ethical norms. 
When necessary, drugs were administered 
as following. Treatment with etoricoxib (COX-2 selective inhibitor) was administered in drinking water with saccharin to improve tolerance. Etoricoxib was renewed every 2 days in colored bottles for light protection to avoid its degradation. The concentration of drug was calculated to obtain a dose of 5mg/kg/day. Bosentan (dual antagonist of ET A/ET B receptors of endothelin-1) treatment was given by gavage (100 mg/ kg/ day) starting the day 
before infection and until the day of sacrifice.
Infection model
In vivo infections were performed with Y 
Trypanosoma cruzi strain (obtained from Dr. John David, Department of medicine, Harvard Medical School, Boston, Massachusetts, U.S.A.). Blood trypomastigotes were routinely maintained by infecting IFN-γ receptor deficient mice (129 Ifngrttm1Agt/J) (Huang et al., 1993) purifying parasites from their blood. These mice were a gift from Manfred Kopf (Max-Planck-Intitute for Immunobiology, Freiburg, Germany).Groups of 3-6 mice were infected with 2.000 typomastigotes per mice (unless stated 
different) by intraperitoneal injection, keeping a group of non-infected mice. Parasitemia levels were checked every 2 days by directly inspection with a microscope. Parasite counting 
was performed using 5 μl drop of tail vein blood. At different days post infection mice were euthanized in a CO2 chamber and blood and various tissues were collected. Samples were processed for RNA, DNA and protein isolation, 
histology, confocal immunofluorescence analyses, magnetic cell sorting or cell culture.
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TABLE 2. QUANTITATIVE PCR PROBES
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TABLE 3. BUFFERS & SOLUTIONS
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2. In vitro generation of parasites and 
infectionVero (ATCC number CCl-81) epithelial cells were grown in RPMI complete medium containing 5% FCS, 2mM L-glutamine, 100U/ml penicillin, 100µg/ml streptomycin, 1000U/ml and 0,1 mM non-essential amino acids. (Gibco, Grand Island, 
NY) at 37ᵒC in an atmosphere containing 5% CO2. Axenic culture of Y strain trypomastigotes were collected from extracellular medium of Vero cells 5 to 6 days after infection. Only plates without visible extracellular amastigotes or dead cells in the medium were selected for the experiments. Media were shortly centrifuged 2 minutes at 150 x g to remove dead cells and aggregates and always counted and purity checked using a Neubauer hemocytometer. 
These purified parasites were used to infect adherent cells during 16 hours in the incubator at 37 Celsius degrees with a M.O.I. (multiplicity of infection) 5 parasites per cell in 2% FCS RPMI. After the incubation, culture plates were directly processed for protein extraction or other assays. Warm PBS to wash the cell was used if were necessary. Three different strains were maintained in epimastigote vital form: Y which belongs to 
T. cruzi II type, CL-Brener (T. cruzi VI type) and Dm28 (T. cruzi I type), according to their genetic variability (Zingales et al., 2009). Epimastigotes forms of T. cruzi were grown in LIT (Liver Infuse Tryptose) medium (Castellani et al., 1967). The macrophage cell line RAW 264.7 (ATTC Code: TIB-71) purchased from ATTC were used in some in vitro experiments.
3. Real time PCR for parasite detection  Hearts were perfused with PBS and 0,1% heparin (1.000 U/ml) and were minced into small pieces with an sterile scalpel blade. DNA was isolated with High PurePCR Template 
preparation Kit (Roche). In order to quantify 
T. cruzi DNA, we followed the qPCR assay described by (Piron et al., 2007). 100, 10, 1, 
0.1 and 0.01 pg of DNA purified from Y strain epimastigotes were used to generate the standard curve. Experimental heart tissue qPCR reactions contained 100 ng of total DNA and Tnf murine gene was used as a loading control.
4. mRNA analysis by quantitative RT-PCR Total RNA was extracted from heart tissue perfused with PBS and heparin, cut in small pieces using a sterile scalpel blade, followed by mechanical disruption using a PT 1300 D homogenizer (Kinematica Polytron, Fisher 
Scientific) in TRIzol reagent (Invitrogen) as indicated by the manufacturer. For quantitative real time polymerase chain reaction (qPCR) analysis, reverse transcription of total RNA was performed using the components of the High Capacity cDNA Archive Kit (Applied Biosystems. Life Sciences) or the SuperScript Enzyme 
(Invitrogen, Life Sciences). Amplification of different genes using TaqMan MGB probes and the TaqMan Universal PCR Master Mix (Applied Biosystems) on an ABI PRISM 7900 HT instrument (Applied Biosystems. Life Sciences). For cell-cultured cells, samples were treated as mentioned above except for the mechanical disruption. All samples were assayed in 
triplicate. Quantification of gene expression by real-time PCR was calculated by the comparative threshold cycle (CT) method as described in (Schmittgen and Livak, 2008). RQ= 2-ΔΔCT. 
All quantifications were normalized to the ribosomal 18S to control variability in the initial 
concentration of RNA and conversion efficiency of the reverse transcription reaction.
5. Protein expression analyses Protein extracts were prepared from heart tissue perfused with PBS and heparin, cut 
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in small pieces using a sterile scalpel blade followed by mechanical disruption using a PT 1300 D homogenizer (Kinematica Polytron, 
Fisher Scientific) in Triton X-100 based protein lysis or RIPA buffer. Protein concentration was determined by the bicinchonic acid method (BCA, Pierce) using Bovine Serum Albumin for the standard curve. Cultured cells were treated as mentioned above except for the mechanical disruption.  Western blot analyses were performed as follows: 15 or 50 µg of cell or tissue extract were fractionated on SDS polyacrylamide gel and transferred to a Nitrocellulose membrane Hybond-ECL (Amersham Biosciences) and blocked in 5% dry fat free milk or 5% bovine serum albumin in 0.1% Tween-20 Tris Buffered Saline. Primary antibodies were diluted in blocking buffer and membranes were incubated overnight at 4-8 Celsius degrees. Then membranes were incubated with horseradish peroxidase 
conjugated secondary antibody after washing the primary antibody. Detection was carried out with Supersignal detection reagent (Pierce) 
and photographic film exposure. Fiji package software was used to quantify band intensity normalizing band areas of the sample to their respective loading control.
6. Histological studiesCardiac tissues from mice were placed, after been cut in two, in 10% neutral buffered formalin for at least 4 hours at room temperature followed by incubation in 70% ethanol overnight. 
Samples were then embedded in paraffin (Tissue Embedding Station Leica EG1160), and 5µm tissue sections were prepared (motorized Microtome Leica RM2155) over slides. Samples 
were deparaffinized and rehydrated using a Tissue Processing Station Leica TP1020. Slides were stained using the Masson´s Trichrome staining and mounted permanently in 
Eukkitt´s quick-hardening mounting medium (Biochemika, Fluka analytical). The sections were microscopically analyzed in a Leica microscope (DMD 108, Leica microsystems Wetzlar GmbH, Germany) using the 20x 
magnification objective lens. Lamp intensity 10 and f/Stop 12. Ventricular myocardium micrographs were taken avoiding pericardium, endocardium, auricles and big vessels in order to make the process reproducible. Nine different pictures of different sections, separated by at least 50 microns, per heart were taken. The 
degree of inflammatory-cell infiltration were 
quantified using the Fiji package (Schindelin et al.) and the plugin Advance Weka Segmentation developed by Ignacio Arganda Carreras (MIT, USA). The macro used is detailed in Appendix2. 
Classifier used is available in the attached CD.
7. Confocal immunofluorescence  Organs were removed from mice at different 
times post infection, cut and fixed in a 4% paraformaldehyde PBS buffered solution. After at least 2 hours incubated at room temperature were transferred to a 30% sucrose PBS solution incubate overnight at 4-8 Celsius degrees, until the tissue sections reach the bottom of the tube in order to cryoprotect the sample. Tissues were then embedded in Tissue-Tek OCT in Cryomolds (Sakura, Japan) to allow cryostat sectioning and frozen using dry ice. 10 µm sections were cut using a cryostat Leica 
CM1900. Slides were fixed in acetone for 10 min at room temperature, washed and incubated 10 min with NH4Cl to avoid autofluorescence; then were washed with PBS, permeabilized with 
PBS 0.1% Triton X-100, blocked and incubated overnight at 4˚C with primary antibodies in the blocking buffer. The samples were washed in PBS and secondary antibodies were added at the dilutions shown in Materials table in the 
blocking buffer and incubated overnight at 4ᵒC 
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again. After washing with PBS, samples were washed with water. Hydrophobic ink Dako Pen was used when different sections were located in the same slide and different antibodies were used. Nuclei were stained using 1 microgram/ml of DAPI (268298, Merck). Prolong Gold Antifade Reagent (Invitrogen) was used to mount the 
slides that were kept at 4ᵒC until observation. Transparent nail polish was used to seal the samples. Stained slides were observed with a confocal laser scanning microscope, LSM710 coupled to an Axioimager.M2 microscope (Zeiss). The micrographs were processed 
using the software ZEN (Zeiss) or Fiji Package. Antibodies controls are shown in Appendix 1.
8. Lipid Droplets staining
Confocal immunofluorescence was used to detect lipid droplets with Oil Red O (ORO) in propylene Glycol 26079-15 purchased from Electron Microscopy Sciences. To set up the staining and detection of lipid droplets, peritoneal cavity macrophages were used. Cells were incubated with deferoxamine 375 
μM overnight at 37ᵒC and the following day stained to detect lipid bodies (Hu et al., 2003). These macrophage lipid droplets were used to obtain the absorption/emission spectrum of ORO thanks to the confocal laser scanning microscope, LSM710 coupled to an Axioimager.
M2 microscope (Zeiss). Modified protocol of the already described above for confocal 
immunofluorescence was used to stain lipid droplets in frozen tissues. With the addition of 1 hour of incubation with 0.5 % ORO in Propylene Glycol (PEG) and the following differentiate step with 85% PEG 1min at room temperature. These steps were carried out after the antibody staining and before mounting.
9. PBMCs, spleen cell suspension Spleens were aseptically removed from mice 
kept in medium at 4ᵒC until disaggregation in 40µm nylon cell strainers (Falcon). Blood was obtained by cardiac punction and treated with heparin. Single suspension cells were depleted of erythrocytes by hypotonic lysis, washed with cold PBS and processed for RNA isolation or protein extraction. For some experiments cells were cultured in RPMI. (Gibco, Grand 
Island, NY) 5% FCS at 37ᵒC in an atmosphere containing 5% CO2.
10. Peritoneal cells isolation Peritoneal cavity from euthanized mice was washed with 5 ml of sucrose (116g/l) in PBS. Cells were plated in complete RPMI. (Gibco, 
Grand Island, NY) at 37ᵒC in an atmosphere containing 5% CO2. After 4h, non-adherent cells were removed by washing three times with warm PBS, and fresh complete RPMI was restored. In several experiments 1 ml of 10% (w/v) thyoglicollate (Gibco, Grand Island, NY) 
was injected to elicit an aseptic inflammation to recruit macrophage after 4 days. These cells were harvested as described above. In some experiments LPS (L-8273 Sigma-Aldrich) 1 microgram/ml was used in order to obtain a positive control for Western Blot and Confocal 
Imnunofluorescence. In other cases coverslips were coated with Poly-L-Lisine (Sigma-Aldrich) to allow the binding of not adherent cells.
11. Isolation of LY6G+ and CD11b+ cells by 
magnetic sorting15 BALB/c or C57BL/6 mice were infected i.p. with 2.000 Y strain trypomastigotes. At 21 d.p.i. for BALB/c and 14 d.p.i. for C57BL/6 , mice were euthanized in a CO2 chamber and hearts were aseptically removed, perfused with 10 ml PBS-heparin solution, and kept in cold HBSS. Then, hearts were pooled in a cell culture dish, washed thoroughly with HBSS and minced into small pieces with a sterile surgery blade. Mouse 
50
MATERIALS & METHODS
hearts (maximum 4 per tube) were transferred into the gentleMACS C tube containing 4.7 ml of HBSS. 300μL of Collagenase II solution (600 U/
ml) and 10 μl DNase I solution (60U/ml) were added. Then, were disrupted with gentleMACS Dissociator, incubated 30 min at 37ºC and disrupted one more time using the appropriate protocol of disaggregation. After centrifugation homogenized tissue was suspended in HBSS. To obtain a single cell suspension a cell strainer (70μm mesh size) was utilized. After red blood cells lysis cell suspension were washed and processed following Milteny Biotec instructions for magnetic sorting. Same magnetic sorter protocol was used when spleen, peritoneal cavity cells or blood single cell suspension were used.For Ly6G+ cell sorting, anti Ly-6G MicroBead kit (Milteny Biotec GMbH) was used with MACS LS columns and MACS Separators Magnet (Miltenyi Biotec GmbH) following manufacturer instructions. Ly6G- fraction of the cell suspension was afterwards processed for CD11b+ cell sorting using CD11b Microbeads (Milteny Biotec 
GMbH). These purified cells were cultured to perform an AA conversion assay or process to isolate RNA or obtain protein extracts.
12. Proliferative assays Spleen cells were obtained as mentioned above, counted, suspended in complete RPMI, 5% FCS and 200.000 cells per well were plated 
in flat 96 well plates. Cells were stimulated with 5µg/ml purified anti-CD3 (clone 145-
2C11, BD Pharmingen) and 1 µg/ml purified anti-CD28 (clone 37.51, BD Pharmingen) or with 1µg/ml concanavalin A (Type IV-S 
γ-irradiated. C0412, Sigma-Aldrich) and, when indicated, cyclooxygenase inhibitors (10 μM Indomethacin, 0.1 μM NS398, 0.1 μM Celecoxib) were added. At these concentrations 
the inhibitors could efficiently avoid PGE2 
production in LPS activated macrophages. After incubation at 37°C and 5% CO2 for 48h, 1µCi [3H] thymidine (Amersham, Little Chalfont, UK or PerkinElmer, Massachusetts, USA) was added to each well. The cultures were collected 18 h later and then processed for measurement of incorporated radioactivity. Cultures were 
transferred to a glass fiber filter using a 96 well 
plate harvester. After drying, a paraffin film containing the scintillator was melted on the 
filter and let it solidify (Wallac, Turku, Finland). MicroBeta scintillation counter (Wallac, Turku, Finland) was used to measure [3H] thymidine incorporated into the DNA of the cells.
13. PGE2, cytokines and anti-T. cruzi 
antibodies by ELISA.Supernatant of cultured cells or plasma/serum obtained from blood of infected mice 
were frozen at -70ᵒC until were assayed. PGE2 level were measured with PGE2 EIA KIT from Cayman Chemical (Michigan, USA), TNFα with ELISA kit from R&D systems (Minneapolis, USA). In order to titer anti-T. cruzi antibodies 0.1 microgram of T.cruzi epimastigote extract were 
added to each well of MAXISORP plate (NUNC) and incubated overnight. Plasma diluted 1:100 from infected and not infected animal were added after washing and incubated 2.5 hours. Anti-mouse total IgG, IgG2a or IgG1 HRP-
conjugated secondary antibodies were used to detect plasma antibodies. O-Phenylenediamine dihydrochloride was (Sigma-Aldrich) was use to reveal the peroxidase activity reading the optic density at 450 nanometers with a Microplate Reader.
14. Migration assay200.000 mouse thyoglicollate elicited peritoneal cells were cultured in the upper compartment of permeable 8 µm pore TransWell® plates (Corning, Amsterdam, The 
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Netherlands) during at least 3 hours in 2% FCS RPMI medium. Cells were left to migrate during 24 hours in response to 5% FCS or 5% FCS plus 10 ng/ml of the chemokine CCL5, (478-MR from R&D Systems) located in the lower compartment. To eliminate non-migrating cells of the upper compartment 2 gently washes with PBS were 
done. . Cells were fixed with 5% Glutaraldehyde (type II, G-6257 Sigma-Aldrich) in PBS during 20 minutes. After washing, the TransWell membrane was stained with 0.5 % Crystal Violet (C-6158, Sigma.-Aldrich) in water/methanol during 20 minutes. Two washes with PBS and one with water followed the staining. Cells attached to the upper compartment of the membrane were carefully removed using a cotton bud. 8 different micrographs were taken per well to cover almost all its surface. Leica DFC420 C camera coupled to a Leica DM IL microscope at 200x magnification was used. The experiments were performed in duplicate and data is represented as relative migration (number migrated cells to 5% FCS+ RANTES)/ (number migrated cells to 5% FCS). 
15. Arachidonic Acid incorporation assayY and Dm28 T. cruzi strains epimastigotes were cultured as described above. 25, 100 and 250 million parasites were incubated in 0.5 
ml LIT medium with 50μM [14C] Arachidonic Acid (PerkinElmer, Massachusetts, USA) for 30 minutes. Cells were centrifuged 5 min at 3.000 x g, supernatants were transferred to a new tube and cell pellets were washed and hypotonic lysed. 2.5ml of scintillation liquid Optiphase Hisafe 2 (Perkin Elmer, Massachusetts, USA) was added , well mixed and after 24 hours of stabilization were measured with the scintillation counter Rack Beta (Wallac, Turku, Finland).
16. Arachidonic Acid conversion assay 250 million Y, Dm28 , Cl-Brener T.cruzi strain epimastigotes or 25 millions of trypomastigotes were centrifuged, washed with 0%FCS Medium and suspended in 0.5 ml of medium (0% FCS LIT or RPMI for epimastigotes or trypomastigotes 
respectively) with or without 2 μM Hematin (Sigma-Aldrich) . Some parasites tubes were sonicated in order to get total parasite extracts before the addition of arachidonic acid (AA).1 million macrophages or other cell type were cultured in 6 well plate and left 1 hour at 37ᵒC before conversion assay was performed. To obtain a positive control macrophages were incubated 6 hours with LPS (Sigma-Aldrich) 1 microgram/ ml and 2,5 ng/ml of gamma-Interferon (Sigma-Aldrich). 
25μM [14C] Arachidonic Acid purchased from PerkinElmer (Massachusetts, USA) was added to each sample described above and incubated 
30 minutes at 37ᵒC. 2% acetic acid in cold methanol was added to extract and preserve AA derivatives. Samples were mixed by vortex and the air inside the tube was substituted by inert 
nitrogen gas. Samples were kept frozen at -70ᵒC until HPLC was performed.HPLC device composed by a Beckman Solvent Module 126 with the column Ultraphere ODS (C-18, Beckman-Coulter) 5 μm diameter sphere particle, 4,5 mm and 25 cm column diameter and length respectively and a Beckman 171 Radioisotope Detector. Scintillation liquid Ecoscint H purchased from National Diagnostics.Prostaglandins were resolved with the 
isocratic flow (1ml/min) of the mobile phase: Acetonitrile/water/acetic acid 33:67:0.1 v/v/v.Radioactive standard were kindly donated by Mercedes Camacho (Hospital de la Santa Crey I Sant Pau, Barcelona). These standard 
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were produced using 14[C] Arachidonic Acid and different cell types expressing the respective enzymes. 14[C] Arachidonic Acid incubated in medium was used like input control.
17. Flow citometrySurface cell staining was performed in 96 well plates. Fc receptors on cells were blocked 
by incubating with purified anti-CD16/CD32 (Mouse BD Fc Block) (clone 2.4G2, BD 
Pharmingen) for 5 min at 4ᵒC. Cells were then 
stained with respective directly conjugated 
antibodies 20 min at 4ᵒC. Cells were washed with cold PBS 1%BSA and single cell suspensions 
were fixated with paraformaldehyde 1% in PBS for 10 min at 4ºC.  Data were analysed with the FlowJo software (TriStar, Ashland, OR, USA).
18. Statistical analysis For in vivo experiments, data are shown as means and SD (Standard deviation) otherwise is mentioned. “n” indicates number of mice or biological replicates of shown data. All in vitro experiments were performed at least three 
times. Significance was evaluated by Student’s t-test when two groups were compared. ANOVA one way followed by Tukey post-test was applied when groups of samples from an experiment had different time points. And ANOVA two way followed by Bonferroni post-test when the experiment had time and mice strain as variables. For survival analysis we choose Gehan-Breslow-Wilcoxon method, which gives more weight to deaths at early time points but is more restrictive than regular log-rank test. GraphPad Prism 5.00 software (La Jolla, CA, USA) was used for statistical analysis.
RESULTS
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Trypanosoma cruzi infection modifies the 
expression of enzymes responsible for 
production of lipid mediators in the heart
We used the murine model of Trypanosoma 
cruzi infection because mice are easy to handle, 
can be modified genetically and develop a 
well described acute phase in the first month after T. cruzi infection. Although we already know that human and mouse immune system differ in some important aspects (Mestas and Hughes, 2004), experimental infections of murine models have provided a big amount of important data regarding Chagas disease. It is becoming accepted that host and 
parasite genetic differences can influence the outcome of the disease. Thus, different strains of mice present distinct susceptibility to parasite infection depending on their genetic background. In our model, BALB/c mice are susceptible to infection, meanwhile C57BL/6 mice are resistant to T. cruzi infection with the Y parasite strain. In the C57BL/6 model 
of infection, cardiac inflammation (analyzed through mRNA expression of cytokines 
such as IFN-γ, TNF-α, IL-4, and IL-10) ends faster than in the BALB/c model, probably 
due to a very efficient immune response. No 
Th1 or Th2 profile is clearly linked to strain susceptibility, although Th1/Th2 balance was higher for C57BL/6 than for BALB/c (Cuervo et al., 2008).In order to study the main enzymes involved in the arachidonic acid metabolism, we infected BALB/c and C57BL/6 mice intraperitoneally with 2.000 blood trypomastigotes of the Y strain of T. cruzi. Figure 1A shows that BALB/c 
infected mice died during the acute phase of infection and C57BL/6 did not. On average, 2 peaks of parasitemia were detected in BALB/c mice at 9 d.p.i. and 21 d.p.i., because in some mice parasitemia increased dramatically before their death. C57BL/6 parasitemia peak was at 9 d.p.i. and was undetectable by 21 d.p.i. (Fig. 1A). Histological analysis of the hearts of infected mice shown in Fig. 1B revealed 
high level of cardiac inflammation in BALB/c infected mice (21 d.p.i.). These mice showed more tissue disturbances and parasitism than the C57BL/6 mice as was previously described in our lab. (Cuervo et al., 2008)Next, we addressed the level of the cyclooxygenases and terminal synthases of prostaglandins and thromboxane, as well aslipoxygenases in the infected cardiac tissue of both murine models over the time of the infection (Fig. 2). Cyclooxygenase-2 gene expression (Ptgs2), but not Cyclooxygenase-1 (Ptgs1), was increased in heart tissue during the acute phase of T. cruzi infection in the same magnitude in both mouse strains. Lipocalin-type PGD synthase (Ptgds) mRNA was already present in cardiac tissue and did not increase its expression upon T. cruzi infection. However, leucocyte type PGD synthase (Hpgds) gene expression was increased. PGD2 can form 
15-deoxi-Δ12,14-PGJ2 and binds to PPARγ 
which has an anti-inflammatory effect (Liu et al.; Scher and Pillinger, 2009). Thromboxane synthase (Tbxas1) gene expression was increased in both strains. It has been 
described that TXA2 induce TNF-α production in monocytes (Caughey et al., 1997) and could 
be in part responsible for the inflammation 
Expression of cyclooxygenases and lipoxygenases during 
Trypanosoma cruzi infection
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Figure 1│ Survival, parasite burden and inflammation of BALB/c and C57BL/6 mice infected with Trypanosoma 
cruzi. A│ Mice survival was monitored daily after infection and parasitemia was quantified every 2 or 3 days. Representative means ± SEM are shown (n=5). ANOVA two way followed by a Bonferroni Post test was performed. Differences between mouse strain are indicated: * p< 0,05 ** p< 0,01. B│ Cardiac tissue sections from non-infected (NI) and Trypanosoma cruzi infected BALB/c and C57BL/6 mice at 21 d.p.i. stained with Masson`s Trichromic. Micrographs were taken as described in 
Materials and Methods. Representative pictures of each group are shown. Black arrows show infiltrating leukocytes and red arrows indicate parasite nests. Scale bar is 100 microns length.
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Figure 2│ Arachidonic acid metabolism related enzymes mRNA expression in the heart during Trypanosoma cruzi 
infection. RNA from heart tissue was isolated from mice at different d.p.i. and from non-infected (NI) mice. qPCR was performed as described in Materials and Methods. Results are expressed as RQ calculated from CT values as described in 
Materials and Methods. Open bars indicate the values of BALB/c mice and filled bars of C57BL/6 mice. Means ± SD from three independent experiments are shown (n=9). Comparison between infected mice respect to non-infected mice for each strain is indicated: * p<0.05 **p<0.01 ***p<0,001. Differences between infected strains is indicated by # p<0.01 generated by T. cruzi infection (Ashton et al., 2007).Expression of the gene encoding 5-lipoxygenase (5-LO, Alox5), key enzyme of leukotriene production, decreased in heart tissue of infected mice. In contrast, 5-LO activating protein, FLAP (Alox5ap) expression was increased in infected mice (10 fold respect to non-infected mice). Changes in FLAP expression have been involved in post-transcriptional regulation of 5-LO 
functions (Byrum et al., 1997; Evans et al., 2008). Interestingly, Alox15, that codifies 12/15 Lipoxygenase (12/15-LO), involved in 
resolution of inflammation, showed increased expression in both murine models. The higher level of Alox15 and Hpgds in C57BL/6 mice respect to BALB/c mice at 14 d.p.i. suggests a role of these enzymes in resolution of the 
infection. In agreement, cardiac inflammation ends earlier in C57BL/6 than in BALB/c mice.
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Myeloid cells in inflamed cardiac tissue 
express COX-2 
COX-2 induction in macrophages after infection has been described in different models (Lee et al., 1992). Therefore, we next analysed its expression in magnetic sorted myeloid cells isolated from hearts of T. cruzi infected BALB/c and C57BL/6 mice when 
inflammation was maximal. Using an antibody against Ly6G we obtained the granulocyte population. From Ly6G- population, CD11b+ cells (monocyte/macrophage) were selected (Fig. 3). 
As previously described, Arg-1 and iNOS were expressed by Ly6G- CD11b+ cells (Cuervo et al., 2011). These Ly6G- CD11b+ cells also expressed 
COX-2 protein, but 12/15 LO expression could not be detected by immunoblotting, in spite of its mRNA induction in whole cardiac extracts. 
Figure 3│ Protein expression of heart infiltrating 
myeloid cells during Trypanosoma cruzi infection. Ly6G+ and CD11b+ cells were obtained from pooled infected 
mouse hearts at the peak of inflammation using magnetic separation. Total protein extracts were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. 
Proteins were detected using specific antibodies. One experiment out of two independent experiments is shown. N.D. stands for non-determined. Arrows indicate the 
position of loaded positive control bands for COX-2 and PGDSh. Anti-actin antibody was used as a loading control.
This suggests that 12/15 LO is not expressed by Ly6G+ or Ly6G- CD11b+ cells. On the other hand, Ly6G- CD11b+ cells from BALB/c infected mice expressed hPGDS, which is responsible for production of the pro-resolution prostaglandin PGD2 (Urade et al., 1989). These cells expressed more EP-2, receptor of PGE2, than Ly6G+ cells. 
Interestingly, COX-2 gene expression was much higher in myeloid cells obtained from infected cardiac tissue than in blood, indicating that 
COX-2 is induced in inflamed tissue (Fig. 4). 
Figure 4│ Ptgs2 expression in CD11b+ cells isolated 
from Trypanosoma cruzi infected blood and heart 
tissue. CD11b+ cells were obtained from pooled infected BALB/c mouse hearts or blood at 21 d.p.i. using magnetic beads as described in Materials and Methods RNA was isolated and qPCR was performed. Results are expressed as RQ calculated from CT values as described in Materials and Methods using the infected CD11b+ blood cells for normalization. Means ± SD of two independent experiments is shown. Hearts from C57BL/6 mice were processed and analysed by confocal microscopy at 14 d.p.i in order to study the pattern of cellular 
expression of COX-2. CD68 was used as a marker to detected macrophages within the tissue. CD68+cells were clearly present in the infected hearts where they showed a strong and spread intracellular staining due aggrupation 
of infiltrating cells. We also found that COX-2 was expressed in the perinuclear region of 
CD68 positive and negative infiltrating cells (Fig. 5C and 5D). No specific staining was 
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observed in not infected tissues (Fig. 5A) or sections incubated with secondary antibodies alone (Fig. 5B). COX-2 expression by activated lymphocytes has been previously described (Iniguez et al., 1999), but we could not detect 
the presence of the enzyme in infiltrating CD4+ cells (Fig. 6A to 6C). Similar results were obtained when BALB/c mice at 21 d.p.i. were 
analysed with CD68 and CD4 markers (Not 
shown).CD68+ Arginase-1+ iNOS+ cells are present in T. cruzi infected cardiac tissue and have been characterized as MDSCs (myeloid derived suppressor cells) by their gene signature and suppressor function (Cuervo et al., 2011). 
Figure 5│COX-2 and CD68 expression in Trypanosoma cruzi infected cardiac tissue.Heart tissue was isolated at 14 d.p.i. from infected or non-infected C57BL/6 mice and frozen in OCT. Section of the organs were stained with DAPI for 
nuclei (blue) and antibodies against the macrophage marker CD68 (green) and the enzyme COX-2 (red). Pictures are representative of more than 3 sections analyzed in at least 3 different mice from three independent experiments. A│ Non-infected cardiac tissue. B│ Secondary antibody staining control using infected tissue. C│ Cardiac tissue from infected mice at 14 d.p.i. D│ Detail of the infiltrating cells shown in B. Magnification of the framed area in C. White arrowheads indicate 
two different COX-2+ CD68– cells. Scale bar is 20 microns length. 
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As it was found that Ly6G- CD11b+ sorted 
cells expressed the COX-2 enzyme, confocal analysis were performed in heart sections to 
elucidate if COX-2 co-localized with Arg-1 in MDSCs. Preliminary data showed no cells co-
expressing COX-2 and Arg-1 (Fig. 7).
Inflammatory cells from infected cardiac 
tissue but not T. cruzi produce PGE2 and 
PGF2α In order to identify the arachidonic acid 
(AA) derivatives produced by the infiltrating myeloid cells of the infected hearts, a 
Figure 6│COX-2 and CD4 expression in Trypanosoma cruzi infected cardiac tissue. Heart tissue was isolated at 14 d.p.i. from infected or non-infected C57BL/6 mice and frozen in OCT. Section of organs were stained with DAPI for nuclei 
(Blue) and antibodies against the lymphocyte marker CD4 (green) or the enzyme COX-2 (red). Pictures are representative of more than 3 sections analyzed in at least 3 different mice from at least two independent infections. A - C│ Detail of the 
infiltrating cells in T. cruzi infected heart. 3 confocal sections are shown. D│ Secondary antibody staining in infected tissue. Scale bar is 20 microns length. 
Figure 7│COX-2 is not expressed by CD68+Arg-1+ cells in T. cruzi infected cardiac tissue. Heart tissue was isolated at 21 d.p.i. from infected or non-infected BALB/c mice and frozen in OCT. Section of organs were stained with DAPI for nuclei 
(blue) and antibodies against the macrophage marker CD68 (green) and the enzymes Arg-1 (magenta) and COX-2 (red). Colocalization of CD68 and Arg-1 results in white color (combination of green and magenta). Upper and middle rows of panels show different pictures of infected cardiac tissue. The yellow arrow indicates an Arg-1 expressing CD68+ cell. White 
arrows indicate COX-2 expressing cells. Lower row of panel shows the secondary antibody control using infected tissue. Scale bar is 20 microns length. Pictures are representative of several sections analyzed in one experiment. 
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Figure 8│Cardiac infiltrating myeloid cells metabolyze arachidonic acid into PGE2 and PGF2α. Leukocytes were 
purified from cardiac tissue of BALB/c mice at 21 d.p.i., Ly6G+ and Ly6G-Cd11b+ cells were sorted magnetically and incubated with 25µM radioactive arachidonic acid. Samples were resolved using HPLC as described in Materials and Methods. Black solid lines represent samples in hematin-containing buffer and red solid line represents the overlaid standards. A│ Input without cells. B│Ly6G+ cells. C│ Ly6G-CD11b+ cells. Data from one experiment out of two performed is shown. 
metabolic assay was performed. LY6G+ and Ly6G- CD11b+ magnetically purified cells were cultured in the presence of radiolabeled AA. Radioactive PGE2 and PGF2α, but not thromboxane or PGD2, were present in the supernatants of Ly6G- CD11b+ cells, but not in Ly6G+ cells (Fig. 8). This experiment indicates that the Ly6G- CD11b+ population is able to synthesize these two prostaglandins from AA without the collaboration of other cell type. Next, we analyzed the production of AA derivative in cells from peritoneal lavages of 
infected animals. It is known that different 
stimuli induce macrophage infiltration in the peritoneum (Ghosn et al., 2010). We expected 
to find macrophages in the peritoneal cavity of T. cruzi infected animals because is the 
route chosen for parasite injection. We found that peritoneal adherent cells from T. cruzi infected BALB/c mice are able to convert exogenous AA into PGE2 (Fig. 9A). To further study this, we sorted the peritoneal cells with an antibody against CD11b antigen coupled to magnetic beads. Peritoneal CD11b+ cells from 
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Figure 9│ AA metabolism of peritoneal CD11b+ cells from mice infected with Trypanosoma cruzi. Leukocytes were obtained from the peritoneal cavity (PECS) of non-infected and infected BALB/c mice at 21 d.p.i by peritoneal lavage. CD11b+ 
cells were magnetically sorted using a specific antibody against CD11b and incubated with radioactive AA. The samples were 
resolved using HPLC. Black solid line represents samples injected in hematin-containing buffer. Red solid line represents the overlaid standards. A│ Input without cells. B│Total PECS. C│ CD11b+ cells from non-infected mice. D│ CD11b+ cells from infected mice. E│ CD11b- cells from non-infected mice. F│ CD11b- cells from infected mice. A representative experiment out of two performed is shown.
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not infected animals were able to convert AA in different metabolites (Fig. 9C) but interestingly peritoneal CD11b+ from infected animals only produced PGE2 (Fig. 9D). Neither infected nor control CD11b- cells (Fig. 9E and 
9F) were able to produce PGE2. This result suggests that macrophages are a primary source of PGE2 in different tissues during the acute phase of T. cruzi infection. 
To clarify whether the production of prostaglandins is due only to the monocyte/macrophage CD11b+ cells, we performed an in vitro infection of macrophages. RAW 264.7 cells (a murine macrophage cell line) 
were infected with purified T. cruzi cultured trypomastigotes. Figure 10 shows that no 
COX-2 neither iNOS protein expression was detected in infected cells. However, LPS stimulated the expression of both enzymes in RAW 264.7 cells. RAW 264.7 cells produced PGD2 without stimulation other than culture in the cell plate (Fig. 11B). This macrophage cell line metabolized AA into PGF
2α
, PGE2 and 
Figure 10│ iNOS and COX-2 protein expression of an in 
vitro T. cruzi infected macrophage cell line. RAW cells were incubated overnight or not with LPS (1 μg/ml) or parasites. Total protein extracts were resolved in duplicate by SDS-PAGE and transferred to a nitrocellulose membrane. The presence of the proteins was detected 
using specific antibodies. Anti-actin antibody was used as a loading control. A representative experiment out of three is shown. 
PGD2 upon stimulation with LPS and IFN-γ (Fig. 11C). In fact, preferential PGD2 over PGE2 secretion by stimulated RAW 264.7 cell has been described (Cao et al., 2008). However, T. 
cruzi infection did not change the pattern of exogenous AA derivative production by RAW 264.7 cells. (Fig. 11D). These data suggest that T.cruzi alone is unable to induce COX-2 induction in macrophage cell type. 
In vitro production of AA derivatives by 
Trypanosoma cruzi has been previously reported (Kubata et al., 2002)(Ashton et al., 2007). To determine the role of the parasite on AA conversion, we performed similar experiments as described by Ashton et al (Ashton et al., 2007). We used different vital forms of the parasite: axenic epimastigotes, tripomastigotes alone or mixed with amastigotes from in vitro infection 
of fibroblasts. In order to reproduce the protocols used before by others we added hematin. Besides, similar reactions were performed simultaneously in iron-free buffer. No eicosanoids were detected when AA was incubated alone in the iron containing buffer (Fig. 12A). Living or homogenized parasites of three different parasite strains were used in these experiments. None of them produced any known prostaglandin or thromboxane when AA was added exogenously without iron in the culture medium (Fig. 12B-C). Interestingly, two radioactive peaks appeared at minutes 12 
and 32 of the HPLC run. The first AA derivative eluted had approximately the same elution time as 6-oxo-PGF1α, the main metabolite of prostacyclin. The second one did not elute at the time of any of the standards used. However, since production of AA derivatives was iron-dependent, we can conclude that T. cruzi parasites alone cannot generate derivatives 
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Figure 11│ Arachidonic acid metabolism of in vitro infected macrophages. RAW cells were incubated or not with LPS + IFN-γ or infected or non-infected with parasites 5:1 M.O.I. (multiplicity of infection) and 25µM radioactive AA was added. 
Samples were resolved using HPLC. Solid line represents the injected mock-incubated AA. Red line represents superimposed standards A│AA input. B│ Non-infected cells. C│ LPS and IFN-γ stimulated cells. D│ T. cruzi infected cells. A representative experiment out of three performed is shown.
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Figure 12│ Arachidonic acid metabolism of Trypanosoma cruzi culture parasites. 10x108 living or 15x108 homogenized parasites were incubated with 75µM radioactive AA. The samples were resolved using HPLC as described in Materials 
and Methods. Black solid lines represent the injected samples in hematin containing buffer. Red solid line represents the 
superimposed standards. Blue lines represent the injected sample in hematin-free buffer. A│AA Input. B│ Homogenized parasites. C│ Living parasites. Similar results were obtained when trypomastigotes or trypomastigotes mixed with amastigotes were used. This experiment was performed with three different T. cruzi strains (Y, Dm28 and CL-Brener) three times. A representative experiment performed with Y strain is shown.
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from AA. To elucidate if parasites efficiently incorporated AA we added radioactive material to the culture and separated the cells from the supernatant by centrifugation. As expected, parasites incorporated radioactive AA into the cells (Fig. 13).
al., 2009). However, 12/15-LO expression in cardiomyocytes was not observed in T. 
cruzi infected hearts. Rather it seemed to be 
expressed by inflammatory cells (Fig. 15). Next, we tried to characterize the cellular source of 12/15-LO using antibodies to 
recognize macrophages and fibroblasts. These cells are implied in tissue repair (Lambert et al., 2008; Souders et al., 2009; van den Borne et al.). On the other hand, 12/15-LO expression by these cells is related to wound healing (Gronert et al., 2005). Hence, we used 
macrophage (CD68) and fibroblast (Vimentin) markers trying to identify 12/15-LO expressing cells. However, 12/15-LO protein was neither found in CD68 nor in vimentin positive cells (Fig. 16B-C). Surprisingly, we also detected vimentin staining the parasites indicating a possible surface deposition (Fig. 
16C). Thus, no cellular 12/15-LO source could 
be clearly identified in the infected hearts. 
Figure 13│Trypanosoma cruzi incorporation of 
exogenous arachidonic assay. 25µM radioactive AA was added to different numbers of parasite, incubated, centrifuged and then radioactivity in the pellet and the supernatant was measured in a scintillation counter. The experiment was performed in Y and Dm28 T. cruzi strains with similar results. Results for the Dm28 strain experiment are shown.
12/15-Lipoxygenase expression is 
augmented during T. cruzi infection in 
cardiac tissueWe found that Alox15 gene was up-regulated during T. cruzi infection in the heart, as described before (Fig. 2F). We confirmed that the expression of this enzyme was IL-4 dependent as shown by strong reduction 
when IL-4 receptor deficient mouse were infected (Fig. 14). In accordance with a study using a different experimental model (Brinckmann and Kuhn, 1997), the presence of 12/15-Lipoxygenase (12/15-LO) was 
confirmed by confocal microscopy using the antibody provided by H. Kühn (Dioszeghy et al., 2008). Kayama and collaborators have described a role of cardiomyocyte-expressing 12/15 LO in cardiac failure (Kayama et 
Figure 14│Expression of 12/15 LO mRNA in cardiac 
tissue of wild-type and IL-4 receptor deficient mice 
infected with Trypanosoma cruzi. Heart tissue RNA was isolated at different days post infection (d.p.i.) and qPCR was performed.Results are expressed as RQ calculated from CT values as described in Materials and Methods. Open bars indicate the values of BALB/c mice and grey 
filled bars of IL4-receptor deficient mice. Means ± SD from a representative experiment out of two are shown (n=3). Differences between wild-type and IL-4R-/- mice are indicated with * p<0.05.
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Figure 15│12/15-LO expression is augmented during T. cruzi infection in cardiac tissue. Hearts were isolated at 21 d.p.i. from infected or non-infected BALB/c mice and frozen in OCT. Sections of organs were stained with DAPI for nuclei 
(blue) and antibodies against 12/15-LO (red). The green background signal is due to autofluorescence. Scale bar is 50 microns length. Pictures are representative of several sections analyzed in at least 3 different mice from three different infections. Arrows indicate 12/15-LO positive cells. Similar results were obtained using the C57BL/6 mouse strain.
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Figure 16│12/15-LO is not expressed by infiltrating macrophages nor fibroblasts in Trypanosoma cruzi infected 
cardiac tissue. Hearts were isolated at 14 d.p.i. from infected or non-infected BALB/c mice and frozen in OCT. Section of organs were stained with DAPI for nuclei (blue) and antibodies for the macrophage marker CD68 (green), the enzyme 
12/15-LO (red) or the intermediate filament cytoskeleton protein present in fibroblast, vimentin (magenta). Different channels and merge of the same sections are shown. A│Upper row represent non-infected stained tissue. B-C│ Two different 
micrograph from inflammatory loci of T. cruzi infected mice D│ Secondary antibody control using tissue from non-infected mice Scale bar is 20 microns length. Arrows indicate 12/15-LO positive cells. Pictures are representative of several sections analyzed in at least 3 different mice from at least two different infections. 
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The increase in COX-2 protein expression in 
infiltrating macrophages and the production of prostaglandins by these cells ex vivo suggested that cyclooxygenase may play a pivotal role in initiation, maintenance and resolution of the immune response upon infection. To 
confirm this, we have used pharmacological 
inhibition as well as genetically deficient mice for cyclooxygenase-2 and for Prostaglandin E 
receptor-2. Deficient and treated animals were infected in a similar manner that wild-type mice. Then, immunological and parasitological parameters were measured over infection.
Role of Cyclooxygenase-2 and PGE2 in Trypanosoma 
cruzi infected heart
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Figure 17│Effect of inhibition of COX-2 by etoricoxib 
treatment in T. cruzi infected mice. Groups of T. cruzi infected mice were treated or not with etoricoxib. Mice survival was monitored daily after infection and parasitemia was checked every 2 or 3 days. Black lines and solid symbols represent data from infected individual mice and red lines and solid symbols represent data from infected and etoricoxib treated mice (n=5). A│ Parasitemia of BALB/c (left graph) and C57BL/6 (right graph) mice. 
B│ DNA from heart tissue was isolated at 21 d.p.i. and qPCR using T. cruzi DNA standard was performed (n=3 non-treated mice and n=5 treated mice). C│ Percent of survival. Gehan-Breslow-Wilcoxon test between BALB/c infected and BALB/c Infected & Treated groups give a p value of 0,0981 (n= 7). Data from a representative experiment are shown.
Figure 18│ Histologic analysis of cardiac tissue of BALB/c mice during Trypanosoma cruzi infection treated with 
the COX-2 specific inhibitor etoricoxib. At 21 d.p.i. heart tissue was processed for Masson`s Trichromic staining and micrograph were taken as described in Materials and Methods. Representative pictures of each group were selected. Black 
arrow shows the infiltrating leukocytes and red arrow indicates parasite nests. Scale bar is 100 microns length.
Pharmacological inhibition of COX-2
COX-2 inhibition slightly decreased survival 
in the susceptible model of infection.Both BALB/c and C57BL/6 mice were infected intraperitoneally with 2.000 blood trypomastigotes of T. cruzi. Parasitemia and 
survival was measured over time. COX-2 
specific inhibitor Etoricoxib was administered in drinking water as explained in Material and 
Methods. Mice were sacrificed at maximum of 
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Figure 19│ Histologic analysis of cardiac tissue of C57BL/6 mice treated with the COX-2 specific inhibitor etoricoxib 
during Trypanosoma cruzi infection. At 21 d.p.i. heart tissue was processed for Masson`s Trichromic staining and micrograph were taken as described in Materials and Methods. A│ Representative pictures of each group were selected. 
Black arrow shows the infiltrating leukocytes and red arrow indicates a parasite nest. Scale bar is 100 microns length. 
B│ Graph showing the quantification of cell infiltration using FIJI software. Not significant changes were observed. Dot plot and means from one experiment are shown (n=4).
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Figure 21│Expression of cytokines, chemokines and enzymes of L-arginine metabolism related enzymes in the 
heart of Trypanosoma cruzi infected mice treated with the COX-2 specific inhibitor etoricoxib. Heart tissue RNA 
was isolated at 21 d.p.i. from infected, infected and treated or non-infected BALB/c (open bars) and C57BL/6 (filled bars) mice. Citokine, chemokine and enzyme gene expression was analysed by quantitative PCR with different probes: A│Ifng, 
B│ Il10, C│ Il6, D│Ccl2, E│ Ccl5, F│ Cxcl9, G│Arg1 and H│ Nos2. Not significant changes with the inhibitor treatment were 
observed. But the differences between infected and non-infected groups were significant. Means ± SD from a representative experiment is shown (n=3 for BALB/c and n=5 for C57BL/6 mice). 
cardiac inflammation, 14 d.p.i for C57BL/6 and 21 d.p.i. for BALBc and heart tissue was collected. Etoricoxib treatment exacerbated parasitemia and reduced survival of BALB/c mice but did not change parasitemia or survival of C57BL/6 mice during the acute phase of T. cruzi infection. However, heart parasite burden was unaltered (Fig. 17). These results indicate that COX-2 inhibition in the BALB/c model increases mice susceptibility in spite of no changes in parasite load in cardiac tissue. 
Cardiac inflammation is not altered in 
treated animalsWe next analysed by histology cardiac 
inflammation in the infected hearts. High 
leukocyte infiltration and parasite nests were found in BALB/c mice treated or not with the 
COX-2 inhibitor. Due to the high degree of 
inflammation, we were not able to quantify 
cardiac infiltration. However, microscopic examination showed no differences between groups (Fig. 18). C57BL/6 model at 14 d.p.i. 
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Figure 22│ Parasite burden in Trypanosoma cruzi infected wild-type and COX-2-/- mice. Wild-type (open circles and 
bars) and COX-2-/- (filled circles and bars) mice were infected with T. cruzi intraperitoneally. A│ Parasitemia checked every 2 days. Means ± SD are shown. B│ DNA from heart tissue was isolated at 7, 14 and 21 d.p.i. and T. cruzi specific qPCR with was 
performed. Representative means ± SD from at least three experiments are shown (n=4, for wild-type and COX-2-/-mice). 
Difference at the peak of parasitemia is significant * p< 0,05.
showed less inflammation than BALB/c at 21 d.p.i. (Fig. 19A) and inflammation was 
quantified using the FIJI software. No changes between treated and not treated groups were observed (Fig. 19B). Thus, treatment with 
a COX-2 specific inhibitor does not prevent 
cardiac cell infiltration during the acute phase of T. cruzi infection. 
Next, we studied the expression of several genes involved in the immune response against 
T. cruzi infection. Infected animals at 14 or 21 d.p.i were compared to their non-infected controls. In agreement with our previous results no changes in immune cell surface 
receptor expression was observed upon COX-2 inhibitor treatment (Fig. 20). In addition, we studied the expression of several genes that 
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have previously been related to T. cruzi-induced immune response. The expression of cytokines (Ifng, Il10, Il6), chemokines (Ccl2, Ccl3 and Cxcl9) and the enzymes Arg1 and Nos2 were increased during T. cruzi infection but no changes were observed with Etoricoxib treatment. These results indicate the lack of effect in cardiac 
immune response due to COX-2 inhibition (Fig. 21).
Genetic deletion of 
Cycloxygenase-2 
COX-2 deficient mice show less parasitemia 
but no changes in heart parasite burden
Both wild-type and COX-2 deficient mice were infected intraperitoneally with 2000 blood trypomastigotes of T. cruzi. Parasitemia 
and survival was measured over time. COX-
2 deficient mice showed three times less parasitemia than wild-type infected controls at the peak of parasitemia (Fig. 22A). However, 
COX-2 deficiency did not affect cardiac parasite burden in infected mice, indicating that changes in parasitemia were not relevant for the outcome of the disease (Fig. 22B). Previous studies in the laboratory with different mouse models of infection, lead us to think that only big changes (at least more than 5 times) in parasitemia may 
influence the outcome of the disease. No wild-
type nor COX-2-/- infected mice died during the experiments that last until 8 weeks in some cases, even when 20.000 trypomastigotes were 
injected (Not shown). These parasitological 
data indicates that COX-2-/- and wild type 
(C57BL/6-129Sv) mice are resistant models of infection. 
Anti T. cruzi-specific antibody production is 
not altered in COX-2-/- infected miceIL-4 enhances the production of IgG1. But 
IFN-γ was shown to stimulate the secretion of IgG2a in concentrations at which it inhibits IL-4 induced production of IgG1 (Coffman et al., 1989). Since serum IgG1/IgG2a balance is related to the Th2/Th1cytokine balance, we determined anti-T.cruzi IgG1, IgG2a and total IgG levels throughout acute infection by ELISA. As shown in Fig. 23, the antibody level was similar in the two strains of mice over time, 
independently of COX-2 expression. These 
Figure 22│ Parasite burden in Trypanosoma cruzi 
infected wild-type and COX-2-/- mice. Wild-type (open 
circles and bars) and COX-2-/- (filled circles and bars) mice were infected with T. cruzi intraperitoneally. A│ Parasitemia checked every 2 days. Means ± SD are shown. B│ DNA from heart tissue was isolated at 7, 14 and 21 d.p.i. and T. cruzi 
specific qPCR with was performed. Representative means ± SD from at least three experiments are shown (n=4, 
for wild-type and COX-2-/-mice). Difference at the peak of 
parasitemia is significant * p< 0,05.
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results indirectly indicated that deletion of 
COX-2 gene expression did not alter the Th1/Th2 systemic balance during infection.
Macrophages of COX-2 deficient mice present 
less lipid bodies than wild-type upon T. cruzi 
infectionIt has been previously described that during 
T. cruzi infection macrophages increase the production of lipid bodies. These cellular organelles are one of the prostaglandin 
production sites identified (D’Avila et al., 2011). We have analyzed the presence of lipid bodies using Oil Red-O staining in infected heart sections and visualized the results by confocal microscopy. We observed that lipid bodies were less in number and smaller in size in cardiac 
infiltrating macrophages of COX-2 deficient mice than in wild-type mice (Fig. 24). Unfortunately, we were not able to quantify the signal due the background of the dye.
Cardiac inflammation is reduced in COX-2-/- 
miceStaining of T. cruzi infected heart sections 
from COX-2-/- mice showed less inflammatory 
infiltrates at 14 and 21 d.p.i. than in wild-type mice (Fig. 25A). Infiltration was quantified from images using the FIJI software and the 
Figure 23│Plasma antibodies against Trypanosoma cruzi during acute phase in COX-2 deficient mice. Blood was obtained by cardiac puncture from infected or non-infected mice and plasma was isolated. The ELISA was performed coating the plate with T. cruzi extracts from culture as described in Materials and methods. Means ± SD from two experiments of are 
shown (n=6, for wild-type and COX-2-/-mice). 
Figure 24│Lipid bodies formation within inflammatory 
cells in hearts of wild-type and COX-2 deficient mice Heart tissue was isolated at 14 d.p.i. from infected wild-
type or COX-2 deficient mice and frozen in OCT. Sections of organs were stained with DAPI for nuclei (blue) and antibodies for the macrophage marker CD68 (red) and Oil Red O (ORO) for lipid bodies (green). ORO also slightly 
stains muscle fibres. White arrows indicate the presence of lipid bodies. Representative images from 3 animals per group are shown. Scale bar is 20 microns length. 
differences of cell infiltration between COX-2-/- 
and wild-type mice were confirmed (Fig. 25B). In order to analyse the characteristics of 
the infiltrating cells, gene expression was 
quantified by RT-PCR and infected animals were compared to their non-infected controls. This would provide information about the nature 
of COX-2-/- cardiac inflammation and immune 
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Figure 25│Histologic analysis of cardiac tissue of Trypanosoma cruzi infected wild-type and COX-2-/- mice. Heart tissue was processed for Masson`s Trichromic histology staining at 14 and 21 d.p.i. Micrographs were taken as described in Materials and Methods. A│ Representative pictures of each group of mice. B│ Graph showing the quantification of cell 
infiltration using the FIJI software. Dot plot and means from one representative experiment of two are shown (n=5, for wild 
type and COX-2-/-mice). Differences between mouse strains are indicated *** p<0,001, ** p<0,01. Scale bar is 100 microns length.
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Figure 26│Cell infiltration, L-arginine and AA metabolizing enzymes expression during Trypanosoma cruzi 
infection in the heart of wild-type and COX-2 deficient mice. Expression was analysed by quantitative PCR. Heart tissue 
RNA was isolated at 7, 14 and 21 d.p.i. from infected, non-infected wild-type (open bars) or COX-2-/- mice (filled bars). Data 
were expressed as RQ calculated from CT values . Specific probes were utilized to analyze gene expression corresponding to: 
A│ Cd45, B│ Cd4, C│ Cd8, D│Cd68, E│Cd11c , F│ Arg1, G│ Nos2, H│ Ptgs1 and J│ Ptges. Means ± SD from a representative 
experiment out of four is shown (n=5, for wild-type and COX-2-/-mice). Differences between mouse strains are indicated * p<0.05 **p<0.01 ***p<0,001.
response. Samples were collected from the first three weeks of T. cruzi infection. Inflammation of cardiac tissue appeared at 14 d.p.i. in both 
wild-type and COX-2-/- mice. In agreement with 
histological findings, COX-2-/- mice showed less expression of the common leukocyte marker 
Cd45 at 14 d.p.i. than wild-type mice, but no changes were observed at 21 d.p.i. (Fig, 26A). Expression of the cellular markers Cd4, Cd68, and Cd11c gene, related with Th lymphocytes, macrophages and dendritic cells, respectively, 
was reduced at 14 and 21 d.p.i in COX-2-/- respect to wild-type mice (Fig, 26B,D,E). Expression of the CTL marker Cd8 was reduced in COX-2-/- at 14 d.p.i. and could be related with Cd45 expression at this moment (Fig, 26C). These results 
confirm the histological findings, revealing that lymphocytes and probably monocytes have a 
reduced participation in COX-2-/- infected mice 
cardiac inflammation. In contrast, Cd8 mRNA was strongly increased at 21 d.p.i. in wild-type 
and COX-2-/- mice, indicating that CTL activity 
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could compensate the decrease in other types 
of cells infiltrating the heart to fight against infection. There were not differences between mouse strains in Arg1 expression and data deviation was high within experimental groups (Fig. 26F). Nos2 mRNA decreased in COX-2-/- at 14 d.p.i., but surprisingly, it was higher than in wild-type at 21 d.p.i. (Fig. 26G). However, protein analysis by western blot showed less expression of both enzymes related with 
L-arginine metabolism at 14 d.p.i. in COX-2-/- mice respect to wild-type mice (Fig. 27). There was no induction of Ptgs1 (COX-1) expression 
to compensate the COX-2-/- deficiency. Ptges expression was increased upon infection but was 
less expressed in heart tissue from COX-2-/- mice (Fig. 26H,I). Ptges decreased expression seems 
to be associated with the reduced inflammation 
found in COX-2-/- T. cruzi infected mice. These 
results suggest that infiltrating leukocytes could be responsible for Ptges mRNA levels.
Figure 27│iNOS and Arginase-1 protein expression 
in Trypanosoma cruzi infected cardiac tissue of wild-
type and COX-2 deficient mice. At 14 d.p.i. hearts were collected and total protein extracts were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. Presence of iNOS and Arg-1 in infected and non-infected 
tissue was detected using specific antibodies. Ponceau staining is presented as a loading control. The extracts from 6 different infected mice were loaded. One representative experiment out of three is shown.
To characterise the immune response in COX-2-/- infected mice, gene expression of cytokines and chemokines were analysed. The expression of chemokines (Ccl2, Ccl3, Ccl4, Ccl5, Ccl7 and 
Cxcl9) and cytokines (Ifng, Tnf, Il6, Il4, Il13 and 
Il10) were significantly increased during T. cruzi 
infection of wild-type and COX-2-/- mice (Fig. 
28). However, chemokine expression presented 
different patterns in wild-type and COX-2-/- mice. 
Ccl3, Ccl5 and Ccl7 expression was significantly 
higher in wild-type mice than in COX-2-/- mice at 
14 d.p.i., but no significant changes were found between them at 21 d.p.i. (Fig. 28A,D,E). In contrast Ccl3 and Cxcl9 expression was similar 
at 14 d.p.i., but higher in COX-2-/- mice than in wild-type mice at 21 d.p.i. (Fig. 28B,F). Finally, 
Ccl4 expression was significantly reduced at 
14 d.p.i. but increased at 21 d.p.i. in COX-2-/- mice respect to wild-type mice (Fig. 28C). The decrease in the expression of four out of six chemokines studied could explain the decrease 
in inflammation observed by histologic analysis at 14 d.p.i. In addition, higher expression of Cxcl9 
could explain how the COX-2-/- model maintains the same level of Cd8 expression (Kastenmuller et al., 2013). Expression of pro-inflammatory cytokines Ifng, Tnf and Il6 was lower in COX-2-/- at 14 d.p.i respect to wild-type mice (Fig. 
28G,H,I). Expression of Il6 was drastically reduced at 21 d.p.i. in both mouse strains (Fig. 
28I). Ifng and Tnf expression did not decrease at 
21 d.p.i. in COX-2-/- when compared to the group 
sacrificed at 14 d.p.i. (Fig. 28G,H). Il4 and Il13 
did not decrease in COX-2 deficient mice (Fig. 
28J,K). Ifng was low and Il4 expression was high 
at 14 d.p.i. in COX-2-/- mice (Fig. 28K), indicating 
a possible imbalance of the Th1/Th2 profile. 
The anti-inflammatory cytokine Il10 showed less expression at both 14 and 21 d.p.i. in the 
COX-2-/- mouse model. Taken together these data suggest that inflammation is reduced 
in COX-2-/- but is maintained for longer time. 
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Figure 28│ Chemokine and cytokine expression in the heart of wild-type and COX-2 deficient mice during 
Trypanosoma cruzi infection. Expression was analysed by quantitative PCR of the corresponding mRNAs. Heart tissue 
RNA was isolated at 7, 14 and 21 d.p.i. from infected, non-infected wild-type (open bars) or COX-2-/- mice (filled bars). qPCR 
was performed and data were expressed as RQ calculated from CT values . Specific probes were utilized to analyze gene expression corresponding to: A│ CCl2 B│ Ccl3, C│ Ccl4, D│Ccl5, E│Ccl7, F│ Cxcl9, G│ Ifng, H│ Tnf, I│ Il6, J│ Il4, K│ Il13, and L│Il10. Means ± SD from two representative experiment out of four is shown (n=5, for wild-type and COX-2-/-mice). Differences between mouse strains are indicated * p<0.05 **p<0.01 ***p<0,001.
80
RESULTS.2
To check whether this process had a systemic 
incidence, we next analyzed TNF-α plasma level. 
At 14 d.p.i. TNF-α plasma level was increased 
in both wild-type and COX-2-/-models. But meanwhile wild-type mice showed a decrease 
in TNF-α plasma level at 21 d.p.i., in COX-2-/- mice was still high. (Fig. 29).
Figure 29│TNF-α concentration in serum of wild-type 
and COX-2 deficient mice during Trypanosoma cruzi 
infection. Serum from non-infected and infected wild-
type and COX-2-/- mice were collected at 14 and 21 d.p.i. 
Cytokine quantification by ELISA was performed following manufacturer instructions. Open bars represent the values 
of wild-type mice and filled bars COX-2-/- mice. Means ± SD from two experiments are shown (n=6, for wild-type and 
COX-2-/- mice). Differences between mouse strains are indicated * p<0.05.
Figure 30│ Edn1 expression during the acute phase 
of Trypanosoma cruzi infection in cardiac tissue. RNA from heart tissue was isolated at 7, 14, 21 and 28 d.p.i. and qPCR was performed. Results are expressed by RQ calculated from CT values as described in Materials and Methods. Open bars indicate the values for BALB/c mice 
and filled bars for C57BL/6 mice. Means ± SD from three independent experiments are shown (n=9, for wild-type 
and COX-2-/- mice). Differences between infected and non-infected mice is indicated ***p<0,001.
Endothelin-1 receptors are 
not involved in cardiac COX-2 
expression Endothelin-1 (ET-1) is the most potent vasoconstrictor peptide and has been related with T. cruzi infection physiopathology (Machado and Camargos, 2008) (Petkova et al., 2001). ET-1 has been found in different 
experimental models up regulating COX-2 expression, like endothelial (Lin et al., 2013), epithelial (Peng et al., 2008) and smooth muscle cells (Deacon and Knox, 2010). As was previously described, (Petkova et al., 2001) 
Edn1 mRNA is induced in T. cruzi infected heart in the mouse model (Fig. 30). We investigated the effects of treatment with Bosentan, a dual antagonist of ET A/ET B (receptors of ET-1), on the course of T. cruzi infection in C57BL/6 mice. 
Bosentan significantly increased parasitemia 
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Figure 31│ Parasite burden of Trypanosoma cruzi infected mice treated with an inhibitor of endothelin receptors. C57BL/6 mice were infected with T. cruzi and one group was treated with the endothelin receptors inhibitor Bosentan by gavage. A│ Parasitemia was monitored every 2 or 3 days. B│ DNA from heart tissue was isolated at 14 d.p.i. and qPCR using 
T. cruzi DNA standard was performed. Means ± SD from one experiment are shown (n=4). Differences between treated and non-treated infected mice is indicated * p< 0,05.
Figure 30│ Edn1 expression during the acute phase 
of Trypanosoma cruzi infection in cardiac tissue. RNA from heart tissue was isolated at 7, 14, 21 and 28 d.p.i. and qPCR was performed. Results are expressed by RQ calculated from CT values as described in Materials and Methods. Open bars indicate the values for BALB/c mice 
and filled bars for C57BL/6 mice. Means ± SD from three independent experiments are shown (n=9, for wild-type 
and COX-2-/- mice). Differences between infected and non-infected mice is indicated ***p<0,001.
with no increment of cardiac burden (Fig. 31). Bosentan did not affect the infection-associated increase in the cardiac levels of the cytokines 
Il10 or Tnf (Fig. 32B,C). Bosentan treatment of infected animals did not reduce the levels of 
COX-2 mRNA in the cardiac tissue (Fig. 32A). No change in cardiac hypertrophy was observed in Bosentan treated animals (Fig. 32D). 
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Genetic deletion of Prostaglandin 
E receptor 2 (EP-2)
The COX-2 deficient mouse is an interesting model of infection which has helped us to study 
the role of this enzyme in inflammation onset of T. cruzi infection. This enzyme enhances the production of PGH2 and with collaboration of the terminal synthases elaborates PGs, prostacyclins and thromboxanes (Stables and Gilroy, 2011). We cannot conclude which mediator is responsible for the effects because 
the use a COX-2-/- model impairs the production of all metabolites. These mediators act through different G protein coupled receptors and EP-2 is one of the four PGE2 receptors (Narumiya et al., 1999). PGE2 is the main COX-2 metabolite 
found in inflammation and is produced by 
infiltrating myeloid cells in T. cruzi infected cardiac tissue as we shown in Chapter 1. Hence, Dr. Shu Narumiya kindly provided us with the EP-2-/- in C57BL/6 mouse background and the same infection protocol was used to determine the role of this receptor in T. cruzi elicited 
inflammation. 
EP-2 deficiency did not modify parasite 
burden in Trypanosoma cruzi infected miceAs in previous experiments, both 
wild-type and EP-2 deficient mice were infected intraperitoneally with 2000 blood trypomastigotes of T. cruzi. Parasitemia and survival was measured every other day. No differences in parasitemia or heart parasite burden were observed between wild-type and 
EP-2 deficient mice (Fig. 33). No EP-2-/- mice died during the T. cruzi infection experiments. These results could indicate that the routes of parasite elimination are not directly affected by EP-2 signaling.
Figure 33│ Parasite burden in Trypanosoma cruzi 
infected wild-type and EP-2 -/- mice. Wild-type (open squares) and EP-2-/- (filled squares) mice were infected. 
A│ Parasitemia was monitored every 2 or 3 days (means ± SD are shown). B│ DNA from heart tissue was isolated at 14 and 21 d.p.i. and qPCR using T. cruzi DNA standard was performed. (n=5, for wild-type and EP-2-/- mice) and shown as dot plot and mean. Data from a representative experiment out of two performed are shown.
Anti-T. cruzi specific antibody production is 
not modified in EP-2-/- infected miceSince serum IgG1/IgG2a balance is related to the Th2/Th1 balance, we determined anti-T.cruzi IgG1, IgG2a and total IgG levels throughout acute infection by ELISA. As shown in Fig. 34, the antibody level was similar in the two strains of mice over time, independently of the EP-2 expression.
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Figure 34│Plasma antibodies against Trypanosoma cruzi during acute phase in EP-2 deficient mice. Blood was obtained by cardiac puncture from infected or non-infected mice at 21 d.p.i and plasma was isolated from wild-type (open bars) and EP-2-/- (filled bars) mice. The ELISA was performed coating the plate with T. cruzi extracts from culture. Means ± SD from two representative experiments of are shown (n=9). 
PGE2 signaling through EP-2 inhibition 
reduces cardiac inflammation 
Histologic analysis of cardiac inflammation in T. cruzi infected hearts from EP-2-/- showed 
less inflammatory infiltrates at 14 and 21 d.p.i. (Fig. 35A). Images were quantified using the FIJI software and the differences in cell 
infiltration between EP-2-/- and wild-type mice 
were confirmed (Fig. 35B).In order to analyse the characteristics of the 
infiltrating cells, gene expression was quantified by RT-PCR and infected animals were compared to their non-infected controls. Plasma and heart samples were collected at 14 and 21 d.p.i. in both wild-type and EP-2-/- mice. Expression of the common leukocyte marker Cd45 was decreased in EP-2-/- at 14 d.p.i but not at 21 d.p.i. (Fig, 36A). This decrease in Cd45 could 
explain the histological findings at 14 d.p.i. Cell surface markers Cd4, Cd8, F4/80 and Cd11c gene expression, related with Th lymphocytes, CTL, macrophages and dendritic cells, respectively, was not reduced at 14 d.p.i. (Fig, 36B-E). However, Cd8, F4/80 and Cd11c gene expression was increased at 21 d.p.i. in EP-2-/- respect to wild-type mice (Fig, 36C-E). Ptgs2 (COX-2) gene expression was reduced in EP-2-/- at 14 d.p.i. (Fig. 36F), this result is also in agreement with the histologic analysis showing that EP-2-/- 
mice presented less cardiac inflammation than wild-type mice. No changes were observed in Alox15 gene expression (Fig. 36G). There were no differences between mouse strains in 
Nos2 expression (Fig. 36H), but Arg1 mRNA expression was higher in EP-2-/- mice at 14 and 21 d.p.i. (Fig. 36I). Increment of several of these genes at 21 d.p.i. may be caused by a failure in 
the resolution of inflammation due to the EP-2 
signalling deficiency.To characterise the immune response of infected EP-2-/- mice, gene expression of cytokines and chemokines were analysed. The expression of chemokines (Ccl2, Ccl5 and 
Cxcl9) and cytokines (Ifng, Tnf, Il6, Il4, Il10 and 
Il12) were significant increased during T. cruzi infection of both EP-2-/- and wild-type (Fig. 37). When EP-2-/- mice chemokine expression was compared to wild type expression we observed 
different patterns but quite similar to COX-2-/- infected mice. Ccl2 expression was reduced at 14 d.p.i. in the EP-2-/- but no significant changes were found at 21 d.p.i. (Fig. 37A). In contrast 
Cxcl9 expression remained the same at 14 d.p.i. and increased at 21 d.p.i. in EP-2-/- mice (Fig. 
37C). However, no statistical differences were found in Ccl5 expression (Fig. 37B). Expression 
of pro-inflammatory cytokines Ifng, Il12 and Il6, the Th2 cytokine Il4 and the anti-inflammatory cytokine Il10 was reduced in EP-2-/- at 14 d.p.i. 
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Figure 35│ Histologic analysis of cardiac tissue of Trypanosoma cruzi infected wild-type and EP-2-/- mice. Masson`s Trichromic staining was performed in hearts from mice at 21 d.p.i. Micrographs were taken as described in Materials and Methods. Representative pictures of each group were selected. A│ Representative pictures of infected (21 d.p.i.) and non-infected (NI) wild-type and EP-2-/- mice. B│ Graph showing the quantification of cell infiltration using the FIJI software. Dot 
plot and means for wild-type (open circles) and EP-2-/- (filled circles) mice from one experiment are shown (n=4, for each group of mice). Differences between mouse strains are indicated *** p<0,001. Scale bar is 100 microns length.
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Figure 36│ Cell infiltration and expression of L-arginine and AA metabolizing enzymes during Trypanosoma cruzi 
infection in the heart of wild-type and EP-2 deficient mice. Expression was analysed by quantitative PCR. Heart tissue RNA was isolated at 14 and 21 d.p.i. from infected, non-infected wild-type (open bars) or EP-2-/- mice (filled bars). qPCR 
was performed and data were expressed as RQ calculated from CT values. Specific probes were utilized to analyze gene expression corresponding to: A│ Cd45, B│ Cd4, C│ Cd8, D│F4/80 (Emr1) , E│Cd11c , F│ Ptgs2, G│ Alox15, H│ Nos2 and J│ Arg1. Means ± SD from one representative experiment out of two is shown (n=4, for wild-type and EP-2-/- mice). Differences between mouse strains are indicated * p<0.05 **p<0.01.
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Figure 37│ Chemokine and cytokine expression in heart tissue of wild type and EP-2 deficient mice during 
Trypanosoma cruzi infection. Expression was analysed by quantitative PCR of the corresponding mRNAs. Heart tissue RNA was isolated at 14 and 21 d.p.i. from infected and non-infected wild-type (open bars) or EP-2-/- mice (filled bars). qPCR 
was performed and data were expressed as RQ calculated from CT values. Specific probes were utilized to analyze gene expression corresponding to: A│ CCl2 B│ Ccl5, C│ Cxcl9, D│Ifng, E│Tnf, F│ Il12, G│ Il6, H│ Il4 and I│ Il10. Means ± SD from 
a representative experiment out of two is shown (n=4, for wild-type and COX-2-/-mice). Differences between mouse strains are indicated * p<0.05 **p<0.01 ***p<0,001.
compared to wild-type (Fig. 37D,F,G,H,I). However, Tnf expression did not change at 14 d.p.i. and increased its level at 21 d.p.i. (Fig. 
37E). No changes were observed in TNF-α plasma levels between the mouse models (Fig. 
38). Taken together these data suggest that 
EP-2 signaling has an inflammatory role in T. 
cruzi infected heart. Surprisingly this process 
seems to be TNF-α-independent.
Macrophage activation and not 
migration could responsible for the 
decrease of inflammation of EP-2-/- mice
In order to find an explanation for the 
reduced inflammation in EP-2-/- infected mice and due to the central role of macrophages in T. 
cruzi infection, we decided to analyze the effects 
of EP-2 deficiency in migration and activation. Previous works have described a role for PGE2 
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Figure 38│ TNF-α concentration in serum of wild-type 
and EP-2 deficient mice in Trypanosoma cruzi infection. Serum from non-infected and infected wild-type and EP-2-/- mice were collected. Cytokine quantification by ELISA was performed following manufacturer instructions. Open 
bars represent the values of wild-type mice and filled bars EP2-/- mice. Means ± SD from one experiment are shown (n=5, for each group of mice). 
Figure 39│Cell migration of peritoneal cells in wild 
type and EP-2 deficient mice. A│ Groups of wild-type (open bars) and EP-2-/- (filled bars) mice were injected with thyoglicollate solution and peritoneal exudate cells were collected and counted after 4 days. B│ Thyoglicollate elicited cells were cultured in Transwell plates as described in Materials and Methods to perform a macrophage migration assay to RANTES. This migration was normalized to migration from 2% FBS to 5% FBS. Means with SD from 5 mice per group are shown. 
in leukocyte migration (Panzer and Uguccioni, 2004) . Thus, peritoneal macrophages were used 
in our migration experiments. We first studied the migration in the aseptic peritonitis model in response to thyoglicollate. No differences were found between EP-2-/- and wild type in total number of cells at 4 days post infection, time at which most of the peritoneal cells were macrophages (Fig. 39A). We performed an in 
vitro migration assay using these macrophages placed in a two chamber system separated by permeable membrane with 8 µm pores. CCL5 in RPMI 5% FCS was used as stimulus for cell migration, but neither we found any difference between EP-2-/- and wild type (Fig. 39B). As no differences were found in migration, we next focus in activation of macrophages, as they play 
a key role in the initiation of inflammation. When macrophages become activated they express high levels of MHC-II in order to present antigen to lymphocytes. Spleens from wild-type and EP-2-/-mice were collected and 
cells were analyzed by flow citometry. Myeloid cells were selected using the CD11b marker antibody and MHC-II expression was analyzed 
(Fig. 40A). The results show that the percentage of CD11b+ cells from EP-2-/- that express MHC-II 
was lower than wild type. Mean fluorescence intensity (which is related with the level of expression per cell) was also decreased in EP-2-/- and is indicative of activation impairment. Despite we have not analyzed lymphocyte and other cell type activation, we can concluded that EP-2 signaling is important for macrophage MHC-II surface expression and could be 
related with the reduced cardiac inflammation.  
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Figure 40│ MHC-II surface expression of EP-2 deficient macrophages. Spleens from infected and non-infected mice, wild-type and EP2-/- mice were collected at 14 d.p.i. mechanically disrupted and analyzed by flow citometry. A│ Representative quantile countour plots (10% probability) are shown. MHC-II positive cells are gated with a blue square. CD11b+ were previously gated according to isotypic controls. B│ Dot plot representing the percentage of MHC-II expressing cells within CD11b+ gated cells. C│ Dot plot showing mean fluorescence intensity of the same populations. Data from a representative experiment of two are shown (n=5). Differences between mouse strains are indicated *p<0.05, ***p<0.001.
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A generalized immunosuppression has been described in T. cruzi experimental infected animals (Abrahamsohn and Coffman, 1995). Several mechanisms have been proposed to explain this phenomenon being the action of PGE2 one of them (Michelin et al., 2005). 
All the previous work was performed using 
COX-2 selective and non-selective inhibitors administered in vivo to the infected animals or added ex vivo to the cultured cells, reviewed in (Machado et al., 2011). However, the role of PGE2 in immunosuppression has not been completely elucidated. To further address this we performed in vitro 
stimulation of spleen cells from infected COX-2 deficient mice. As previously described (Goni et al., 2002) spleen cells from T. cruzi infected wild type animals showed a NO-dependent suppression of proliferation upon concanavalin A stimulation. Remarkably, a reduced immunosuppression was found at 14 d.p.i and 21 d.p.i. in spleen cells from 
COX-2-/- infected mice (Fig. 41A). However, no changes were observed in the spleen 
Role of cyclooxygenases in the immunosuppression observed in 
the acute phase of Trypanosoma cruzi infection
Figure 41│Splenomegaly and spleen cell proliferation 
in the acute phase of Trypanosoma cruzi infection of 
wild-type and COX-2 deficient mice. Spleens from in-
fected and non-infected wild type (open circles) and COX-2-/- (filled bars) were collected at 14 and 21 d.p.i. Spleen cells were mechanically obtained counted and cultured in presence of stimulus. A│ Proliferation of cells stimulated with ConA 1μg/ml. B│ Splenocytes were counted with a hemocytometer. All differences respect to the non-infected 
groups were statistically significant (ANOVA two-way). Differences between mouse strain in cell proliferation are indicated *p<0,05 (n=6-12, per each group). Dot plot and means from three independent experiments are shown.
Figure 42│Analysis of Gr-1+ cells in spleen of infected 
COX-2 deficient mice. Spleens from wild-type and COX-2-/- infected and non-infected mice were collected at 14 d.p.i. 
Organs were disrupted and analyzed by flow citometry. Numbers of CD11b +/ Gr-1+ of infected wild-type and 
COX-2-/- mice are shown. Open bars represent wild-type 
mice and filled bars represent COX-2-/- mice. Data from a representative experiment of two are shown (n=4). Differences between infected and non-infected group are indicated * p<0,05.
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cell number at any d.p.i. studied (Fig. 41B). Production of NO by CD11b+ GR-1+ spleen 
infiltrating cells has been previously described to play a role in the immunosuppression in the acute phase of infection (Goni et al., 2002). We 
performed flow citometry analysis of this cell 
population in the COX-2 deficient model, finding no changes in cell number respect to wild-type mice (Fig. 42). These results lead us to think that the reduced immunosuppression could be due to a functional recovery of T cells more than a change in CD11b+ GR-1+ infiltration. 
Next, we performed the same experiment using the PGE2 receptor deficient mice (EP-2-/-), but no differences with the wild type were found in proliferation or in total cell number (Fig. 43). It suggests that EP-2 signalling was not essential for the immunosuppression. In order to analyze whether PGE2 generation in vitro was necessary for the immunosuppression we added different cyclooxygenase inhibitors to the culture medium of the spleen cells. No recovery from immunosuppression was observed when 10 µM indomethacin, 0,1 µM NS398 or 0,1 µM celecoxib was added to spleen cell cultures (Fig. 44). Neither was observed when drugs were used 2 times more concentrated in the case of indomethacin and 10 times more concentrated in the case of NS398 and celecoib (Not shown). 
Figure 43│Splenomegaly and spleen cell proliferation 
during acute phase of Trypanosoma cruzi infection 
of wild-type and EP-2 receptor deficient mice. Spleens from infected and non-infected wild-type (open circles) and EP-2-/- (filled circles) mice were collected at 14 d.p.i. A│ Number of spleen cells was counted with a hemocytometer and B│ cells were cultured in presence of ConA 1μg/ml. Dot plot and means ± SD from a representative experiment of two are shown (n=5, per each group of mice).
Figure 44│ Effects of cyclooxygenase inhibitors added 
ex vivo in the proliferation of spleen cells proliferation 
from Trypanosoma cruzi infected mice. Spleens from in-fected and non-infected BALB/c were collected at 21 d.p.i. Spleen cells were cultured in the presence of anti-CD3/CD28 antibodies; 5μg/ml, 1μg/ml . Open and filled bars represent cells from non-infected and infected animals, 
respectively. Not significant changes were observed when cyclooxygenase inhibitors were added (10 µM Indometha-cin, 0,1 µM NS398 or 0,1 µM Celecoxib). Means ± SD from two independent experiments are shown (n=9).
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Figure 45│ PGE2 production by spleen cells from 
Trypanosoma cruzi infected mice during acute 
phase of infection. Spleen cells were cultured 48 hours. Supernatants were collected to measure PGE2 using an EIA kit following manufacturer instructions. B│ PGE2 secretion of non-infected and infected C57BL/6 mice at 7, 14 and 21 d.p.i. Differences between infected and non-infected mice are represented *p<0.05. B│ PGE2 secretion of non-
infected and infected wild type (open bars) and COX-2-/- 
(filled bars) at 14 d.p.i. Means ± SD from a representative experiment out of two are shown. (n=3, per each group of mice). 
Figure 46│ Expression of cyclooxygenases and 
prostaglandin E terminal synthase in the spleen 
during the acute phase of Trypanosoma cruzi infection 
in wild-type and COX-2-/- mice. Spleens from infected and 
non-infected wild type (open bars) and COX-2-/- (filled bars) were collected at 14 d.p.i. Spleen cells were mechanically obtained. The RNA was isolated and protein extract were obtained. A│ Graphs showing mRNA quantification of 
Ptgs2 and Ptges by qPCR expressed as RQ calculated from CT values as described in Materials and Methods. Means ± SD from a representative experiment of two are shown (n=5, per each group of mice). Enzyme expression of infected mice were compared to their respective non-infected controls ***p<0.001 *p<0.05. B│15 micrograms of total protein extracts were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. Presence of 
COX-1 and actin were detected using specific polyclonal antibodies. Anti-actin antibody was used as a loading control. The extract from 2 or 3 different mice were loaded. A representative experiment out of two is shown.
We conclude that COX-2 activity is in part responsible for developing the immunosuppression in vivo but COX-2 pharmacological inhibition did not reduce immunosuppression in vitro. Consequently, we analyzed PGE2 secretion of spleen cells 
from infected COX-2-/- and wild-type mice. Splenocytes from infected wild-type mice at 14 d.p.i. and 21 d.p.i. produced PGE2 in culture (Fig. 45A). When cells from infected COX-2 
deficient mice were cultured they surprisingly secreted some PGE2 to the supernatant (Fig. 45B). Nonetheless, we confirmed that 
expression of COX-2 mRNA was absent in COX-2 
deficient mice (Fig. 46A).Then, one possibility to explain PGE2 secretion in COX-2 deficient mice 
could be by up-regulation of COX-1 expression. Indeed, we found an increase of the expression 
of COX-1 protein obtained by western blot that could explain PGE2 secretion by infected COX-2 
deficient mice (Fig. 46C). In addition, studying the mRNA expression of PGE2 synthase (Ptges) in the infected spleen we found an increment 
of its expression in COX-2 deficient and wild-type mice (Fig. 46B). As nitric oxide produced by iNOS was involved in immunosuppression (Goni et al., 2002)(Gutierrez et al., 2009) we studied the expression of this enzyme in protein 
extracts from COX-2 deficient spleen cells. We 
found that COX-2 deficient mice expressed less iNOS protein in spleen after infection (Fig. 47). Therefore, a decrease in iNOS expression could explain the partial recovery of proliferation 
observed in infected COX-2 deficient mice respect to wild-type ones. 
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Figure 47│ Expression of iNOS in spleen of T. cruzi 
infected wild-type and COX-2-/-mice. Spleens from 
infected and non-infected WT and COX-2-/- were collected at 14 d.p.i. Spleen cells were mechanically processed and protein extract were obtained. 15 micrograms of total protein extracts were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. The presence 
of iNOS and actin were detected using specific polyclonal antibodies. Anti-actin antibody was used as a loading control. A│ The extract from 3 infected mice and non-infected controls were loaded. B│ Relative density of iNOS 
specific bands normalized respect to actin bands of one experiment. Data from a representative experiment out of four performed is shown.
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Cycloxygenase-2 (COX-2) is expressed by heart infiltrating macrophages of 
Trypanosoma cruzi infected mice.  Purified infiltrating CD11b+ myeloid cells are able to produce PGE2 and PGF2α, involved in immune regulation. 
12/15 Lipoxygenase gene expression is increased in cardiac tissue during the acute 
phase of Trypanosoma cruzi infection. Enzyme expression is IL-4 receptor dependent.
Trypanosoma cruzi alone does not produce prostaglandins nor thromboxans. 
Trypanosoma cruzi does not have the metabolic routes to elaborate prostaglandins or thromboxans from arachidonic acid.
COX-2 deficiency produces no changes in parasite burden but reduces cardiac 
inflammation induced by Trypanosoma cruzi infection and this acute inflammation 
seems  to be longer. Thus, COX-2 may play a role in the initiation as well as resolution of 
inflammation.
Defective Prostaglandin E receptor-2 signalling reduces immune cell infiltration 
and inflammation in the cardiac tissue during the acute phase of Trypanosoma 
cruzi infection.  This effect can be related with macrophage inability for full activation as evidenced by the decreased ability of EP2-/- macrophages to express MHC-II in the cell surface. 
COX-2 deficiency reduces T cell immunosuppression observed during the acute 
phase of Trypanosoma cruzi infection. Defective iNOS induction in the absence of 
COX-2 could explain the reduced immunosuppression in spleen cells from COX-2-/- mice infected by Trypanosoma cruzi.
96
CONCLUSIONS
Los macrófagos que infiltran el corazón de ratones infectados con Trypanosoma cruzi 
expresan COX-2. Las células mieloides CD11b+ purificadas del infiltrado son capaces de producir PGE2 y PFG2α.
La expresión de la 12/15-Lipoxigenasa aumenta en el tejido cardiaco durante 
la fase aguda de la infección por Trypanosoma cruzi. La expresión de la enzima es dependiente del receptor de IL-4.
Trypanosoma cruzi no es capaz de producir por sí mismo ni prostaglandinas 
ni tromboxanos. Trypanosoma cruzi no posee las rutas metabólicas para producir prostaglandinas y tromboxanos a partir del ácido araquidónico.
La deficiencia de COX-2  no produce cambios en la carga parasitaria  pero reduce la 
inflamación inducida por la infección con Trypanosoma cruzi, aunque prolonga esta 
inflamación durante la fase aguda. COX-2 podría tener un papel tanto en la iniciación 
como en la resolución de la inflamación.
La ausencia de la señalización de PGE2 a través del receptor EP-2 reduce la 
infiltración celular y la inflamación en el tejido cardiaco durante la fase aguda 
de la infección por Trypanosoma cruzi. Este proceso puede estar relacionado con la incapacidad del macrófago de activarse completamente al observarse que los macrófagos 
deficientes para EP-2 expresan menos MHC-II en la superficie.
La deficiencia de COX-2 reduce la inmunosupresión de las células T que sucede en 
la fase aguda de la infección por Trypanosoma cruzi. La reducción de la inducción 
de la iNOS en ausencia de COX-2 podría explicar la reducción de la inmunosupresión del 
bazo en los ratones COX-2-/- infectados con Trypanosoma cruzi.
DISCUSSION
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revealed an increase of COX-2 and 12/15-LO expression (12/15-LO) upon infection and two 
cellular sources of COX-2 were characterized: cardiomyocytes and macrophages. Besides, macrophages isolated from infected heart produces PGE2 from arachidonic acid. We next 
assessed whether COX-2 and PGE2 would be 
important in cardiac inflammation. For this, we 
used mice deficient in COX-2 and PGE2 receptor 
(EP-2) and pharmacological inhibition of COX-2. Our results showed that the extent of myocarditis 
was reduced in the deficient models, suggesting 
a pro-inflammatory role of COX-2 and PGE2 in 
the onset of cardiac inflammation. 
Cyclooxygenases and terminal synthases 
expression in heart of Trypanosoma cruzi 
infected mice Increased levels of prostaglandins in serum were observed when mice were infected with T. cruzi (Cardoni and Antunez, 2004). Since this and other lipid mediators were suggested as important in T. cruzi immune response (Machado et al., 2011), expression of the producing enzymes was analyzed in the infected heart of resistant and susceptible 
murine models. As  expected, COX-2 gene expression was increased in the heart tissue 
due the inflammation. Our laboratory has also recently published that cardiomyocytes 
express COX-2 upon T. cruzi infection (Corral et al., 2013). Nevertheless, in this work we have focused in the macrophage contribution. A previous study has described an increase in 
COX-1 and COX-2 protein expression in infected cardiac tissue by immunohistochemistry (Abdalla et al., 2008); however, we consider that appropriate controls were not presented in that study, In contrast, in the present study, COX-2 protein expression was clearly demonstrated in a CD11b+ CD68+ macrophage population in the infected heart. We found a perinuclear 
  Leukocyte infiltration in Trypanosoma 
cruzi infected heart is a key event in parasite elimination and eventually in pathology generation. During the acute phase of infection a severe myocarditis has been described in humans and experimental models of infection. Many immune cell types have been shown to have a direct or indirect role in parasite elicited immune response (Truyens and Carlier, 2010). The role of cytokines in T. cruzi infection has been widely studied (Abrahamsohn and Coffman, 1996; Graefe et al., 2003; Silva et al., 1995). However, non-protein mediators have also an important role in immune response. For instance, nitric oxide is a gas with many biological actions as vasodilation, intracellular-pathogen killing or regulation of protein function by nitrosylation and is related with the damaging oxidative stress and immunosuppression. Besides, derivatives of fatty acids also have a wide range of actions in the organism. Metabolism of the arachidonic acid leads to generation of eicosanoids which includes compounds as prostaglandins, thromboxanes, leukotrienes and lipoxins (Stables and Gilroy, 2011). All these molecules have important roles in homeostasis and immune response regulation (Harris et al., 2002). The enzymes implied in their production, (cyclooxygenases, lipoxygenases, p450 cytochrome) have been investigated for many years (Dubois et al., 1998; Levy et al., 1993). In fact, NSAIDs, the most widely 
used anti-inflammatory agents, are inhibitors of cyclooxygenases. Despite this, scarce data about the cell source of the key enzymes of eicosanoids production in experimental Trypanosoma cruzi infection exists and the few published using pharmacological inhibition of cyclooxygenases are contradictory (Machado et al., 2011). Thus, we addressed the role of these mediators in the acute phase of T. cruzi infection using a murine model. The analysis of cardiac tissue 
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pattern of COX-2 expression in macrophage, as described (Bozza et al., 2011; Morita et al., 1995). Some of the pictures revealed a 
possible COX-2 expression in the nuclear envelope similar to what has been described in endothelial cells (Parfenova et al., 2001). We corroborated this data by adding radiolabelled arachidonic acid to macrophages isolated from the infected heart, which produced PGE2 and PGF
2α
. This result is in agreement to published data regarding prostaglandins produced during infection (Cardoni and Antunez, 2004; Oliveira et al., 2010). In order to check if macrophages from other origin produce these prostaglandins 
during infection we purified CD11b+ cells from the peritoneum of infected mice and PGE2 production was also evidenced. But these cells were unable to produce all the prostaglandins that the cells from the peritoneum of non-
infected animals can produce. Infiltration of CD11b+ COX-2 expressing cells and exit of the resident peritoneal macrophages could explain the different generation of prostaglandins. In this regard, Cassado Ados et al. have described how the peritoneal cell populations change during T. cruzi infection, from resident to an 
inflammatory phenotype (Cassado Ados et al.). Moreover, we cannot exclude the presence of B-1 cells in our experiment because is already described that these cells can express CD11b in its surface (Hastings et al., 2006) adhere to the culture plate, transform to phagocytes (Almeida et al., 2001; Parra et al., 2012) and 
express COX-2 (Graf et al., 1999). In addition, B-1 cell maturation in T. cruzi infected mice has been described (Merino et al., 2012). Thus, some of this peritoneal cell PGE2 generation could come from B-1 cells. Moreover, induction 
of COX-2 expression by macrophages seems to need a stronger stimuli than infection alone, 
probably TNF-α and IFN-γ (Munoz-Fernandez et al., 1992) because infection alone could pass 
mostly unnoticed by the macrophage regarding its activation status (Thi et al., 2012).We have also found that CD68- cells 
express COX-2 in infected cardiac tissue. Since lymphocytes are important regulators in T. cruzi elicited immune response (Tarleton et al., 1996; Tarleton et al., 1992), infiltrate the infected heart tissue; (Tarleton et al., 1994) 
and COX-2 expression has been shown in T cells upon activation (Iniguez et al., 1999), we 
checked whether infiltrating CD4+ expressed 
COX-2 cells in our samples. However, no COX-2 expression was detected in CD4+ lymphocytes. 
Nevertheless, COX-2 expressing CD8+ T cells cannot be ruled out since PGE2 production by CD8+ T lymphocytes has been described in the context of T. cruzi infection (Celentano et al., 1995; Sterin-Borda et al., 1996). Further study is necessary to accurately determine the non-
macrophage COX-2 sources in the infected 
heart. Multicolor flow cytometry analysis could be the best suited technique to clarify this issue.Increase of Txas and Hpgds gene expression 
suggests the production of TXA2 and PGD2 and its metabolites respectively in infected cardiac 
tissue. TXA2 could have a pro-inflammatory role in monocytes (Caughey et al., 1997) besides its vascular functions (Cheng et al., 2002). In contrast, PGD2 has anti-inflammatory actions (Bellows et al., 2006; Kanaoka and Urade, 2003). Resistant mice (C57BL/6) showed higher expression of Hpgds and lower expression of Txas than the susceptible model (BALB/c). This could be related with the fact 
that inflammation in resistant mice ends earlier than in susceptible mice (Cuervo et al., 2008). The expression of the terminal synthase of prostacyclin, PGI2 (Pgis) (Dorris and Peebles, 2012) was not studied. Nonetheless, it could be of interest to analyze its expression, since PGI2 metabolite has been detected in infected 
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animals (Cardoni and Antunez, 2004). Also, PGI2 could be secreted to counteract the deleterious 
effect of inflammation (Camacho et al., 2011) and ischemic processes that occurs during infection (Marin-Neto et al., 2007). Accurate 
quantification of endogenous eicosanoids in the infected cardiac tissue must be performed in order to have a global perspective to integrate the different mediators in their physiological context (Blaho et al., 2009). 
 On the other hand, COX-2 expressing macrophages seem to be different from the CD11b+ myeloid expressing Arginase 1 
(Arg-1) that also infiltrate the infected heart (Cuervo et al., 2008). This remarkable finding suggests a difference in the function of these two macrophage populations. Resident macrophages of C57BL/6 mice heart have a gene expression signature close to M2 (Pinto et al., 2012) and could be implied in tissue 
repair and fibrosis (Wynn and Barron, 2010). Furthermore, in situ proliferation of resident macrophages has been described in a helminth infection model where the Th2 response is important (Jenkins et al., 2011). In our model, 
monocyte cardiac infiltration could be very 
important to fight the parasite and also to repair the damaged muscular tissue (Arnold et al., 2007). Arg-1+ macrophages could be related 
with repair meanwhile COX-2 expressing 
macrophages could be linked to inflammation. But this explanation is probably simplistic and far from a more complex reality because macrophages are highly heterogeneous cells that can rapidly change their function in response to local microenviromental signals, playing key roles in the initiation and resolution 
of inflammation and tissue homeostasis (Murray and Wynn, 2011), therefore this may constitute an amenable hypothesis to test.Regarding cardiomyocyte contribution to 
prostaglandin secretion, we recently described that T. cruzi infection and Endothelin-1 cooperatively activated the Ca2+/calcineurin/Nuclear Factor of Activated T-cells (NFAT) signaling pathway in atrial myocytes, leading 
to COX-2 protein expression and increased PGE2, TXA2 and PGF2α secretion (Corral et al., 2013). PGF
2α
 and ET-1 (Bouallegue et al., 2007) may contribute in a cooperative way to induce chagasic cardiac hypertrophy (Rossi, 1995; Rossi, 2001) since PGF
2α
 can also activate the NFAT pathway to induce cardiomyocyte enlargement (Lai et al., 1996; Hernandez-Subira E, unpublished results). 
Lipoxygenase expression in cardiac tissue 
during the acute phase of Trypanosoma cruzi 
infectionLipoxygenases (LO) enzymes generate lipid mediators that are involved in a number of 
significant physiological and pathological states (Dobrian et al., 2011). In the present work we have analyzed the expression of 5-LO, 5-LO activating protein (FLAP), 12-LO and 12/15-LO. 5-LO and FLAP are responsible for leukotrienes (LTs) synthesis, which have an important active 
role in inflammation. These enzymes have been studied in different models of cardiovascular disease (Poeckel and Funk, 2010) In addition, LO are considered good targets for anti-
inflammatory therapies (Rubin and Mollison, 2007; Sampson, 2009). Previous works with 
5-LO deficient mice and enzyme inhibitors were 
used to define the role of endogenous LTs in 
inflammatory responses elicited by infection with T. cruzi. One group described how the infected 5-LO-/- mice died meanwhile wild type did not (Borges et al., 2009; Panis et al., 2011). However, another group described how 5-LO 
deficiency improved survival and reduced 
cardiac inflammation (Pavanelli et al., 2010). Despite the fact that both groups used the 
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same mouse and parasite strain combination, Pavanelli et al. used 50 times less parasite than the others to infect mice and this may be 
determinant in the final outcome of T. cruzi infection. On the other hand, when 5-LO was pharmacologically inhibited during T. cruzi infection no changes were found in survival, although LTB4 induced parasite killing by iNOS 
in vitro (Talvani et al., 2002). In our studies we could not detect any increase of Alox5 (5-LO) mRNA, in fact we found a reduction of the mRNA expression in the infected hearts. Nevertheless, Alox5ap (FLAP) gene expression was increased in both BALB/c and C57BL/6 models of infection. Alox5ap induction in the 
inflamed infected heart could be important, even in absence of changes in Alox5 levels, because changes in FLAP expression have been 
shown to modify the profile of LTs produced by 5-LO (Peters-Golden and Brock, 2003). Unfortunately, we could not detect the protein by western blotting in whole cardiac extracts or 
purified macrophages (not shown) and thus, 
the cell source for FLAP was not identified.12/15-Lipoxigenase (12/15-LO) is preferentially expressed in mammals by monocyte and macrophages following the action of T helper type 2 cytokines IL-4 and IL-13 (Heydeck et al., 1998). This enzyme is responsible for production of different lipid mediators that 
have an important role inflammatory diseases (Dobrian et al., 2011). Hydroxyeicosatetraenoic acids (HETEs)metabolites are produced by 
12/15-LO that can bind PPAR-γ exerting anti-
inflammatory properties (Limor et al., 2008; Subbarayan et al., 2006). Lipoxins (LXs) are other 12/15-LO derivatives with an important 
role in the resolution of inflammation (Parkinson, 2006). In the present work mRNA analysis in infected cardiac tissue revealed an 
Alox15 (12/15-LO gene) expression during the acute phase of T. cruzi infection in both BALB/c 
and C57BL/6 mouse strain. The expression was higher in C57BL/6 than BALB/c, which may be related with a better response against the 
parasite and faster resolution of inflammation. 
IL-4 deficient infected mice showed a reduced 
Alox15 expression in heart tissue compared to wild-type mice, indicating its dependency on IL-4. When histological sections were analyzed 
we could not find the cell type that produces the protein. However, we could discard CD68+ 
macrophages and fibroblasts as responsible for the enzyme expression. These results did not 
fit with the accepted the idea that macrophages are the main cells that express the enzyme (Kuhn and O’Donnell, 2006). However, CD68low macrophages have been described to express 12/15-LO (Rabinowitz and Gordon, 1991). The use of an anti-CD11b and anti-12/15-LO antibodies to stain heart tissue sections could provide an answer to this question. 
In order to detect fibroblasts we used an antibody against the intermediate 
cytoskeleton filament vimentin (Lian et al., 2012). Surprisingly, staining of amastigotes was detected (Fig. 16C). One of the reasons for detecting the vimentin signal in the parasites could be unrelated to the cytoskeleton, since vimentin has been described as a macrophage secretion product with antimicrobial properties (Mor-Vaknin et al., 2003), which is deposited in cardiac cells (Ise et al., 2010). Despite the 
absence of definitive characterization of the cell type producing 12/15-LO the fact that is increased in infected hearts suggests a role in the 
infection. During local contained inflammation, 
the first line of host defense, namely the neutrophils, die at the site and can undergo cell death by apoptosis as well as necrosis. As 
part of resolution, LX signal macrophages to enhance the uptake of the remains of these cells (Serhan et al., 2011). It is known that the uptake of apoptotic cells by macrophages 
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induces LXs secretion (Freire-de-Lima et al., 2006). This process can modify the functions 
of the macrophage impairing inflammation and allowing T. cruzi persistence (Freire-de-Lima et al., 2000). In this regard, similar results were found in Leishmania major infection (van Zandbergen et al., 2006; Wenzel and Van Zandbergen, 2009). Moreover, 12/15-LO has been also linked with cardiac infarct (Kayama et al., 2009) and macrophage recruitment (Wen et al., 2008). Therefore, this enzyme may serve in acute T.cruzi infection to enhance macrophage recruitment and once those cells reach the infected heart help to facilitate tissue repair. 12/15-LO deficient mice showed an increased mortality when infected by Toxoplasma gondii (and intracellular parasite)  (Middleton et al., 2009). Hence, the use of 12/15-LO deficient model (Sun and Funk, 1996) could provide an interesting tool to further analyze the role of the enzyme in T. cruzi infection.
Trypanosoma cruzi metabolism of 
arachidonic acidProduction of arachidonic acid (AA) and other fatty acid bioactive metabolites by human pathogens has been described and reviewed (Kubata et al., 2007). Not only protozoan but also helminthes and fungi can produce these mediators. Compared to mammalian lipid mediator production, little is known regarding the biochemistry of their production by eukaryotic microorganisms and no cyclooxygenase–like gene has been described in parasite sequenced genomes (Noverr et al., 2003). Nonetheless, those lipids may regulate some parasite functions (Figarella et al., 2005) as well as to contribute to host-pathogen communication in the context of the immune responses regulation (Kilunga Kubata et al., 1998). Phospholipases (PLs) are the first enzymes implied in AA metabolism because they 
could release free fatty acid from membrane phospholipids. Phospholipase activities have been described in T. brucei, Leishmania sp. and 
T. cruzi. TcPLA1 enzyme has been even cloned from T. cruzi, but despite some evidences, no T. cruzi PLA2 has been well characterized (Belaunzaran et al., 2011). Remarkably, no cyclooxygenase activity has been cloned from 
T. cruzi. However, two different research groups in Japan and USA have described a parasite PGF
2α
 synthase activity (Kubata et al., 2002) and 
a TXA2 synthase activity (Ashton et al., 2007), reviewed in (Machado et al., 2011). In these works, both groups described the conversion of radiolabelled AA into prostaglandins using parasite extracts. In order to check if the PGE2 and PGF
2α 
production that we observed in our experiments could be due to traces of parasites in the culture or in myeloid cells from infected animals harboring intracellular amastigote parasites, we tried to reproduce those published results (Ashton et al., 2007; Kubata et al., 2002). We performed the experiments with living or homogenized parasites from three distinct strains and the three life cycle stages of 
T. cruzi. We could not detect a parasite-derived prostaglandin when the experiments were carried out in absence of hematin. We decided to add the hematin in our reaction buffer in order to reproduce the same published conditions. In those cases we obtained two signals in HPLC runs. One of them seems to correspond to 6-oxo-PGF
1α
 (the main prostacyclin metabolite) and the other did not correspond to any of the 
standards injected. 6-oxo-PGF
1α 
production has not been described in the previous mentioned reports (Ashton et al., 2007; Kubata et al., 2002). Nevertheless, we think that this could be an experimental artifact. There is no logical reason, in my opinion, to add hematin into the reaction buffer in this kind of experiment. Addition of 
heme groups is necessary and justified when 
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a cyclooxygenase activity assay is performed. Hydroperoxides generates the ferryl-oxo complex with the iron of the heme group. This porphyrin-derived complex is a cyclooxygenase prosthetic group key in the catalytic activity (Marnett et al., 1999). Another key aspect leads us to think in a poorly controlled experimental design in Asthon´s report (Ashton et al., 2007). They added stannous chloride to “quench” the reaction. But it has been demonstrated that the addition of stannous chloride  converts PGH2 into PGF2α  avoiding spontaneous non-enzymatic PGE2 and PGD2 generation (Camacho et al., 1998). This stannous chloride 
uncontrolled addition is not justified if the aim of the experiment is to characterize the 
whole prostaglandin profile produced by a cell homogenate. The scarcity of cyclooxygenase activity that we observed in parasites and data regarding AA metabolism in T. cruzi makes less 
plausible even more this justification. However, the parasite could be metabolizing extracellular PGH2 by a transcellular mechanism. Despite the characterization of terminal synthases in T. cruzi, no clear results of prostaglandin generation from AA by T. cruzi have been provided in my opinion by those authors. Therefore, their data must been taken carefully. Nonetheless, as previously mentioned, the T. cruzi scientific community has accepted that T. cruzi produces PGs, further complicating the interpretation of the potential therapeutic role of NSAIDs on Chagas’ disease.
COX-2 deficient reduces cardiac 
inflammation induced by Trypanosoma cruzi 
infection in mice
Since we found that the expression of COX-2 in the T. cruzi infected cardiac tissue was increased during infection, we further analyzed its role in the pathophysiology of the disease. For this, we 
first used a pharmacological approach to inhibit 
COX-2 using BALB/c (susceptible) and C57BL/6 (resistant) mice. We observed that mortality tended to increase in the susceptible model, but not in the resistant model. However, no 
changes in inflammation or parasite load were 
observed after COX-2 inhibition in any of the infected mouse models. We only tried one route of treatment, and it is possible that other routes 
may deliver the drug more efficiently, and thus our results cannot be considered conclusive. Nevertheless, there are contradictory 
reports published with COX-2 inhibitors with contradictory data (Machado et al., 2011). In 
addition, COX-2 inhibitors may interfere with the immune response (Iniguez et al., 1999), but 
more importantly many COX-2 inhibitors have effects independent of their ability to inhibit cyclooxygenase activity (Iniguez et al., 2010; 
Schror, 2011; Xu et al., 2001). Altogether, these precedents discouraged us from pursuing this part of the study.Interestingly, different results were obtained 
with the COX-2 deficient mice. First, we found a slight reduction (three times less) in 
parasitemia in COX-2-/- respect to the wild type mice. However, no changes were observed in 
cardiac parasite burden, in spite that COX-2-/- mice express less iNOS gene, considered to be key for resistance to infection. In a viral model of infection with influenza, COX-2 deficient mice presented a decreased pathogen load respect to wild type mice (Carey et al., 2005). We did 
not observe any significant differences in the levels of T. cruzi specific antibodies despite 
reports showing that immunization of COX-2 
deficient animals with a viral vaccine resulted in a decrease in the levels of antibodies (Ryan et al., 2006). Other laboratories have studied the response to T. cruzi infection in mice deficient in other enzymes of the arachidonic acid pathway 
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(Mukherjee et al., 2011; Sharma et al., 2013). The main drawback to compare our results with those already published is the distinct model of infection used. Sharma et al. used a 
susceptible model and described that deficiency of iPLA2-γ (Ca++ independent PLA2 isoform-γ), which is implied in arachidonic acid membrane release, aggravated infection and survival. 
Others described that COX-1-/- mice showed higher parasitemia than wild-type mice, but did not shown changes in survival (Mukherjee et al., 2011). Using COX-1 and COX-2 deficient 
mice in non-infectious inflammatory models, 
the importance of COX-1 in the initiation of 
inflammation and of COX-2 in cell recruitment has been suggested (Langenbach et al., 1999).
COX-2 deficient mice showed a reduced cardiac 
inflammation induced by Trypanosoma cruzi infection. Our results are in agreement with 
a sepsis model using COX-2-/- mice (Ejima et al., 2003), where they described a less 
inflammatory response than the wild-type 
controls. Importantly, we found that COX-
2 deficiency reduces infiltration of different cell types as lymphocytes and myeloid cells (including MDSCs) in infected heart tissue 
that could explain the lower inflammation. An 
important role of COX-2 derived PGs in migration of immune cells to infected tissues or lymphoid organs is becoming evident from recent results of our laboratory (Diaz_Muñoz et  al., J Immunol. submitted;  Sreeramkumar, et  al submitted). 
The decrease in cardiac inflammation and the expression of L-arginine metabolizing enzymes (iNOS and Arg-1), cytokines and chemokines observed at 14 d.p.i. together with higher 
cardiac IL-4 expression in COX-/- infected mice 
seem to be related with the pro-inflammatory role of PGE2 rather than its immunosuppressive function (Nagamachi et al., 2007; Yao et al., 2009). However, at 21 d.p.i.  the levels of expression of Ccl3, Ccl4 and Cxcl9 chemokines 
were higher in COX-2-/- in comparison with wild-type controls. At this time point, the levels of 
TNF-α and IFN-γ were not reduced compared to 
14 d.p.i. In addition, plasma TNF-α levels were higher at 21 d.p.i. This apparently contradictory data can be explained if we take into account the complexity of eicosanoid generation (Stables and Gilroy, 2011). Thus, in general, a first wave of 
pro-inflammatory mediators (PGE2, PGI2, LTB4) is followed by pro-resolving ones (15d-PGJ2 and lipoxins), process known as lipid mediator class switching. The temporal relationship between separate classes of eicosanoids that represent 
COX and individual LO pathways remains to be established. These temporal relationships are central to the understanding of the role of 
lipid mediators in inflammation in general and during T. cruzi infection in particular. It has been reported that, during the course of a self-
resolving acute inflammatory response that was spatially contained, a clear temporal staging of structurally and functionally distinct classes of eicosanoids occurred . Thus, we believe that a similar effect is taking place in T. cruzi-infected 
COX-2-/- mice. On the other hand, a Th17 response was found to be protective during the acute phase of T. cruzi infection with a low parasite inoculum (da Matta Guedes et al., 2010; Miyazaki et al., 2010), being induced by IL-12 (Cobb and Smeltz, 2012) and osteopontin (Boniface et al., 2009; Santamaria and Corral, 2013). Our laboratory has found that susceptible mice develop a Th17 response that is protective at low parasite inoculum, but pathogenic at high parasite inoculum 
(Sanoja et al. PLoS one submitted). However, when resistant mice (129Sv-C57BL/6 mixed background) were infected with high parasite inoculum, we detected that the expression of genes implied in Th17 development as Stat-3 and Irf4 were reduced in COX-2 deficient mice respect to resistant wild-type mice, although 
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another one as Rorc was not and neither 
Il17 was detected (supplementary figure 
S7). Considering that PGE2 can promote Th17 development (Boniface et al., 2009), the reduced inflammation that we found in 
COX-2-/- mice and the decrease in Stat3 and Irf4 expression could be explained by reduced levels of PGE2 in COX-2-/- mice. However, complete understanding on the role of PGE2/Th17 in T. cruzi infection is difficult. Thus, PGE2 also affect Th1 cells (Sreeramkumar et al., 2012) and Th1/Th17 have complex interactions in the immune regulation (Damsker et al., 2010; Tournadre and Miossec, 2012). Studying 
the effect of COX-2 deficiency in a susceptible genetic background mice (i.e. BALB/c), where the role of Th17 is more evident (Sanoja et al PLoS one submitted) may provide a clear answer to this question. Thus, the role of PGE2 in the Th17 response during T. cruzi infection remains an open issue.ET-1 aggravates the cardiac damage generated during T. cruzi infection (Andrade et al., 2012).  Moreover, ET-1 receptor antagonist has a protective role in heart tissue (Rachid et al., 2006) and central nervous system (Rachid et al., 2010) in a rat model of T. cruzi infection. In contrast, it has been described in mice that the same ET-1 receptor antagonist produces only a minor effect in infected mice (Roffe et al., 2010). We did not detect changes in COX-2 expression upon ET-1 receptor antagonist treatment, in agreement with the previous work performed with mice. However, the 
effect of ET-1 in COX-2 expression in the T. cruzi infected heart is probably being masked by 
other more powerful ET-1-independent COX-2-inducing mechanisms. 
Defective PGE2 receptor EP-2 signalling 
reduces immune cell infiltration and 
inflammation in the cardiac tissue during the 
acute phase of Trypanosoma cruzi infection
COX enzymes are responsible for production of many different prostaglandins with sometimes, opposite actions. This complexity 
makes hard to obtain clear results from COX 
deletion models and specific PG-receptor 
deficient mice should be more suitable for that task (Sugimoto and Narumiya, 2007; Yuhki et al., 2011). Thus, we infected PGE2,-receptor-2 
(EP-2) deficient mice with T. cruzi. EP-2-/- mice, generated in the C57BL/6 genetic background did not show any changes in survival, parasite burden or plasma levels of T. cruzi specific 
antibodies. Cell infiltration was also decreased in EP-2-/- mice as COX-2-/- mice did. They showed decreased gene expression of Ptgs2, Ccl2, Ifng, 
Il12, Il10, Il6 and Il4 revealing the important role of PGE2 in the inflammation onset. However, 
Tnf gene expression and plasma level remains unchanged, in agreement with the in vivo results after bacterial infection (Aronoff et al., 2012).  Nevertheless, in human macrophages 
there was a reduction in TNF-α secretion in response to EP-2 signaling (Ratcliffe et al., 2007). It has been described that MHC-II surface expression is decreased by the use of EP-2 agonists  (Harizi et al., 2003). In contrast, we found that EP-2-/- spleen macrophages from infected mice express low MHC-II in the cell surface. This apparent discrepancy could be attributed to the difference between cell types and in vivo approaches. Nonetheless, the fact that EP-2 is required for CD4+T lymphocyte activation and T cell-dendritic cell interaction (Sreeramkumar , et al. submitted) together with the results presented here, further support a more thoroughly analysis of macrophage and lymphocyte function in T. cruzi infected EP-2-/- mice.
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COX-2 deficiency reduces T cell 
immunosuppression during the acute phase 
of Trypanosoma cruzi infectionA severe suppression of splenic T cell proliferation to mitogens and antigens is a characteristic of the acute phase of T. 
cruzi infection in mice. The impairment of proliferation is associated with high levels of 
IFN-γ and NO and with decreased production of IL-2 in the supernatants of spleen cells cultures from infected mice. Adherent cells, mainly macrophages, are key in this process (Abrahamsohn and Coffman, 1995). Besides the well documented participation of NO as suppressive factor (Goni et al., 2002; Gutierrez et al., 2009), studies with pharmacological 
inhibitors of COX-2 suggested a role of its metabolites in immunosuppression (Abdalla et al., 2008; Michelin et al., 2005; Pinge-Filho et al., 1999). To further clarify this issue we infected 
COX-2 deficient mice and analyzed ex vivo spleen cell proliferation. A reduced immunosuppression 
was found in the spleens from infected COX-2 
deficient mice, compared to control wild-type mice, during the acute phase of T.cruzi infection. We observed that reduced immunosuppression 
in COX-2-/- mice was independent of total and CD11b+Gr-1+ spleen cell number and also from EP-2 signaling. Rather, we found that the effect 
of COX-2-derided PGs in this phenomenon was 
related to its ability to modulate iNOS expression, 
which was decreased in the spleen of COX-2-/- respect to wild-type infected mice. This is in agreement with induction of iNOS expression 
by COX-2-derived PGs in macrophages in other systems (Gaillard et al., 1992; Hori et al., 2001). Cyclooxygenase inhibition in the spleen cells seems to be irrelevant in our in vitro cultures, probably because the immunosuppression at 21 d.p.i. of the BALB/c model was already too severe to be restored pharmacologically, as was published before (Pinge-Filho et al., 1999).Surprisingly, PGE2 levels in the supernatant 
of cells coming from infected COX-2-/- mice 
were not ablated. COX-1 in cooperation with mPGES-1 can secrete PGE2. In agreement with 
this result,, COX-1 and not COX-2 produced PGE2 in the bronco-alveolar lavage of influenza infected mice (Carey et al., 2005). During T. cruzi 
infection COX-1 protein expression was induced in the spleen and could be responsible for 
some of the published actions of COX inhibitors used in the experiments with splenocytes from infected mice. This enzyme usually is constitutively expressed and is usually assumed that its expression does not change (Smith et al., 1996). However, COX-1 induction in immune cells has been described in other models (Samet et al., 1995), in agreement with our results.
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In this appendix we show the experiments we perform to set up the different histological staining of our preparations.
We have used the fluorochrome directly 
conjugated antibody against CD4 tested to flow citometry (557681 ,BD Pharmigen) to perform 
confocal immunofluorescence experiments. In 
Fig. S1 peritoneal lymphocytes (Composto et al., 2011) and mouse thymus are positively stained. 
In order to set up COX-2 and 12/15- LO enzymes staining peritoneal macrophages were selected. After try with different 
antibodies against COX-2, reference 106160 from Cayman Chemical was selected due to its well performance.  LPS activated peritoneal macrophages (Lee et al., 1992) were used like a positive control in Fig. S3. 12/15-LO antiserum raised in guinea pig was a gift from Kühn H (Germany) (Dioszeghy et al., 2008). We have used freshly isolated peritoneal cells like a positive control in Fig. S4.  These cells have been described like one of the higher 12/15-LO expressing cells in mice (Heydeck et al., 1998). Anti-CD68 (macrophage marker) antibody (MCA1957GA ,AbD Serotec) was tested also in this peritoneal cells. 
Anti-Vimentin antibody directly conjugated to Alexa Fluor 647™ (9856 S  from Cell Signaling) 
was used to stain the intermediate filament 
cytoskeleton in fibroblast and heart tissue,   Fig. 
S5 A and B respectively.
Confocal immunofluorescence was used to detect lipid droplets with Oil Red O (ORO) in propylene Glycol 26079-15 purchased from Electron Microscopy Sciences. To set up the staining and detection of lipid droplets peritoneal cavity macrophages were used Fig. 
S6 (Hu et al., 2003). 
Figure S1│CD4 is expressed in lymphocytes. 
A│ Mouse peritoneal cells were bound to Poly-L lysine 
coverslips and prepared for confocal immunofluorescence. Coverslips were stained with DAPI for nuclei (blue) and 
the directly conjugated antibody specific for lymphocyte marker CD4 (red) B│ Normal thymus were isolated from BALB/c mice, frozen in OCT and prepared for confocal 
immunofluorescence. Slices were stained with DAPI for 
nuclei and the directly conjugated antibody especific for lymphocyte marker CD4. Scale bar is 20 microns length. Pictures are representative of two different coverslips or slices.
Figure S2│F4/80 is expressed by liver macrophages. Livers form infected and not infected BALB/c mice were collected, frozen in 
OCT and prepared for confocal immunofluorescence. DAPI staining was used to visualize nuclei (blue) and the antibody raised 
against F4/80 (green) to visualized macrophages. A│ Not infected liver B│ Infected liver C│ Secondary antibody control using 
infected tissue.  Scale bar is 20 microns length. Pictures are representative of three different organs.
To set up the staining of the macrophage marker F4/80 antigen antibody (14-4801-81, eBioscience) mouse liver was used (Fig. S2) because it is known that Küpffer cells express the marker (Kinoshita et al., 2010).  
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Figure S3│COX-2 is expressed in LPS-stimulated macrophages. Peritoneal macrophages were cultured in coverslips and treated or not with E.coli LPS (1 microgram/ml) and prepared for confocal immunofluorescence. Coverslip stained with DAPI for nuclei (blue) and the antibody raised against the enzyme COX-2 (red) A│ Non stimulated macrophages B│ LPS treated macrophages. C│ Secondary antibody control using LPS activated macrophages.  Scale bar is 20 microns length. Pictures are representative of two different coverslips.
Figure S4│ 12/15 Lipoxygenase (12/15-LO) is highly expressed in freshly purified not activated peritoneal 
macrophages. Peritoneal cells were bound to Poly-L lysine coverslips and treated and prepared for confocal 
immunofluorescence. Coverslip were stained with DAPI for nuclei (blue) and the antibody raised against the macrophage marker CD68 (green) or the enzyme 12/15-LO (red). Upper set of panels represent the  separated channels of the same confocal adquisition A│Nuclei stained with DAPI  B│ CD68 positive macrophages  C│12/15 LO expressing cells D│ Merge 
E│ Merge of secondary antibody control.  Scale bar is 20 microns length. Pictures are representative of at least two different coverslips.
Figure S5│Vimentin is abundant in intermediate 
filaments cytoskeleton. A│ Vero cells were bound to 
coverslips and prepared for confocal immunofluorescence. 
A│ Coverslips were stained with DAPI for nuclei (blue) 
and the directly conjugated antibody raised against 
vimentin (green) B│ Infected heart tissue were isolated from BALB/c mice, frozen in OCT and prepared for confocal 
immunofluorescence, stained with DAPI for nuclei and 
the directly conjugated antibody raised against vimentin . Scale bar is 20 microns length. Pictures are representative of two different coverslips or organs.
Figure S6│Lipid bodies are produced in macrophages. Peritoneal macrophages were incubated with deferoxamine 375 μM overnight at 37˚C and the following day stained to detect lipid bodies in coverslips. Coverslips were stained with DAPI for nuclei (blue), the antibody raised against the macrophage marker CD68 (red) and 
Oil Red O (green) to detect lipid bodies. Scale bar is 20 microns length. Pictures are representative of two different coverslips.
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Figure S7│Expression of gene related with Th17 differentiation in cardiac tissue of wild-type and COX-2 deficient 
mice infected with Trypanosoma cruzi. A│ Heart tissue RNA was isolated at 14 d.p.i. and qPCR was performed. Results 
are expressed as RQ calculated from CT values as described in Materials and Methods. No amplification of IL-17 was de-
tected Open circles indicate the values of wild-type mice closed circles of COX-2 deficient mice. Means ± SD from four ex-
periments are shown (n=13). Differences between wild-type and COX-2-/- mice are indicated with * p<0.05. B│ Scheme of Th17 differentiation. Adapted from  Ghilardi N, 2007, Seminar in Immunology
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origen = getDirectory(“Elige la carpeta con las imagenes originales a 
procesar”);
resultados = getDirectory(“Elige la carpeta para guardar los resultados “);
lista = getFileList(origen);
setBatchMode(false);
for (z=0; z<lista.length; z++) {
 showProgress(z+1, lista.length);
 open(origen+lista[z]);
 nombre = lista[z];
 run(“Advanced Weka Segmentation”, “origen + nombre”);
 selectWindow(“Advanced Weka Segmentation”);
	 call(“trainableSegmentation.Weka_Segmentation.loadClassifier”,	“C:\\
Users\\vlabrador\\Desktop\\clasificador.model”);
 wait(3000);
	 call(“trainableSegmentation.Weka_Segmentation.applyClassifier”,	origen,	
nombre, “showResults=true”, “storeResults=false”, “probabilityMaps=false”, 
“”);
 selectWindow(“Advanced Weka Segmentation”);
	 selectWindow(“Classification	result”);
 saveAs(“.tiff”, resultados + nombre + “-Binary”);
 run(“Set Scale...”, “distance=313.67 known=100 pixel=1 unit=µm 
global”);
 run(“Set Measurements...”, “area area_fraction limit display 
redirect=None decimal=3”);
 class1 = nombre + “__Fibrosis”;
 rename(class1);
 //run(“Threshold...”);
 setThreshold(175, 255);
IMAGE J MACRO USED TO   AUTOMATE  IMAGE ANALYSIS
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 run(“Measure”);
 class2 = nombre + “__Fondo”;
 rename(class2);
 //run(“Threshold...”);
 setThreshold(150, 174);
 run(“Measure”);
 class3 = nombre + “__Nucleos”;
 rename(class3);
 //run(“Threshold...”);
 setThreshold(75, 100);
 run(“Measure”);
 class4 = nombre + “__Tejido y Eritrocitos”;
 rename(class4);
 //run(“Threshold...”);
 setThreshold(0, 74);
 run(“Measure”);
 close();
 close();
 close();
 close();
}
selectWindow(“Results”);
saveAs(“Text”, resultados + “Resultados.xls”);
run(“Close”);
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Abstract
Trypanosoma cruzi, the causative agent of Chagas’ disease, induces multiple responses in the heart, a critical organ of
infection and pathology in the host. Among diverse factors, eicosanoids and the vasoactive peptide endothelin-1 (ET-1)
have been implicated in the pathogenesis of chronic chagasic cardiomyopathy. In the present study, we found that T. cruzi
infection in mice induces myocardial gene expression of cyclooxygenase-2 (Cox2) and thromboxane synthase (Tbxas1) as
well as endothelin-1 (Edn1) and atrial natriuretic peptide (Nppa). T. cruzi infection and ET-1 cooperatively activated the Ca2+/
calcineurin (Cn)/nuclear factor of activated T cells (NFAT) signaling pathway in atrial myocytes, leading to COX-2 protein
expression and increased eicosanoid (prostaglandins E2 and F2a, thromboxane A2) release. Moreover, T. cruzi infection of ET-
1-stimulated cardiomyocytes resulted in significantly enhanced production of atrial natriuretic peptide (ANP), a prognostic
marker for impairment in cardiac function of chagasic patients. Our findings support an important role for the Ca2+/Cn/NFAT
cascade in T. cruzi-mediated myocardial production of inflammatory mediators and may help define novel therapeutic
targets.
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Introduction
Chagas’ disease, caused by the infection with the protozoan
parasite Trypanosoma cruzi, constitutes the major cause of infectious
heart disease in Latin America. It is estimated that 10 million people
are infected with T. cruzi in the Central and South America, 100–
120 million are at potential risk of infection and around 50,000 new
cases occur each year [1]. In humans, an acute phase displays
frequently as a non-apparent form with a few or no symptoms.
Thereafter, the patients enter into an asymptomatic, indeterminate
stage, which lasts throughout life in the majority of infected subjects.
The remaining 20–30% of chronically infected individuals develop
cardiac or digestive complications, typically years or decades after
infection. Chronic cardiomyopathy is the most common and severe
manifestation of human Chagas’ disease, causing congestive heart
failure, arrhythmias and conduction abnormalities, which often lead
to stroke and sudden death. This type of dilated cardiomyopathy is
associated with chronic inflammation and fibrosis, cardiac hyper-
trophy and thrombo-embolic events [2].
Compromised microcirculation, caused by T. cruzi infection,
involves endothelial alterations, vasospasm, reduced blood flow
and focal ischemia [3]. Cardiovascular production of vasoactive
mediators has been implicated in the pathogenesis of the
vasculopathy seen in chagasic heart disease [4]. Among other
vasculitis-promoting factors, T. cruzi infection triggers myocardial
overexpression and increased plasma levels of endothelin-1 (ET-1)
in mice and chronic chagasic patients, which correlate with heart
dysfunction [5,6]. A bulk of evidence supports the participation of
this vasoactive peptide, produced by myocardial and endothelial
cells among others, in Chagas’ disease pathogenesis [4,5,7,8–10].
ET-1 activity may result in vascular injury, cardiac remodeling
and enhanced liberation of inflammatory agents [11].
Endothelin-1 is involved in different signaling pathways that
include increase in intracellular calcium levels ([Ca2+]i) and
ERK1/2 activation leading to expression of cyclin D1 and
inflammation-linked genes, all of them contributing to T. cruzi-
mediated cardiac pathology [12,13]. Moreover, ET-1 has been
shown to induce cell hypertrophy in primary cultures of rat
PLOS Neglected Tropical Diseases | www.plosntds.org 1 February 2013 | Volume 7 | Issue 2 | e2034
cardiomyocytes through a calcineurin (Cn)/nuclear factor of
activated T cells (NFAT)-dependent mechanism [14,15]. The
NFAT family includes four ‘classical’ members displaying a high
degree of homology: NFATc1-4, each of which is expressed in
heart tissue [16]. NFAT exists in a highly phosphorylated form in
the cytoplasm, which translocates into the nucleus upon dephos-
phorylation by the phosphatase Cn in response to increases in
[Ca2+]i, where it binds to enhancer elements of downstream genes
leading to transcriptional activation [17].
One of the NFAT target genes associated with inflammation is
cyclooxygenase-2 (COX-2), the inducible enzyme that catalyzes
the rate-limiting step in prostanoid biosynthesis [18–20]. ET-1 is
able to stimulate protein expression of COX-2 and prostacyclin
release in cardiomyocytes [21]. In addition, experimental murine
infection with T. cruzi has been shown to raise the number of
cardiac cells positive for COX-1 and COX-2, as well as the
circulating levels of cyclooxygenase metabolites [22,23]. Both host-
and parasite-derived prostaglandins (PG) and thromboxane A2
(TXA2) are key regulators of pathogenesis during T. cruzi infection
[24]. Remarkably, ET-1 stimulation of cardiac myocytes also
results in NFATc4-dependent up-regulation of hypertrophy
response genes such as atrial natriuretic peptide (ANP) and B-
type natriuretic peptide (BNP) [25,26], potential markers of
myocardial compromise in Chagas’ disease [27,28].
Although ET-1 and eicosanoids have been proposed to play a
role in Chagas’ disease pathogenesis, the link between them has
not yet been addressed. Thus, we have examined the regulation of
Cox2 expression and activity by the combined effect of ET-1 and
T. cruzi infection of cardiomyocytes. Our results show that
induction of Cox2 expression by ET-1 plus T. cruzi in HL-1 atrial
myocytes requires activation of the Ca2+/Cn/NFAT pathway.
NFAT is translocated to the nucleus upon stimulation with the
peptide and subsequent infection where it binds to NFAT response
elements in the promoter region of Cox2 that are essential for
transcriptional induction of the gene. Moreover, trypomastigote
infection of ET-1-pre-treated HL-1 cardiomyocytes significantly
enhanced production of eicosanoids and ANP by these cells. These
findings demonstrate the participation of NFAT in [T. cruzi+ET-
1]-mediated induction of genes involved in the pathogenesis of
chronic Chagas’ heart disease.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations of Spanish Legislation and the European
Council Directive from the Convention for the Protection of
Vertebrate Animals Used for Experimental and Other Scientific
Purposes. All mice were maintained under pathogen-free condi-
tions in the animal facility at the Centro de Biologı´a Molecular,
Universidad Auto´noma de Madrid (Madrid, Spain). The animal
protocol was approved by the Comite´ de E´tica de la Investigacio´n
de la Universidad Auto´noma de Madrid. Animals had free access
to food and water and were handled in compliance with European
codes of practice. Mice were euthanized in a CO2 chamber, and
all efforts were made to minimize suffering.
Cell culture, primary cardiomyocytes and infection
Mouse HL-1 cardiomyocytes were plated onto gelatin/fibro-
nectin pre-coated flasks and cultured in Claycomb medium
(Sigma-Aldrich) supplemented with 10% fetal calf serum,
100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-
glutamine as previously described [29]. Primary cardiomyocytes
were isolated from BALB/c mice and cultured according to
standard protocols [30]. HL-1 and primary cardiomyocytes were
seeded in 6- (56105/well) or 24- (16105/well) well plates and
infected with T. cruzi trypomastigotes (cell:parasite ratio 1:5), Y
strain, routinely propagated in Vero cells. In some experiments,
cell cultures were starved for 18 h and then treated with
recombinant murine interferon-c (25 U/ml IFN-c, R&D Sys-
tems), 1 mg/ml lipopolysaccharide (LPS, Sigma-Aldrich) or
0.3 nM ET-1 (Sigma-Aldrich) for 2 h before infection. Endotoxin
level in the ET-1 batch was ,1 EU/mg, as determined using a
Limulus amoebocyte lysate analysis kit (Whittaker Bioproducts).
Plates were rinsed to remove free parasites and further incubated
in complete medium at 37uC, 5% CO2 for the indicated times.
In vivo infection
Young adult (6- to 8-wk-old) C57BL/6 mice were purchased
from Charles River Laboratories. For infection experiments,
26103 blood trypomastigotes (Y strain) per mouse were inoculated
by intraperitoneal injection as described [31], keeping a group of
non-infected mice. Age-matched BALB/c mice were infected in
parallel. Parasitemia levels were checked every 2 days by direct
inspection and counting parasites in a 5 ml drop of tail vein blood.
Weekly during one month post-infection, groups of 3 mice were
euthanized in a CO2 chamber, and blood and various tissues were
collected. Samples were processed for RNA or histological
analysis.
RNA isolation, reverse transcription and polymerase
chain reaction (PCR)
Total RNA was extracted from HL-1 cells and mouse heart
tissue by using Trizol reagent (Invitrogen) according to the
manufacturer’s instructions. First-strand cDNA was prepared by
incubation of 1 mg of total RNA with murine leukemia virus
reverse transcriptase and random hexamer oligonucleotides (Bio-
Rad Laboratories) at 40uC for 45 min. Then, 5 ml of the reaction
products was amplified by PCR with 1.25 U of Taq DNA
polymerase (Invitrogen). PCR amplification consisted of 94uC for
Author Summary
Chronic cardiomyopathy is the most common and severe
manifestation of human Chagas’ disease, caused by the
protozoan parasite Trypanosoma cruzi. Among diverse
inflammation-promoting moieties, eicosanoids and the
vasoactive peptide endothelin-1 (ET-1) have been impli-
cated in its pathogenesis. Nevertheless, the link between
these two factors has not yet been identified. In the
present study, we found that T. cruzi infection induces
gene expression of ET-1 and eicosanoid-forming enzymes
in the heart of infected mice. We also demonstrated that
HL-1 atrial myocytes respond to ET-1 stimulus and T. cruzi
infection by induction of cyclooxygenase-2 through
activation of the Ca2+/calcineurin/NFAT intracellular sig-
naling pathway. Moreover, the cooperation between T.
cruzi and ET-1 leads to overproduction of eicosanoids
(prostaglandins E2 and F2a, thromboxane A2) and the pro-
hypertrophic atrial natriuretic peptide. Our results support
an important role for NFAT in T. cruzi plus ET-1-dependent
induction of key agents of pathogenesis in chronic
chagasic cardiomyopathy. Identification of the Ca2+/
calcineurin/NFAT cascade as mediator of cardiovascular
pathology in Chagas’ disease advances our understanding
of host-parasite interrelationship and may help define
novel potential targets for therapeutic interventions to
ameliorate or prevent cardiomyopathy during chronic T.
cruzi infection.
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45 s for denaturation, 60uC for 45 s for annealing, and 72uC for
45 s for extension, performed for 30 cycles. The sense and
antisense primers used for murine Cox2 were: 59-tcctcctggaacatg-
gactc-39 and 59-gctcggcttccagtattgag-39, respectively [32]. Aliquots
of 10 ml of the PCR products were electrophoresed in a 1.6%
agarose gel containing ethidium bromide.
Real-time PCR of infected heart tissue
Quantitative real-time RT-PCR analysis was performed using
the High Capacity cDNA Archive Kit (Applied Biosystems), and
amplification of different murine genes (Cox2, Cox1, Tbxas1, Nppa,
Edn1 and ribosomal 18S) was performed in triplicate with the use
of TaqMan MGB probes and the TaqMan Universal PCR Master
Mix (Life Technologies) on an ABI Prism 7900 HT instrument
(Applied Biosystems), as reported previously [31]. Quantification
of gene expression was calculated using the comparative threshold
cycle (Ct) method, normalized to the ribosomal 18S control and
efficiency of the RT reaction (relative quantity, 22DDCT).
Histological and immunohistochemical analysis of heart
Cardiac tissues from mice were placed after been cut in two
pieces in 10% neutral buffered formalin for at least 4 h at room
temperature followed by overnight incubation in 70% ethanol.
Samples were them embedded in paraffin (Tissue Embedding
Station Leica EG1160), and 5-mm tissue sections were prepared
using a motorized Microtome Leica RM2155. Samples were
deparaffinized and rehydrated using a Tissue Processing Station
Leica TP1020. Slides were stained using the Masson’s trichrome
staining and mounted permanently in Eukkitt’s quick hardening
mounting system medium (Biochemika, Fluka Analytical). The
sections were analyzed in a Leica DMD 108 microscope (Leica
Microsystems, Germany). For immunohistochemical studies,
myocardial sections were deparaffinized by routine procedures
and analyzed using anti-murine COX-2 rabbit polyclonal
antibody (Abcam) and biotinylated swine antiserum to rabbit
immunoglobulin (Dako), following a procedure previously de-
scribed [33].
Immunoblot analysis
Immunoblotting was carried out as described elsewhere [19].
Cardiac cells were disrupted and solubilized extracts (20 mg) were
separated in 6% (only for analysis of NFAT translocation to the
nucleus) or 10% sodium dodecyl sulfate-polyacrylamide gels, and
transferred to nitrocellulose filters. After blocking for 2 h with 5%
non-fat dried milk in Tris-buffered saline containing 0.1% Tween-
20, the membranes were probed 2 h at 37uC with murine
monoclonal antibodies against COX-2 (diluted 1:250 in blocking
buffer, BD Biosciences), a-tubulin (1:1000, Sigma-Aldrich), and
with rabbit polyclonal antibodies against NFAT (c1 to c4 isoforms,
1:200, Santa Cruz Biotechnology), prostaglandin E synthase-2
(microsomal, 1:500), thromboxane synthase (1:500, Cayman) and
prostaglandin F synthase/AK31C3 (1:2,000, ProSci). The filters
were washed and incubated with the corresponding secondary
antibody linked to horseradish peroxidase at 1:10,000 dilution,
and the stained bands were visualized by a chemiluminescent
peroxide substrate (Amersham Pharmacia).
Plasmid constructs
Cox2 promoter constructs spanning from 21796 (P2-1900-
LUC) and 2170 (P2-274-LUC) to +104 bp relative to the
transcription start site of the human Cox2 gene and the P2-274-
LUC plasmid with binding sites for NFAT, or AP-1, or both
mutated were described [19]. The pSH102CD418 expression
vector derives from pBJ5 and encodes an NFATc1 deletion
mutant (1–418) that functions as a dominant negative for all
NFAT isoforms [34].
Transfection and luciferase assays
HL-1 cells were transfected by Lipofectamine (Invitrogen) as
described [19]. Briefly, exponential growing cells (26105/well)
cultured in 24-well plates were incubated for 3 h at 37uC with a
mixture of 0.5–1 mg of the corresponding reporter plasmid and
Lipofectamine-containing Opti-MEM (Invitrogen). The total
amount of DNA in each transfection was kept constant by using
the empty expression vectors. Complete medium was then added
to cells and incubated at 37uC for additional 16 h. Transfected
cells were exposed to different stimuli (0.3 nM ET-1, or phorbol
12-myristate 13-acetate -PMA- plus A23187 calcium ionophore -
Ion-, Sigma-Aldrich) and/or T. cruzi-infected as indicated. In some
experiments, FK506 (100 ng/ml, Sandoz Ltd., Tokyo, Japan) was
added for 1 h. Then, cells were harvested and lysed. Luciferase
activity was determined by using a luciferase assay system
(Promega) with a luminometer Monolight 2010 (Analytical
Luminescence). Transfection experiments were performed in
triplicate. Data of luciferase activity are presented as fold induction
(observed experimental relative luciferase units (RLU)/basal RLU
in absence of any stimulus). Results were normalized for extract
protein concentrations measured with a Bradford assay kit (Pierce,
Thermo Fisher Scientific).
Intracellular calcium measurements
Agonist-induced changes in [Ca2+]i were detected using the
Ca2+-sensitive dye Fura-2/AM as described [35]. Briefly, cell
monolayers at 80% confluence were trypsinized, washed and then
loaded with 1 mM Fura-2/AM under continuous stirring for
30 min at 37uC. The cells (26106/ml) were exposed to 0.3 nM
ET-1 and/or infected with T. cruzi trypomastigotes (cell:parasite
ratio 1:5), and placed in an Aminco Bowman Series 2
spectrofluorometer (Thermo). Uninfected cultures were used as
controls. At the indicated times, the fluorescence signal of Fura-2
was recorded, with excitation and emission at 340 and 510 nm,
respectively.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from ET-1-treated and/or T.
cruzi-infected HL-1 cells as described [36] with minor modifica-
tions. Purity of fractions was proven by analyzing cytoplasmic and
nuclear marker proteins including a-tubulin (cytoplasmic), and
topoisomerase IIb and c-jun (nuclear). In brief, 5 mg of nuclear
protein was incubated with 1 mg of poly(dI–dC) DNA carrier in
DNA binding buffer (10% (wt/vol) polyvinylethanol, 12.5% (vol/
vol) glycerol, 50 mM Tris, pH 8, 2.5 mM dithiothreitol, 2.5 mM
ethylenediaminetetraacetic acid) for 30 min at 4uC. Then, 105
counts per minute (c.p.m.) (108 c.p.m./mg) of the 32P-labeled
double-stranded oligonucleotide (2 mg) were added, and the
reaction was incubated at room temperature for 30 min. A
synthetic oligonucleotide containing the NFAT consensus se-
quence 59-gggtggggtggggaaagccgaggcgga-39 (nucleotides 298 to
273) in the rat Cox-2 promoter was used as probe/competitor in
EMSAs. For competition experiments, a 50-fold molar excess of
unlabeled oligonucleotide was added before the addition of the
probe. Supershift assays were performed by incubating nuclear
extracts with either normal rabbit IgG or anti-NFATc4 antibody
for 15 min at 4uC before the addition of the probe. DNA-protein
complexes were resolved by electrophoresis in 4% non-denaturing
polyacrylamide gels and were subjected to autoradiography.
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Measurements of metabolites
For eicosanoid measurements, HL-1 cells were maintained for
12 h in culture medium supplemented with 0.5% fetal calf serum,
then pre-treated or not with 10 mM indomethacin (Sigma-Aldrich)
or 10 mM NS-398 (Alexis) for 1 h, and further stimulated with
0.3 nM ET-1 for 2 h. After treatment, cardiomyocytes were
infected with T. cruzi trypomastigotes for 24 h. At that time, media
supernatants were collected and analysed for PGE2, PGF2a and
TXB2 by ELISA (Cayman) according to manufacturer’s specifi-
cations. In addition, eicosanoid levels were determined by ELISA
in the sera from both uninfected and T. cruzi-infected C57BL/6
mice at 21 days of infection.
For ANP measurements, 24-h supernatants from ET-1-stimu-
lated and/or T. cruzi-infected HL-1 cells, as well as serum
specimens from both uninfected and T. cruzi-infected mice, were
analyzed by ELISA (Kamiya Biomedical) following the instruc-
tions of the supplier.
For ET-1 measurements, the sera from uninfected and T. cruzi-
infected mice were analyzed by ELISA (Phoenix Pharmaceuticals),
according to the manufacturer’s guidelines.
Statistical analysis
Statistical analysis was performed by using GraphPad Prism 5.0
software. Arithmetics means and standard error of the means
(s.e.m.) were calculated. Significant differences among groups were
made by using the one-way analysis of variance test followed by
Tukey’s test. A difference between groups of P,0.05 was
considered significant.
Results
Trypanosoma cruzi infection induces the expression of
markers of cardiac damage and eicosanoid enzymes in
the heart
As shown in previous works from our group [30,37],
C57BL/6 mice proved susceptible to infection with the Y
strain of T. cruzi, albeit less severely than BALB/c mice, and
survived acute infection (Figure 1A,B). Intense myocardial
parasitism and inflammatory pathology were observed at 21
days of infection, together with enhanced COX-2 expression
revealed by immunohistochemistry in both cardiomyocytes
and heart-infiltrating leukocytes (Figure 1C). Accordingly, T.
cruzi-infected C57BL/6 mice showed an augmented (up to 100
fold) expression of myocardial Cox2 mRNA (Figure 1D)
coincident with the highest parasite burden in the heart and
maximum severity of myocarditis [30]. In addition, we
detected a parallel increase (up to 15 fold) in the expression
of the TXS gene (Tbxas1). However, no effect was observed on
the expression of Cox1 mRNA (data not shown). Overall,
results similar to those above were found in T. cruzi-infected
BALB/c mice. Moreover, mRNA levels of ET-1 (Edn1) and
ANP (Nppa), a prognostic marker for impairment in cardiac
function of chagasic patients [28], were up-regulated in heart
tissue of infected C57BL/6 mice (Figure 1D). Upon infection,
ET-1 increased in the two mouse genetic backgrounds. This
enhanced mRNA expression in the heart of infected animals
was accompanied by elevated serum levels of both peptides
and circulating eicosanoids (TXB2 and PGF2a) (Figure 1E). It
is important to note that observed values from BALB/c and
C57BL/6 animals cannot be directly compared to each other,
since data are normalized to non-infected values that can differ
between both mouse strains.
Trypanosoma cruzi- and endothelin-1-regulated Cox2
expression in mouse cardiomyocytes
The observed Cox2 mRNA expression in infected heart could
come from infected cardiomyocytes, endothelial cells, fibroblasts
and/or infiltrating leukocytes. Hence, we tested whether cardio-
myocytes up-regulate Cox2 upon T. cruzi infection in vitro. A strong
induction of COX-2 protein expression was observed in neonatal
cardiomyocyte primary cultures infected with T. cruzi, comparable
to that induced by a well-known pro-inflammatory stimulus as
LPS plus IFNc (Figure 2A). To better examine the molecular
regulatory mechanism of gene expression of this inducible enzyme
by infection, we used the terminally differentiated murine HL-1
cardiomyocyte cell line infected with T. cruzi. Although some
reports have described an impaired inflammatory ability of HL-1
cells to express NO synthase-2 or to activate NF-kB [38], others
find the opposite [39]. Nonetheless, in our hands these cells retain
contractile and phenotypic characteristics of the adult cardiomy-
ocytes and they are much better suitable for transfection
experiments than immature cardiac myocytes, as it has been
described [40]. After 3 h of parasite infection, Cox2 mRNA could
not be detected. Similarly, a very weak Cox2 induction was also
noted in cardiomyocytes cultured in the presence of 0.3 nM ET-1.
However, when ET-1-pre-treated HL-1 cells were infected with T.
cruzi trypomastigotes ([T. cruzi+ET-1]), a strong increase in Cox2
mRNA expression was detected (Figure 2B). These findings were
confirmed by analysing COX-2 protein (Figure 2C).
The above results suggested that the combined effect of T. cruzi
infection and ET-1 treatment on Cox2 expression was taking place
at the transcriptional level. To confirm this, HL-1 cardiac cells
were transfected with a Cox2 promoter/luciferase construct
spanning from nucleotide 21796 to +104 bp relative to the
human Cox2 gene transcription start site (P2-1900-Cox-2-LUC).
As shown in Figure 2D, T. cruzi plus ET-1 (0.3 nM) induced a
four-fold increment (P,0.05) in luciferase activity in transiently
transfected cells compared to untreated controls. In contrast, T.
cruzi-infected cardiomyocytes and ET-1-stimulated uninfected cells
showed very little increase. Interestingly, addition of the Cn
inhibitor FK506 (100 ng/ml) significantly attenuated [T. cru-
zi+ET-1]-mediated induction of Cox2 promoter.
Transcriptional regulation of the Cox2 promoter by the
combined effect of Trypanosoma cruzi and endothelin-1
To map the Cox2 promoter region responsible for [T. cruzi+ET-
1] inducibility, we used several Cox2 promoter deletion/mutation
constructs. Deletion up to 2170 (P2-1900 to P2-274) of the Cox2
promoter region did not significantly affect [T. cruzi+ET-1]
inducibility (Figure 2E). Given the relevance of the region
spanning from nucleotides 2170 to 246 for the recorded
induction of the Cox2 promoter, we next determined the
contribution of the known transcription factor sites present in this
region [19] to the overall transcriptional regulation of [T.
cruzi+ET-1]-dependent Cox2 expression. Transfection experiments
showed that mutation of the dNFAT (P2-274 dNFAT mut) or
pNFAT (P2-274 pNFAT mut) sites resulted in a 65 and a 60% loss
in the [T. cruzi+ET-1]-induced Cox2 promoter activity, respective-
ly, whereas double mutation of both NFAT (P2-274 p- and
dNFAT mut) sites drastically reduced this activation. Conversely,
mutagenesis of the AP-1-like site (P2-274 AP-1 mut) present in this
region did not significantly diminish the inducibility of the Cox2
promoter by [T. cruzi+ET-1]. To further confirm the central role
of NFAT activation in the transcriptional regulation mediated by
T. cruzi in ET-1-stimulated HL-1 cells, we co-transfected a
dominant-negative version of NFAT (dnNFAT), previously
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Figure 1. Trypanosoma cruzi infection induces Cox2, Tbxas1, Edn1 and Nppa in infected heart tissue. (A and B) C57BL/6 (black circles) and
BALB/c (white circles) mice were infected with 26103 blood-trypomastigote forms of the Y strain. (A) Parasitemia expressed as the mean 6 standard
error of the mean (s.e.m.) of the number of parasites per 5 ml of blood. (B) Percent of mice survival. Results are representative of 2 independent
experiments, each performed with 6 mice per group. (C) Tissue inflammation, parasitism and COX-2 expression in heart from uninfected (left panels)
and T. cruzi-infected (21 days post-infection, right panels) mice. Representative results of histological analysis (Mason’s trichrome staining) of cardiac
tissue specimens from BALB/c and C57BL/6 mice (top and center panels, respectively) are shown. Bars = 100 mm. Bottom panels display
representative results of COX-2 immunostaining (IS) in the hearts from C57BL/6 mice. Original magnification for microphotographs6400. (D) Cox2
(COX-2), Tbxas1 (TXS), Edn1 (ET-1) and Nppa (ANP) gene expression in the heart during the acute phase of infection in C57BL/6 and BALB/c mice. RNA
from heart tissue at different days post-infection was used to perform RT-PCR with specific probes, and normalized to ribosomal 18S RNA as
described in ‘Materials and Methods’. Values are expressed as means 6 s.e.m. from 3 independent infections, each performed with 3 mice per group.
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described to abolish NFAT-dependent promoter activity [19],
together with the P2-274-Cox-2-LUC plasmid. Interestingly,
expression of dnNFAT abrogated [T. cruzi+ET-1]-induced tran-
scription of the reporter (Figure 2E), supporting the hypothesis of
the involvement of NFAT signaling in the regulation of Cox2 gene
expression by the cooperation between ET-1 and T. cruzi infection
in cardiomyocytes.
Trypanosoma cruzi infection leads to activation of the
Ca2+/Calcineurin/NFAT intracellular signaling pathway in
endothelin-1-treated cardiomyocytes
T. cruzi trypomastigote invasion of cardiac myocytes triggers a
transient [Ca2+]i elevation [41]. Similarly, upon the addition of
trypomastigotes to HL-1 cells, we observed a transient [Ca2+]i
response associated to a considerable, sustained increase in [Ca2+]i
during the invasion process (Figure 3A). Comparable outcome,
although with higher [Ca2+]i levels, was obtained in T. cruzi-
infected HL-1 cells pre-treated with 0.3 nM ET-1.
In HL-1 cells, basal expression of several isoforms of NFAT
proteins (c1, c3 and c4) was detected by immunoblot analysis.
Interestingly, stimulation with T. cruzi plus ET-1 induced a
remarkable increase in the expression of NFATc4 and to a lesser
extent, NFATc1 and NFATc3 (Figure 3B). Moreover, NFATc4
was present in the cytoplasm of untreated cardiac cells, but upon
parasite infection of ET-1-stimulated cardiomyocytes, it was
translocated into the nucleus. Pre-treatment with FK506
(100 ng/ml), a Cn inhibitor, prevented this translocation, thereby
resulting in an accumulation of cytoplasmic NFATc4 protein
(Figure 3C). To a much lesser extent, we also observed NFATc1
and NFATc3 migration to the nucleus (data not shown). Together,
the above results indicate the activation of the NFATc4 isoform by
[T. cruzi+ET-1] through a Ca2+/Cn signaling process.
To analyse NFATc4 binding to the NFAT sequences of the
Cox2 promoter, we performed EMSAs with nuclear extracts of
atrial HL-1 myocytes (Figure 3D). PMA (15 ng/ml) supple-
mented with Ion (1 mM) was used as a control stimulus. The
NFAT oligonucleotide probe from Cox2 promoter specifically
bound nuclear proteins from [T. cruzi+ET-1]- and
[PMA+Ion]-treated HL-1 cells, which was efficiently competed
with a 50-fold molar excess of cold oligonucleotide (Cox-2-
NFAT). These inducible complexes were severely diminished
in nuclear extracts from cells stimulated with T. cruzi plus ET-1
in the presence of FK506. No NFAT binding could be
demonstrated in response to ET-1 stimulation in the absence of
parasites or T. cruzi infection alone. To determine unambig-
uously the presence of the NFATc4 protein in the complexes,
we performed super shifting with an NFATc4-specific anti-
body. This antibody clearly displaced the migration of the
bound probe, allowing the formation of more retarded
complexes likely constituted by DNA/NFAT/antibody
(Figure 3D). As the NFATc4-specific antibody completely
supershifted the complex, it is indicative that c4, but no other
NFAT isoform, is bound to Cox2 promoter DNA in detectable
amount. As a negative control, normal rabbit IgG was used.
Taken together, these data suggest the binding of NFATc4 to
the corresponding sites within the Cox2 promoter in response
to T. cruzi infection of ET-1-pre-treated HL-1 cells.
Trypanosoma cruzi infection of endothelin-1-treated HL-1
cardiomyocytes enhances the production of eicosanoids
and atrial natriuretic peptide
To assess whether [T. cruzi+ET-1]-mediated induction of Cox2
expression was associated with an increase in its enzymatic
activity, eicosanoid release by HL-1 cells was measured.
Compared to mock-treated cells, stimulation of myocytes with
0.3 nM ET-1, or trypomastigote infection over a 24-h period, or
the combination of both, induced a significant production of COX
metabolites, mainly TXB2, the stable metabolite of TXA2, and
prostaglandins E2 (PGE2) and PGF2a. Particularly, a striking
increase of TXB2 levels, significantly higher than those obtained
with T. cruzi and ET-1 separately, was detected in response to [T.
cruzi+ET-1] (Figure 4A). Likewise, induction of the Ca2+/Cn/
NFAT/COX-2 pathway and eicosanoid production were also
achieved in ET-1-primed HL-1 cells exposed to a parasite lysate
preparation, thereby suggesting that cardiac cell invasion by
trypomastigotes is not absolutely required to produce the
cooperative effect with the peptide (not shown). TXB2, PGE2
and PGF2a synthesis was drastically reduced in the cells incubated
with indomethacin (10 mM), a non-steroidal anti-inflammatory
drug known to inhibit both COX-1 and COX-2 enzymatic
activity, or with a COX-2-selective inhibitor (NS398, 10 mM),
indicating the important involvement of COX-2 in eicosanoid
production upon ET-1 stimulation and T. cruzi infection of HL-1
cardiomyocytes. Treatment of HL-1 cells with COX inhibitors or
Cn antagonist had no significant effect on cardiomyocyte-T. cruzi
association and did not affect the capacity of the parasites to
transform into amastigotes and multiply intracellularly (not
shown). Furthermore, analyses for microsomal prostaglandin E
synthase-2 (mPGES-2), prostaglandin F synthase (PGFS) and
thromboxane synthase (TXS), enzymes that convert the COX
product PGH2 to PGE2, PGF2a and TXA2, respectively, revealed
that [T. cruzi+ET-1] also induced the expression of TXS and
PGFS proteins in atrial HL-1 myocytes (Figure 4B).
In addition, stimulation with ET-1 promoted a three-fold
increased (P,0.05) release of ANP. Compared to that observed in
mock-treated controls, T. cruzi also up-regulated ANP levels in the
supernatants of 24-h-infected cells, which were significantly
augmented by the cooperative action of [T. cruzi+ET-1]
(Figure 4C).
Discussion
Trypanosoma cruzi induces multiple responses in the heart, a
critical organ of infection and pathology in the host. We herein
demonstrated that Cox2 mRNA and protein are induced in mouse
heart tissue during T. cruzi infection correlating with cardiac
parasite load and myocarditis. This up-regulation was also
associated to induction of TXS and of two markers of heart
dysfunction previously implicated in Chagas’ disease pathogenesis,
such as ET-1 and ANP [7,10,27]. Up-regulation of Cox2 mRNA
and protein in myocardial tissue of infected C57BL/6 mice is
consistent with a previous report [22] that revealed increased
COX-2 protein expression in the heart of infected BALB/c mice.
Moreover, several evidences have suggested a role of cycloox-
oygenase-derived eicosanoids in the cardiopathogenesis of Chagas’
disease (revised in [42,43]).
*P,0.05. (E) Levels of circulating peptides (ET-1 and ANP) and eicosanoids (PGF2a and TxB2) in the sera of uninfected (black bars) and T. cruzi-infected
(grey bars) C57BL/6 mice. Mouse sera were collected before and after 21 days of infection, and were assayed in triplicate by capture ELISA for ANP
(top panel), ET-1 (central panel), PGF2a and TxB2 (bottom panel). Each bar represents the mean values for groups of 6 mice 6 s.e.m. Similar results
were obtained in two additional experiments. *P,0.05; **P,0.01.
doi:10.1371/journal.pntd.0002034.g001
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Figure 2. Trypanosoma cruzi infection of endothelin-1-pre-treated HL-1 cardiomyocytes induces cyclooxygenase-2 expression. (A)
COX-2 protein expression in primary BALB/c cardiac myocytes infected with T. cruzi. Neonatal mouse heart cells were isolated and ex vivo infected
with Y strain trypomastigotes (cell:parasite ratio 1:5) for 24 h. To obtain a positive control, the cells were incubated with 25 U/ml recombinant IFN-c
plus 1 mg/ml LPS. Uninfected cells (Mock) were used as controls. The levels of COX-2 and b-actin proteins were analysed by immunoblotting as
described under ‘Materials and methods’. (B) Effects of ET-1 pre-treatment and T. cruzi infection of HL-1 cardiomyocytes on Cox2 mRNA expression.
HL-1 atrial muscle cells were stimulated with 0.3 nM ET-1 for 2 h, and/or infected with T. cruzi trypomastigotes (cell:parasite ratio 1:5) for 3 h, and the
levels of Cox2 mRNA were assessed by reverse transcription and PCR; Actb (b-actin) was used as a loading marker. (C) Effects of ET-1 pre-treatment
and T. cruzi infection of HL-1 cardiomyocytes on COX-2 protein expression. HL-1 atrial muscle cells were stimulated with 0.3 nM ET-1 for 2 h, and/or
infected with T. cruzi trypomastigotes for 3 h, and the levels of COX-2 and a-tubulin proteins were analysed by immunoblotting. (D) Effects of ET-1
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Using adult HL-1 atrial myocytes, we further demonstrated that
cooperation between T. cruzi and ET-1 stimulated Cox2mRNA and
protein expression leading to the release of eicosanoids. ET-1 seems
to be mainly implicated in the establishment of chagasic cardiomy-
opathy rather than in the control of infection. Previous studies on T.
cruzi-infected ET-1 null mice have highlighted the pathogenic role
of cardiac myocyte-derived ET-1 in Chagas’ heart disease, but these
animals did not display higher parasitemia nor lower survival rate
than infected wild-type mice [8]. In chagasic heart dysfunction,
locally produced ET-1 acts on cardiac myocytes in both an
autocrine and/or paracrine manner and chronically induces muscle
injury [5,7]. In addition, exposure of neonatal rat ventricular
cardiomyocytes to ET-1 has been shown to result in higher COX-2
and prostacyclin formation [21,44]. In our study, ET-1 induced a
dose-dependent increase (not shown) in COX-2 activity and
eicosanoid biosynthesis in HL-1 cells subsequently infected with
T. cruzi. Tomimic the pathological microenvironment characteristic
of T. cruzi-mediated cardiomyopathy, a 0.3 nM ET-1 concentra-
tion, close to that detected in the circulation of infected mice and
patients exhibiting cardiac involvement [5,6], was selected for pre-
treatment of cardiomyocytes.
Trypanosoma cruzi invasion of HL-1 cells increased [Ca2+]i,
similar to previous report on primary cardiomyocytes [41].
Furthermore, ET-1 induces Ca2+ release in cardiac myofibers
[45]. Alterations in [Ca2+]i regulation are frequently recorded in
Chagas’ disease. In cardiomyocytes from chagasic patients there is
a dysregulation of the diastolic [Ca2+]i, while Ca
2+ channel
blockers display therapeutic potential against chronic chagasic
cardiomyopathy [46,47]. It has been largely established the
requirement for sustained increases, including Ca2+ oscillation
frequency, in [Ca2+]i to mediate Cn activation and the nuclear
translocation of NFAT [48]. Few studies so far have addressed the
impact of T. cruzi infection on the Cn/NFAT pathway in host
cells. NFAT has been identified as an important element in innate
immunity to T. cruzi and also involved in parasite immune evasion
[49,50]. The Ca2+/Cn/NFAT pathway has proven functional in
adult mouse heart muscle cells and ET-1 has been shown to
activate this signaling route in HL-1 atrial myocytes [51,52].
Noticeably, NFAT proteins have been described as key molecules
for the regulation of Cox2 gene transcription in many different cell
types [19,53–55]. Our present report constitutes the first
demonstration that the cooperative effect of ET-1 and T. cruzi
infection transcriptionally controls Cox2 expression through
activation of the Cn/NFATc4 signaling cascade in cardiomyo-
cytes. Particularly, the two NFAT binding sites in the Cox2
promoter appear to be critical for the observed induction.
Mutation of any of these sites strongly diminished Cox2
transcription raised by T. cruzi infection of ET-1-stimulated
cardiomyocytes, and dominant negative NFAT prevented that
stimulation.
Interestingly, this Cn/NFAT pathway has a pivotal role in
pathological cardiac hypertrophy [26]. In this regard, we found
that ET-1 plus T. cruzi infection leads to enhanced production of
the pro-hypertrophic ANP, a prognostic factor for impairment in
cardiac function of chagasic patients [28]. Augmented ANP was
previously observed in atrial muscle cells upon ET-1 stimulation
[56] and, during T. cruzi infection, ET-1 and ANP seem to be
important late factors in myocardial remodeling and hypertrophy
[10,27]. Increased ANP production is somehow linked to the
myocardial regulatory pathway induced by [T. cruzi+ET-1]. Thus,
PGE2 and PGF2a are known to promote ANP synthesis and
release [57,58], while Ca2+ influx is involved in ET-1-triggered
ANP expression [59]. More interestingly, NFATc4 was found to
regulate several hypertrophy-associated gene transcription in
cardiomyocytes, including ANP [26,58]. Taken the data together,
it is likely that Ca2+ elevation, induced by [T. cruzi+ET-1], has led
to NFATc4 activation, COX-2 induction and augmented ANP
secretion by HL-1 cells.
A dual role of cyclooxygenase-derived eicosanoids in the course
of Chagas’ disease has been postulated (revised in [42,43]).
Morever, the same COX metabolites that mediate host survival
during the acute phase may contribute to the progression of
cardiac remodeling and heart damage in the chronic phase [60].
The mechanisms involved in the increased prostanoid production
in parasite-infected hosts are not yet fully understood. Our findings
indicate that the combined effect of ET-1 priming and T. cruzi
infection mimics what likely takes place in the heart during
infection, inducing eicosanoid-forming enzyme activity through
the Ca2+/Cn/NFAT signaling pathway, and leading to enhanced
release of prostanoids by atrial cardiomyocytes. Acutely infected
mice display elevated PGF2a plasma levels, whereas PGE2 has
been found to favor the development of cardiac fibrosis and
functional deficits after infection by T. cruzi [23,61]. TXA2,
measured as the stable metabolite TXB2, is the main eicosanoid
produced during chronic infection with T. cruzi and this pro-
inflammatory agent could be responsible of several of the
pathophysiological features of chagasic cardiomyopathy [23,24].
TXA2 may exacerbate cardiomyocyte apoptosis, facilitate cytokine
biosynthesis by monocytes, activate endothelial cells, and also
promote platelet activation, aggregation and degranulation [62]. It
is conceivable that the liberated TXA2 might play a role in a
feedback loop for ET-1 expression/response, as efficient regulation
of ET-1 by a TXA2 mimetic in rat heart smooth muscle cells has
been documented [63]. Moreover, the released PGF2a could
further induce COX-2 expression and activity, as occurs in
carcinoma cells [64]. Enhanced levels of eicosanoids synthesized
by [T. cruzi+ET-1]-activated HL-1 cells were down-regulated by
addition of COX-2 inhibitors, indomethacin or NS398. In this
regard, meloxicam or etoricoxib, two specific COX-2 inhibitors,
minimized the amount of inflammation and fibrosis in the cardiac
tissue of infected mice, whereas delayed treatment with aspirin,
which blocks COX-1 and COX-2 indistinctly, improved cardiac
dysfunction in a murine model of Chagas’ heart disease [22,60].
However, the potential benefits of COX inhibition for chronic
pre-treatment and T. cruzi infection of HL-1 cardiomyocytes on the inducibility of the Cox2 promoter. Cells were transiently transfected with the P2-
1900-Cox-2-LUC reporter construct, and then stimulated with 0.3 nM ET-1 for 2 h, and/or infected with trypomastigotes for 3 h. For some
experiments, FK506 (100 ng/ml) was added to [T. cruzi+ET-1]-activated cardiomyocytes. PMA+Ion was used as a standard stimulus. Luciferase activity
is expressed as fold induction relative to the transfection with empty expression vector. Data are the means 6 s.e.m. of three independent
experiments, each performed in triplicate. *P,0.05. (E) Involvement of NFAT in Cox2 induction by T. cruzi plus ET-1. HL-1 cells were transiently
transfected with the P2-1900-Cox-2-LUC reporter construct, with the P2-274-Cox-2 promoter construct, or with the same construct containing distal
and/or proximal NFAT sites (dNFAT and pNFAT, respectively), and/or actvated protein-1 (AP-1) site mutated (indicated by X). For some experiments,
the cells were transiently co-transfected with the P2-274-Cox-2-LUC reporter plasmid along with a dominant-negative version of NFAT (dn-NFAT).
Three hours later, the cells were stimulated with ET-1 (0.3 nM) for 2 h and infected with T. cruzi parasites for 3 h. Luciferase activity is expressed as
percentage of induction (mean 6 s.e.m.) relative to that achieved in P2-1900-Cox-2-LUC transfected cells. One out of three separate experiments
performed is shown. *P,0.05; ** P,0.001 (respect to the P2-274 construct).
doi:10.1371/journal.pntd.0002034.g002
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Figure 3. Activation of the Ca2+/Calcineurin/NFAT intracellular signaling pathway in endothelin-1-stimulated and Trypanosoma
cruzi-infected cardiomyocytes. (A) HL-1 cells, exposed or not to 0.3 nM ET-1, were loaded with the Ca2+ indicator Fura-2/M and changes in [Ca2+]i
upon T. cruzi infection were recorded. Uninfected cells were used as a control. Arrows indicate the time (min) when either culture medium (M) or T.
cruzi trypomastigotes (T) was added. The results presented are representative of three independent experiments. (B) ET-1 stimulated and T. cruzi-
infected HL-1 cardiomyocytes were disrupted and the protein expression of the four NFAT isoforms (c1 to c4) was analysed by immunoblotting.
Alpha-tubulin protein levels were determined as a control of loading. (C) HL-1 cells were incubated for 2 h with ET-1 (0.3 nM) and subsequently
infected with T. cruzi trypomastigotes for 3 h. For some experiments, FK506 (100 ng/ml) was added 1 h before stimulation. Fractionated extracts from
both untreated and treated cells were analysed by immunoblotting with an antiserum to NFATc4. The phosphorylated cytosolic (P-NFATc4) or
dephosphorylated nuclear (NFATc4) forms of the factor are indicated. Cyto, cytosolic extracts; Nucl, nuclear extracts. (D) Electrophoretic mobility shift
assay (EMSA) analysis to determine NFATc4 binding to the NFAT sites of the Cox2 gene (Cox-2 NFAT). HL-1 myocytes were stimulated with 0.3 nM ET-
1 for 2 h and/or infected with T. cruzi trypomastigotes for 3 h. For some experiments, FK506 (100 ng/ml) was added 1 h before stimulation. Mock-
treated cells were considered as controls. PMA (15 ng/ml) supplemented with 1 mM Ion was used as a standard stimulus. Nuclear extracts were
analysed by EMSA using a Cox-2 NFAT radiolabeled probe. A 50-fold molar excess of unlabeled Cox-2 NFAT oligonucleotide (T. cruzi+ET-1+Cox-2
NFAT) was added to determine specific binding. NFATc4 antibody or normal rabbit IgG was added to the extracts before incubation with the probe.
Arrows indicate specific supershifted complexes. This is representative of at least three independent experiments.
doi:10.1371/journal.pntd.0002034.g003
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Figure 4. Production of eicosanoids and atrial natriuretic peptide by endothelin-1-stimulated and Trypanosoma cruzi-infected HL-1
cardiac cells. (A) Cardiomyocytes were serum-starved for 12 h, then incubated for 1 h in the presence of cyclooxygenase inhibitors (10 mM
indomethacin -Indo- or 10 mM NS-398) and further stimulated with 0.3 nM ET-1 for 2 h. After treatment, the cells were infected with T. cruzi
trypomastigotes for 24 h. HL-1 myocytes infected with the parasite or stimulated with ET-1 alone were included in the assay. Culture supernatants
were collected and analysed for PGE2, PGF2a and TxB2 (TxA2 stable metabolite) by ELISA (Cayman). The results represent means 6 s.e.m. of three
individual experiments assayed in triplicate. *P,0.05 and **P,0.001 compared with mock-treated cells; #P,0.05 and ##P,0.001 compared with NS-
398- and Indo-treated cells, respectively. (B) Effects of T. cruzi infection and ET-1 stimulation on the expression of prostanoid terminal synthases in
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chagasic patients are still unknown. Even though T. cruzi-derived
TXA2 and PGF2a have been associated with pathogenesis [24,43],
no consistent evidence of parasite COX-2 and TXAS expression is
available so far. As we detected overexpression of myocardial
enzymes by using mouse-specific probes/antibodies and damp-
ened eicosanoid production in cardiomyocytes treated with
mammalian enzyme-specific inhibitors, our data mostly reflect
the contribution of prostanoids secreted by host cells to Chagas’
myocarditis.
In conclusion, we have demonstrated that eicosanoid-convert-
ing enzymes are expressed in the infected heart and also that
cardiomyocytes respond to ET-1 and T. cruzi infection by
induction of COX-2 through activation of the Ca2+/Cn/NFAT
intracellular signaling pathway. The cooperation between T. cruzi
and ET-1 also led to overproduction of eicosanoids and the pro-
hypertrophic factor ANP. These results support an important role
for NFAT in [T. cruzi+ET-1]-dependent induction of key agents of
pathogenesis in chronic chagasic cardiomyopathy. Identification of
the Ca2+/Cn/NFAT cascade as mediator of cardiovascular
pathology in Chagas’ disease advances our understanding of
host-parasite relationship and may help define novel potential
targets for therapeutic interventions to ameliorate or prevent
cardiomyopathy during chronic T. cruzi infection.
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Myeloid-Derived Suppressor Cells Infiltrate the Heart in
Acute Trypanosoma cruzi Infection
Henar Cuervo,* Ne´stor A. Guerrero,*,† Sofı´a Carbajosa,* Alain Beschin,‡,x
Patrick De Baetselier,‡,x Nu´ria Girone`s,*,†,1 and Manuel Fresno*,†,1
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, affects several million people in Latin America. Myocarditis,
observed in the acute and chronic phases of the disease, is characterized by a mononuclear cell inflammatory infiltrate. We
previously identified a myeloid cell population in the inflammatory heart infiltrate of infected mice that expressed arginase I. In
this study, we purified CD11b+ myeloid cells from the heart and analyzed their phenotype and function. Those CD11b+ cells were
∼70% Ly6G2Ly6C+ and 25% Ly6G+Ly6C+. Moreover, purified CD11b+Ly6G2 cells, but not Ly6G+ cells, showed a predominant
monocytic phenotype, expressed arginase I and inducible NO synthase, and suppressed anti-CD3/anti-CD28 Ab-induced T cell
proliferation in vitro by an NO-dependent mechanism, activity that best defines myeloid-derived suppressor cells (MDSCs).
Contrarily, CD11b+Ly6G+ cells, but not CD11b+Ly6G2 cells, expressed S100A8 and S100A9, proteins known to promote recruit-
ment and differentiation of MDSCs. Together, our results suggest that inducible NO synthase/arginase I-expressing CD11b+
Ly6G2 myeloid cells in the hearts of T. cruzi-infected mice are MDSCs. Finally, we found plasma L-arginine depletion in the
acute phase of infection that was coincident in time with the appearance of MDSCs, suggesting that in vivo arginase I could be
contributing to L-arginine depletion and systemic immunosuppression. Notably, L-arginine supplementation decreased heart
tissue parasite load, suggesting that sustained arginase expression through the acute infection is detrimental for the host. This
is, to our knowledge, the first time that MDSCs have been found in the heart in the context of myocarditis and also in infection by
T. cruzi. The Journal of Immunology, 2011, 187: 2656–2665.
C
hagas disease, which is caused by the protozoan parasite
Trypanosoma cruzi, affects ∼18 million people in Latin
America, with 120 million at risk, thus remaining a major
cause of morbidity and mortality in that region (1). Myocarditis
that occurs as a result of infection is the most serious and frequent
manifestation of chronic Chagas disease and appears in 30% of
infected individuals several years after the infection. The patho-
genesis is thought to be dependent on an immune-inflammatory
reaction to a low-grade infection (2, 3). T. cruzi has a complex life
cycle involving several life stages in both vertebrates and insect
vectors. It infects and replicates in macrophages and cardio-
myocytes and many other cell types. Resistance to the disease is
associated with a Th1 response, which efficiently controls in-
fection through IFN-g production and further increased activity
of inducible NO synthase (iNOS; also termed NOS2), which
metabolizes L-arginine (a semiessential amino acid) and produces
NO (4). In addition, during acute infection, there is suppression of
T cell proliferation that is partially caused by NO (5). Moreover,
the development of severe cardiomyopathy in Chagas disease is
also thought to be due to a Th1-specific immune response (6).
In contrast, L-arginine can also be used by arginase I, which
produces ornithine that in turn is metabolized by ornithine de-
carboxylase to produce polyamines needed for growth of all eu-
karyotic cells. In this regard, arginase I expression was found to
be upregulated in macrophages infected with T. cruzi and asso-
ciated with parasite survival (7, 8).
In mice, arginase I has been described to be expressed by dif-
ferent myeloid cell subsets such as alternatively activated mac-
rophages (also called M2 macrophages) and myeloid-derived
suppressor cells (MDSCs), among others. Whereas M2 macro-
phages are thought to express arginase I but not iNOS (9), MDSCs
can express both enzymes (10). M2 macrophages induced by type
2 and regulatory cytokines have been implicated in parasite
growth (11) and can be defined by an M2 gene signature (12). In
contrast, MDSCs accumulate during acute and chronic immune
responses to pathogens, tumor growth, trauma, and other immu-
nological responses (13). These cells are commonly identified in
mice by the coexpression of CD11b and Gr-1 (Ly6G/Ly6C) sur-
face markers. However, this population shows important pheno-
typic differences depending on the anatomical site where they are
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located or the pathological condition. In addition, in tumor-
induced MDSCs, discrete subpopulations with distinct T cell
suppressive activity have been identified (14). Therefore, a rigid
classification for MDSCs is not actually available, and their def-
inition is still a matter of debate.
Arginase I and iNOS, either separately or in combination, can
inhibit T cell responses. L-Arginine is required for T cell pro-
liferation, and the threshold of L-arginine concentration in mam-
malian plasma that permits fully functional T cell proliferation is
100 mM (15). Moreover, combined activity of arginase I and iNOS
enzymes has been shown to be important in the suppressive ac-
tivity of mouse MDSCs in tumors (16), but there also exists var-
ious evidence of the role of MDSCs, iNOS, and L-arginine
depletion in infectious diseases such as chronic infections with
helminths (17). In addition, in experimental infections with T.
cruzi, the existence of an IFN-g–induced, NO-dependent mecha-
nism of T cell suppression has been described (5, 18).
We have previously reported the existence of a population of in-
filtrating myeloid cells expressing arginase I in the hearts of mice
during the acute phase of Chagas disease (19). The aim of this
work was to characterize the heart-infiltrating myeloid CD11b+
cells in acute T. cruzi infection. We found that the heart-infiltrating
myeloid CD11b+ cells included granulocytic Ly6G+ and mono-
cytic Ly6G2 subpopulations; the phenotype and function of the
latter cells indicate that they are closely related to the so-called
MDSCs. The monocytic myeloid cell subset, but not the granu-
locytic subset, expressed arginase I and iNOS activity and was
able to inhibit T cell proliferation in vitro in an NO-dependent
manner. Persistent arginase I expression leads to a decreased
plasma L-arginine concentration during acute infection. Notably,
supplementation of infected mice with L-arginine diminished
parasite load. To our knowledge, this is the first report about
MDSCs infiltrating the heart, in the context of myocarditis, and of
plasma L-arginine depletion during acute T. cruzi infection, which
are able to downregulate the immune response. This may have
consequences in chronic cardiac Chagas disease.
Materials and Methods
Parasites and mice
Young adult (6- to 8-wk-old) BALB/c and C57BL/6 mice were purchased
from Charles River Laboratories. All the infections were performed with the
Y strain of T. cruzi. Blood trypomastigotes were routinely maintained by
infecting mice and purifying them from their blood. For experiments, 2 3
103 trypomastigotes per mouse was inoculated by i.p. injection. Para-
sitemia was monitored by the Brener method as described (20). When
indicated, mice were supplemented with 1 mg/ml L-NG-nitroarginine
methyl ester (hydrochloride) (L-NAME) or 3.75 mg/ml L-arginine in the
drinking water, which was replaced every other day.
Ethics statement
This study was carried out in strict accordance with the recommendations of
Spanish legislation and the European Council directive from the Convention
for the Protection of Vertebrate Animals Used for Experimental and Other
Scientific Purposes (21). All mice were maintained under pathogen-free
conditions in the animal facility at the Centro de Biologı´a Molecular,
Universidad Auto´noma de Madrid (Madrid, Spain). The animal protocol
was approved by the Comite´ de E´tica de la Investigacio´n de la Universidad
Auto´noma de Madrid. Animals had free access to food and water and were
handled in compliance with European norms. Mice were euthanized in
a CO2 chamber, and all efforts were made to minimize suffering.
Elicitation of organs and T, CD11b, and Ly6G magnetic cell
sorting
In each experiment, 5–15 BALB/c or C57BL/6 mice were infected i.p.
Mice were euthanized, at different days postinfection, in a CO2 chamber,
and hearts were aseptically removed, perfused with 10 ml PBS–heparin
solution, and kept in cold HBSS. Then, hearts were pooled in a cell culture
dish, washed thoroughly with HBSS, and minced into small pieces with
a sterile surgical blade. Heart pieces were then processed with a Gentle-
Macs (Miltenyi Biotech) and with an enzyme mixture following the
directions of the manufacturer. The cell pellet was resuspended in RPMI
1640 supplemented with 5% FBS. Blood from infected and noninfected
mice was obtained by cardiac puncture and treated with heparin. Spleen
cells were obtained by mechanical disruption of spleens and passed
through a 40-mm cell strainer (BD Falcon). Single-cell suspension of
PBMCs and spleen cells was depleted of erythrocytes by hypotonic lysis
and washed with cold PBS. Peritoneal cell exudates were obtained after
peritoneal cavity lavage of noninfected mice with 7 ml of a solution of
sucrose (116 g/l) in PBS. CD11b+ cells were purified from heart, blood,
spleen, and peritoneal lavage cells using CD11b microbeads (Miltenyi
Biotec). T cells were isolated from spleen cells of noninfected mice with
the Pan T cell kit using MACS LS columns and MACS Separators (Mil-
tenyi Biotec) following the manufacturer’s instructions. CD11b+ and T
sorted cells were analyzed by flow cytometry and showed 95% cell purity.
For Ly6G+ cell sorting, an anti-Ly6G microbead kit (Miltenyi Biotec) was
used with the above-mentioned separating system. The Ly6G2 fraction of
the cell suspension was 95% pure and was afterward processed for CD11b
sorting and Giemsa staining.
mRNA analysis by quantitative RT-PCR
Total RNA was extracted from heart, blood, or isolated cells in TRIzol
reagent (Invitrogen) as indicated by the manufacturer. For quantitative RT-
PCR analysis, in indicated experiments, reverse transcription of total RNA
was performed using the components of the High Capacity cDNA Archive
Kit (Applied Biosystems), and amplification of different genes [Arginase
(Arg)1, Arg2, NO synthase (Nos)2, Tlr2, Tlr4, PG (Pstg)1, Ptgs2, Ccl2,
Ccl3, Ccl5, Ccl17, Cxc2, Cxcl9, Cxcl10, Cxcl12, Il1b, Il4, Il6, Il10, Il12a,
Il13, Tnf, Ifng, Tgfb, S100 calcium binding protein (S100)a8 and S100a9,
and ribosomal housekeeping S18] was performed using the corresponding
mouse TaqMan MGB probes and the TaqMan Universal PCR Master Mix
(Applied Biosystems) on an ABI Prism 7900 HT instrument (Applied
Biosystems). M2 gene signature expression was carried out, in indicated
experiments, using Superscript II reverse transcriptase (Invitrogen) for
reverse transcription and iQ SYBR Green Supermix (Bio-Rad, Hercules,
CA) for quantitative RT-PCR in an iCycler (Bio-Rad) for the identified
common M2 signature including macrophage mannose receptor (Mrc1),
found in inflammatory zone (Fizz) 1 (Retlna), macrophage galactose-type
C-type lectin (Mgl)2, Chitinase 3-like 3/4 (Ch3l3/4), cadherin-1 (Cdh1),
plasma platelet–activating factor acetylhydrolase (Pla2g7), prosaposin
(Psap), selenoprotein (Sepp)1, folate receptor (Folr)2, and triggering re-
ceptor expressed on myeloid cells (Trem)2 as previously described (12). All
samples were run in triplicate. Quantification of gene expression by real-
time PCR was calculated by the comparative threshold cycle (CT) method
following the manufacturer’s instructions. All quantifications were nor-
malized to the housekeeping gene, as indicated, to account for the vari-
ability in the initial concentration of RNA and in the conversion efficiency
of the reverse transcription reaction (DCT) and to values from control
samples (CD11b+ cells from blood or peritoneal exudates, as indicated)
from noninfected mice (DDCT). The relative quantity (RQ) when using
TaqMan probes was calculated as RQ ¼ 22DDCT . Graphs were plotted as
RQ or log RQ. The fold induction for M2 gene expression analysis was
normalized against the housekeeping gene S12.
Protein expression analyses
Protein was determined by Western blot analyses. Protein extracts were
prepared in PBS containing 0.1% Triton X-100, 100 mg/ml pepstatin, 100
mg/ml aprotinin, and 100 mg/ml antipain. Protein concentration was de-
termined by the bicinchoninic acid (BCA) method (Pierce). Western blot
analyses were performed as follows: 20 mg tissue extract was fractionated
on SDS 10 or 15% polyacrylamide gel and transferred to a nitrocellulose
membrane (Hybond-ECL; Amersham). When indicated, protein loading
was visualized by Ponceau staining (Sigma). Primary Abs were diluted as
follows: goat anti-mouse arginase I (V-20; Santa Cruz Biotechnology)
1:1000, S100A8 and S100A9 (R&D Systems) 1:500, purified anti-mouse
iNOS (BD Transduction) 1:500, and goat anti-mouse actin (I-19; Santa
Cruz Biotechnology) 1:1000. Then, the membranes were incubated with
HRP-conjugated rabbit anti-goat (Sigma) 1:10,000 or goat anti-mouse
(Pierce) 1:1000 Abs. Detection was carried out with Supersignal de-
tection reagent (Pierce) and photographic film exposure.
Flow cytometry
Staining was performed in 96-well plates (Nunc). Single-cell suspensions
were fixated with paraformaldehyde 1% in PBS for 1 h at 4˚C. Cells were
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washed with cold PBS throughout the whole staining procedure. Fc
receptors on cells were blocked by incubating with purified anti-CD16/
CD32 Ab (Mouse BD Fc Block; BD Pharmingen) for 15 min at 4˚C. Cells
were then stained with the different conjugated Abs, washed, and acquired
on a FACSCanto Cytometer (Becton Dickinson). For intracellular staining,
after the staining of surface molecules, cells were incubated 15 min in the
presence of 0.2% saponin, washed, and incubated for 20 min with anti-
CD68, washed again, and acquired as mentioned above. All data were
analyzed with the FlowJo software (Tree Star).
Abs used were the following: PE–Cy7–conjugated or Alexa Fluor 647-
conjugated anti-CD11b (clone M1/70; BD Pharmingen), FITC-conjugated
or PE-conjugated anti-Ly6G/Ly6C (Gr-1, clone RB6-8C5; BD Pharmin-
gen), Alexa Fluor 647-conjugated anti-Ly6C (clone AL-21; AbD Serotec),
PE-conjugated anti-CD68 (FA-11; AbD Serotec), PE-conjugated anti-
MHC class II (I-A/I-E, clone M5/114.15.2; eBioscience), PE-conjugated
anti-F4/80 (clone BM8; AbD Serotec), PE-conjugated anti-CD11c (clone
HL3; BD Pharmingen), FITC-conjugated anti-CD49b (clone DX5; eBio-
science), and FITC-conjugated anti-CCR3 (clone 83101; R&D Systems).
PE-conjugated Armenian hamster IgG1 (BD Pharmingen), PE-conjugated
rat IgG2a (BD Pharmingen), FITC-conjugated rat IgG2a (BD Pharmin-
gen), Alexa Fluor 647-conjugated rat IgG2a (AbD Serotec), PE–Cy7–
conjugated rat IgG2b (BD Pharmingen), and FITC-conjugated rat IgM
(eBioscience) Abs were used as isotypic controls.
Proliferation assays
Purified CD11b+ cells from hearts of infected mice and blood from non-
infected mice were obtained as described earlier, counted, and resuspended
in complete RPMI 1640 with 0, 100, and 1000 mM L-arginine supple-
mented with 5% FBS. A total of 2 3 105 cells per well were plated in flat
96-well plates (Nunc). T cells sorted from the spleens of noninfected mice
were resuspended in the same media and plated with or without CD11b+
purified cells isolated from hearts of infected mice or blood or spleens
from noninfected mice in a 1:1 ratio. Cell cultures were stimulated with 5
mg/ml purified anti-CD3 (BD Pharmingen) and 1 mg/ml purified anti-
CD28 Ab (BD Pharmingen), and, when indicated, 24 mM Nv-hydroxy-
nor-L-arginine (nor-NOHA; Calbiochem) or 2 mM NG-monomethyl-L-ar-
ginine (L-NMMA; Calbiochem) were added. After incubation at 37˚C and
5% CO2 for 24 h, 1 mCi [
3H]thymidine (Amersham Pharmacia Biotech)
was added to each well. Cells were then harvested on a glass-fiber filter by
use of a Cell Harvester (Skatron Instruments), and radioactivity was esti-
mated in a microb counter (Maxwell) and incorporation expressed as
counts per minute.
L-Arginine determination in plasma and culture supernatants
Plasma and 1:10 diluted supernatants from cultured cells were centrifuged
at 14,000 rpm to remove protein precipitates, and 5 ml was subjected to
HPLC analysis for L-arginine determination using an HPLC chromato-
graph coupled to a triple quadrupole mass spectrometer (Varian 1200L;
Agilent Technologies).
Statistical analysis
For in vivo experiments, data are reported as means 6 SEM from triplicate
determination of a representative experiment of at least two independent
experiments with different experimental conditions. Results shown from
in vitro experiments are representative of at least two experiments per-
formed in triplicate. Significance was evaluated by Student t test with
GraphPad Prism version 5.00 for Windows (GraphPad Software, San
Diego CA); the Welsh correction was applied when different variances
were observed. All differences mentioned were significant compared with
controls (*p , 0.05, **p , 0.01, and ***p , 0.001).
Results
Characterization of CD11b+ cells from the hearts of
T. cruzi-infected mice
We previously described a population of myeloid cells expressing
arginase I infiltrating the hearts of mice during acute T. cruzi in-
fection (19). To characterize further the myeloid-infiltrating cells,
CD11b+ populations from hearts of infected mice (HI) were iso-
lated at the time in which arginase I heart tissue expression was
maximal [14 d postinfection (dpi) and 21 dpi in C57BL/6 and
BALB/c mice, respectively] (19). For comparison purposes, we
used CD11b+ cells from peripheral blood of noninfected mice
(BNI) because hearts from the latter mice were devoid of CD11b+
cell infiltration. CD11b+ cells from the blood of infected mice (BI)
were also purified and characterized. The results showed that ar-
ginase I protein expression was strongly upregulated in CD11b+
HI cells in comparison with CD11b+ BNI cells both in C57BL/6
and BALB/c infected mice (Fig. 1). Arginase I protein was also
expressed in CD11b+ BI cells, but at lower level than that in
CD11b+ HI cells. Arginase I protein expression was higher in
BALB/c than in C57BL/6 mice in the three cell types investigated
likely reflecting the fact that BALB/c mice are more prone to
develop Th2 and M2 responses (22). Notably, iNOS protein ex-
pression was detected in CD11b+ HI cells, but not in CD11b+ BI
and BNI cells from C57BL/6 and BALB/c mice (Fig. 1).
We analyzed the expression of several genes by quantitative RT-
PCR in CD11b+ HI purified cells from infected BALB/c mice at
21 dpi, including: proinflammatory/M1-associated cytokines and
chemokines genes required for protection against T. cruzi in-
fection; anti-inflammatory/regulatory/M2-associated cytokines and
chemokines that favor parasite replication; and TLRs involved
in T. cruzi recognition. Gene expression analysis of the genes
coding for arginase I (Arg1) and iNOS (Nos2) in infected BALB/c
paralleled the protein expression data (Fig. 2A versus Fig. 1). The
expression of Arg2 in CD11b+ HI and BI cells was impaired
compared with that in CD11b+ BNI cells. In contrast, in CD11b+
HI cells, gene expression of Tlr2 in comparison with that in
CD11b+ BNI cells was increased, whereas Tlr4 was reduced (Fig.
2B). Ptgs1 and Ptgs 2 genes coding for cyclooxygenase 1 and 2
enzymes and involved in the production of inflammatory media-
tors were downregulated and upregulated, respectively, in CD11b+
HI cells in comparison with that in the CD11b+ BNI cells (Fig.
2C). M1 chemokine genes, previously reported to be expressed in
heart tissue during T. cruzi infection, such as Ccl2 and Cxcl9 (23)
were found to be expressed at higher levels in CD11b+ HI cells
with respect to CD11b+ BNI cells, whereas Ccl3, Ccl5, Cxcl2,
Cxcl10, and Cxcl12 showed a more discrete induced expression.
The M2-associated chemokine gene Ccl17 did not show a signif-
icant increment of expression in CD11b+ HI cells (Fig. 2D).
CD11b+ HI cells also showed strong gene expression encoding for
the regulatory cytokine IL-10 (Il10) and, at a lower level, proin-
flammatory cytokines such as Il6, Ifng, Il12a, and Tnf, whereas
other anti-inflammatory cytokines showed downregulation (Il4,
Il13, and Tgfb1; Fig. 2E). It should be mentioned that in general,
the trend of the modulation of expression was similar in CD11b+
HI and BI cells of the different genes tested, with the exception of
FIGURE 1. Expression of iNOS and arginase I proteins in CD11b+ HI
cells from T. cruzi-infected C57BL/6 and BALB/c mice. Mice were
infected i.p. with 2 3 103 blood trypomastigotes of the Y strain and
sacrificed at day 14 and 21 postinfection as indicated, and infected hearts
and blood from infected and noninfected mice were collected. After me-
chanical and enzymatic digestion of heart tissue and PBMCs purification,
CD11b+ cells were purified with CD11b microbeads. Protein extracts were
isolated; 20 mg loaded in 10% SDS-PAGE gels and subjected to Western
blot analyses using anti-arginase I or anti-iNOS Abs. Data are represen-
tative of three independent experiments.
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the genes coding for Ptgs2, Il4, and Ccl17, which were down-
regulated in BI cells but upregulated in HI cells compared with
that in BNI cells (Fig. 2). We also investigated gene expression of
the CD11b+ HI isolated cells by quantitative RT-PCR of 10
markers of M2 activation previously described (12). The results
showed that some M2 genes such as Psap, Trem2, Ch3l3/4, Cdh1,
and Folr2, but not others such as Retlna, Sepp1, and Mgl2, were
significantly overexpressed in CD11b+ HI cells compared with
that in purified CD11b+ of noninfected BALB/c mice (Table I).
Therefore, we can conclude that heart-infiltrating CD11b+ cells
during T. cruzi infection do not show a typical M1 or M2 signa-
ture, likely reflecting the heterogeneity of the CD11b+ population.
Heterogeneity of the CD11b+ cells purified from the hearts of
T. cruzi-infected mice
Next, the composition of the CD11b+ HI sorted population was
analyzed by flow cytometry. Within purified CD11b+ cells, ∼70%
were Ly6G2 and 25% were Ly6G+ (Fig. 3A), suggesting the
presence of two major subpopulations, respectively a monocytic
and a granulocytic subpopulation. This was supported by the
FIGURE 2. Gene expression in CD11b+ cells purified from hearts of T. cruzi-infected BALB/c mice. BALB/c mice were infected i.p. with 23 103 blood
trypomastigotes of the Y strain. Mice were sacrificed at day 21 postinfection, and infected hearts and blood from infected and noninfected mice were
elicited. After mechanical and enzymatic digestion of heart tissue and PBMCs purification, CD11b+ cells were purified with CD11b microbeads. HI, black
bars; BI, dashed bars; BNI, white bars. mRNA was isolated from cells, and (A) ArgI, ArgII, and Nos2, (B) Tlr2 and Tlr4, (C) Ptgs1 and Ptgs2, (D)
chemokines (Ccl2, Ccl3, Ccl5, Cxcl2, Cxcl9, Cxcl10, Cxcl12, and Ccl17), and (E) cytokines (Il1b, Il4, Il6, Il10, Il12a, Il13, Tnf, Ifng, and Tgfb1) expression
was analyzed by quantitative RT-PCR using TaqMan probes. Data are the mean of three independent experiments. Statistically significant differences of HI
and BI with respect to BNI are shown: *p , 0.05, **p , 0.01, ***p , 0.001.
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observation that 1) CD11b+Ly6G2 cells expressed higher levels of
Ly6C (monocytic marker), CD68 (mature macrophage marker),
and MHC class II molecules compared with those of CD11b+
Ly6G+ cells and 2) the CD11b+Ly6G+ cells included a higher
percentage of CCR3+ eosinophils than that of the CD11b+Ly6G2
cells. DX5+ NK cells were detected only in the CD11b+Ly6G+ cell
population. Finally, neither CD11b+Ly6G2 nor CD11b+Ly6G+
cell subpopulations expressed the B cell marker B220 (data not
shown), the macrophage marker F4/80, or the dendritic cell
marker CD11c (Fig. 3B). Together, these data show that CD11b+
HI cell composition is heterogeneous with mainly a monocytic
and a granulocytic/NK cell fraction.
CD11b+ cells isolated from heart tissue of infected mice
suppress T cell proliferation by an NO-dependent mechanism
In addition to arginase I and iNOS expression, suppression of T cell
proliferation is the characteristic that best defines MDSCs (10, 13).
Thus, we analyzed T cell proliferation upon anti-CD3/anti-CD28
Ab stimulation in the presence of CD11b+ HI cells using CD11b+
BNI cells as control. Fig. 4A shows that compared with CD11b+
BNI cells, CD11b+ HI cells were able to suppress proliferation of
stimulated T cells. The addition of iNOS inhibitor L-NMMA to
the cultures, but not of arginase inhibitor nor-NOHA, partially
restored T cell proliferation (Fig. 4A), suggesting that CD11b+ HI-
mediated suppression was likely mediated by an NO-dependent
mechanism. However, it is known that extracellular L-arginine
concentrations below 100 mM impair fully functional T cell pro-
liferation (15). Therefore, we studied T cell proliferation in me-
dium containing different concentrations of L-arginine (0, 100, and
1000 mM) in the presence and absence of CD11b+ cells from
spleens of noninfected mice (NI), (Fig. 4B and 4C, respectively).
The results showed that T cell proliferation was dependent on
L-arginine concentration, and addition of CD11b+ cells to the cul-
ture significantly incremented T cell proliferation with respect to
T cells alone. Therefore, to test the contribution of arginase I to
T cell suppression by L-arginine depletion, we lowered L-arginine
concentration in the culture medium to 100 mM and compared the
effect of CD11b+ HI cells (Fig. 4D) with cultures of T cells alone.
The results showed that when T cells were cultured with CD11b+
HI cells, there was a strong suppressive effect on T cell pro-
liferation. Addition of iNOS and arginase I inhibitors to activated
T cells cultured alone did not significantly affect their pro-
liferation. However, similar to cultures performed in .1 mM L-
arginine (Fig. 4A), there was a partial recovery of T cell pro-
liferation in the presence of L-NMMA, but not in the presence of
Table I. M2 gene signature expression levels in CD11b+ HI as
determined by real-time PCR
Gene Fold Increasea
Fizz (Retlna) Not detected
Pla2g7 2.05
Psap 16.71b
Sepp1 0.15
Trem2 5.81b
Mgl2 0.1
Ch3l3/4 26,075.97b
Mrc1 5.33b
Cdh1 112.89b
Folr2 6.81b
aOn day 21 postinfection, normalized with the ribosomal S12 gene and expressed
relative to peritoneal exudates cells from noninfected mice. Data are shown as mean
of three individual experiments.
bFold increase .5.
FIGURE 3. Flow cytometry analysis of CD11b+ cells purified from hearts
of T. cruzi-infected BALB/c mice. Mice were infected i.p. with 2 3 103
blood trypomastigotes of the Y strain. Mice were sacrificed at day 21
postinfection, and infected hearts were elicited. After mechanical and en-
zymatic digestion of heart tissue, CD11b+ cells were purified with CD11b
microbeads. Cells were stained with anti-CD11b–PE–Cy7 or anti-CD11b–
Alexa Fluor 647, anti-Ly6G/Ly6C(Gr-1)–FITC or anti-Ly6G/Ly6C(Gr-1)–
PE, anti-Ly6C–Alexa Fluor 647, anti-CD68–PE, anti-MHCII–PE, anti-F4/
80–PE, anti-CD11c–PE, anti-CCR3–FITC, and anti-CD49b(DX5)–FITC
Abs and analyzed in FACSCanto. Gray histograms represent isotypic Ab
labeling and white histograms specific staining as indicated. A, Double
staining with Ly6G/Ly6C and CD11b Abs. B, Staining of CD11b+Ly6G2
and CD11b+Ly6G+ gated populations with Ly6C, CD68, F4/80, MHCII,
CD11c, CCR3, and DX5 Abs. Data are representative of at least three in-
dependent experiments. MHCII, MHC class II.
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nor-NOHA (Fig. 4B), suggesting that, in vitro, even at reduced
L-arginine concentration, suppression of proliferation is mostly
mediated by NO. In agreement, the concentration of nitrite in-
creased significantly in the culture supernatants in the presence of
CD11b+ cells, and this was inhibited upon addition of L-NMMA
(Fig. 4E). Finally, Fig. 4F shows that the concentration of L-ar-
ginine was still above the threshold that allows basal T cell pro-
liferation (∼100 mM). Additional L-arginine present in the
supernatants (150 mM) could come from the FBS added to the
RPMI 1640 medium and from intracellular pools. Notably,
CD11b+ HI cells caused a drastic reduction of L-arginine con-
centration in medium when these cells were cocultured with ac-
tivated T cells. This was significantly recovered in the presence of
arginase inhibitor, indicating that arginase is active in CD11b+ HI
cells. Taken together, the above results indicate that CD11b+ HI
cell in vitro T cell immunosuppression is mediated by iNOS.
Purified CD11b+Ly6G2 monocytic cells isolated from heart
tissue of infected mice express iNOS and arginase I and
suppress, in vitro, T cell proliferation by an NO-dependent
mechanism
To characterize in more detail the cells expressing arginase I and
iNOS, Ly6G+, CD11b+Ly6G2, and CD11b2Ly6G2 cells isolated
from hearts of T. cruzi-infected mice were cultured with activated
T cells. Fig. 5A and Table II show that, after magnetic sorting,
∼35% of the cells were Ly6G+ and 65% were Ly6G2, in agree-
ment with flow cytometry analysis (Fig. 3). We recovered an av-
erage of 1.57 3 105 (60.30 3 105) Ly6G+ cells and 2.96 3 105
(60.57 3 105) Ly6G2 per heart of BALB/c infected mice. Mi-
croscopic examination of 20 different fields of Giemsa-stained
cells showed that the phenotype of the Ly6G2 cells was pre-
dominantly monocytic, whereas Ly6G+ cells were ∼70% granu-
locytic and 30% nongranulocytic (Table II and Supplemental
FIGURE 4. Suppression of T cell proliferation in the presence of CD11b+ HI cells from T. cruzi-infected BALB/c mice. Mice were infected i.p. with 23
103 blood trypomastigotes of the Y strain. Mice were sacrificed at day 21 postinfection, and infected hearts were collected. After mechanical and enzymatic
digestion of infected heart tissue (HI) and isolation of blood from noninfected mice (BNI), CD11b+ cells were purified with CD11b microbeads. T cells
were isolated from spleens of noninfected mice (T) with the Pan T cell kit, and the proliferation assays were set up as follows. A, T cells were activated with
anti-CD3 and anti-CD28 Abs and cultured with RPMI 1640 with 1 mM L-arginine in the presence of CD11b+ BNI or CD11b+ HI cells and the presence or
absence of iNOS (L-NMMA) and arginase I (nor-NOHA) inhibitors. B and C, Activated T cells were cultured with CD11b+ cells isolated from noninfected
mice (B) or alone (C) in presence of indicated concentrations of L-arginine. D, Activated T cells were cultured with 100 mM L-arginine in the presence or
absence of CD11b+ HI cells and inhibitors (L-NMMA and nor-NOHA). E, Concentration of nitrites (NO2Na) was measured in the supernatants of the
cultures from D with the Griess reagent. F, Concentration of extracellular L-arginine was measured in the supernatants of the cultures from D using an
HPLC chromatograph coupled to a mass detector. Data are representative of at least two independent experiments. Statistically significant differences with
respect to cultures with RPMI medium of each condition are shown: *p , 0.05, ***p , 0.001.
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Fig. 1). CD11b+Ly6G2 cells, but not Ly6G+ cells, expressed ar-
ginase I and iNOS by Western blot (Fig. 5B). We also detected
arginase I expression in CD11b+Ly6G2 cells isolated from the
blood of infected mice but not from noninfected mice (Fig. 5B),
in agreement with previous observations in PBMC lysates (19).
CD11b+Ly6G2 cells, but not Ly6G+ cells, from hearts of infected
mice suppressed anti-CD3/anti-CD28–stimulated T cell prolifer-
ation in comparison with T cells alone and T cells cultured with
CD11b+ NI (Fig. 5C). Suppression was partially reverted in the
presence of L-NMMA, indicating that it is mediated by NO. These
results strongly support that CD11b+Ly6G2 are MDSCs.
Ly6G+ granulocytic cells isolated from heart tissue of infected
mice express S100A8 and S100A9
MDSC recruitment into several tissues has been shown to be de-
pendent on S100A8 and S100A9 proteins (24). Coinciding with the
presence of monocytic MDSCs, our results showed that S100a8
and S100a9 gene and corresponding protein expression (Fig. 6A
and 6B, respectively) were detected in heart tissue in the acute
phase of T. cruzi infection in BALB/c mice, showing highest ex-
pression at 21 dpi coincident with previously described maximum
arginase I and iNOS expression (19). We also detected expression
of S100a8 and S100a9 gene and protein in C57BL/6 infected mice
(Supplemental Fig. 2), although lower than that in BALB/c mice,
correlating with the different kinetics of arginase I expression in
heart tissue of this strain of mice infected with T. cruzi (19). In
agreement with previous observations, the expression of another
important chemokine involved in monocyte heart recruitment in
T. cruzi infection, CCL2 (25), showed itself to be overexpressed
in CD11b+ HI cells with respect to control cells (Fig. 2D) follow-
ing similar kinetics as S100A8 and S100A9 in heart tissue of
both BALB/c and C57BL/6 mice (Supplemental Fig. 3).
We next investigated the cellular origin of S100A8 and S100A9
in the heart infiltrate of T. cruzi infected mice. We found that
S100A8 and S100A9 proteins were expressed in Ly6G+, which did
not express iNOS and arginase I, but not in CD11b+Ly6G2 cells,
which do express iNOS and arginase I (Figs. 4 and 6C). Therefore,
S100A8 and S100A9 proteins expressed by granulocytic cells
might be implicated in the recruitment and/or differentiation of
heart-infiltrated, arginase I/iNOS-expressing MDSCs in T. cruzi-
infected mice.
T. cruzi infection in mice causes plasma L-arginine depletion
Arginase I expression in MDSCs during T. cruzi infection can
decrease L-arginine availability. Thus, we studied whether circu-
lating L-arginine levels were affected in infected mice. In C57BL/
6 mice, there was a substantial decrease in plasma L-arginine
concentration (,50 mM) at 14 dpi, and in BALB/c mice the re-
duction was observed for longer periods (at 14 and 21 dpi) (Fig.
7A, 7B). These results correlated with our previous kinetics of
arginase I expression in the hearts of both C57BL/6 and BALB/c
mice (19) and indicated that during in vivo infection, arginase I-
expressing cells in heart tissue and/or in peripheral blood could
cause plasma L-arginine depletion that can account for suppres-
sion of T cell proliferation observed in the acute phase.
To evaluate the relevance of MDSCs in hearts of T. cruzi-
infected mice, we treated mice with the iNOS inhibitor L-NAME.
The inhibition of iNOS resulted in a dramatic increase in para-
sitemia, mortality, and parasite load in heart tissue with respect
to untreated mice (Supplemental Fig. 4). This result confirms the
in vivo relevance of iNOS and, by extension, NO-producing
MDSCs in T. cruzi infection. Of greater interest, L-arginine sup-
plementation reduced parasite burden in heart tissue (Fig. 7C),
indicating that restoration of L-arginine levels is beneficial for the
host.
Discussion
The understanding of the pathogenesis of myocarditis induced by
T. cruzi is crucial to develop therapeutic strategies aiming to ame-
liorate the inflammation that leads to heart dysfunction. In this
FIGURE 5. Expression of iNOS and arginase I in CD11b+ Ly6G2 HI
cells suppresses T cell proliferation. BALB/c mice were infected i.p. with
2 3 103 blood trypomastigotes of the Y strain. Mice were sacrificed at day
21 postinfection, and infected hearts and blood were elicited. Hearts were
mechanically and enzymatically digested and PBMCs purified from blood
of infected and noninfected mice. Cells were purified with Ly6G
microbeads, and the resulting Ly6G2 cells were subsequently purified with
CD11b microbeads. A, Average number and percentage of purified cells
per heart of T. cruzi-infected BALB/c mice. B, Protein content was
quantified by BCA method and analyzed; 20 mg loaded in 10% SDS-PAGE
gels and subjected to Western blot with Abs against arginase I and iNOS.
A representative Ponceau-stained band is shown as loading control. C,
Proliferative assay of anti-CD3– and anti-CD28–stimulated T cells in the
absence and presence of purified CD11b+ cells isolated from noninfected
mice (CD11b+ NI cells), Ly6G+ HI cells, and Ly6G2 HI cells. Data are
representative of at least two independent experiments. The statistically
significant difference with respect to cultures of T cells alone and in the
presence of CD11b+ cells from noninfected mice is shown: *p , 0.05.
Table II. Phenotype of magnetically sorted cells isolated from hearts of
mice at 21 dpi according to Giemsa staining
Cell Type Microscopic Examination % (20 Fields)
CD11b+Ly6G+ 70 granulocytic
30 nongranulocytic
CD11b+Ly6G2 98 monocytic
2 nonmonocytic
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regard, the mouse model of T. cruzi infection recapitulates many
of the functional and pathological alterations of the human dis-
ease. Thus, in the myocardium of acutely infected mice, there is
an inflammatory reaction characterized by lymphoid and myeloid
cell infiltration and expression of inflammatory mediators thought
to be responsible for the pathogenesis (19). To date, most of the
research has focused on the characterization of the infiltrating
T lymphocytes in the myocarditis associated with T. cruzi in-
fection whereas very little is known about myeloid cells present in
this heart inflammatory infiltrate. Our previous results showed that
myeloid cells infiltrating the heart, and to a minor extent PBMCs
from T. cruzi-infected mice, expressed arginase I (19). In this
study, we have purified those cells and analyzed their gene ex-
pression, phenotype, and function.
The myeloid CD11b+ population in the hearts of mice acutely
infected with T. cruzi expresses markers of M1 and M2 subsets
and is composed of two main subpopulations: immature mono-
cytic Ly6G2 and granulocytic Ly6G+. The monocytic Ly6G2
cells, but not the granulocytic Ly6G+ cells, express iNOS and
arginase I and are able to suppress T cell proliferation. The
granulocytic Ly6G+ cells, but not monocytic Ly6G2 cells, express
S110A8 and S100A9 proteins. According to marker expression
and especially suppressive function, our results indicate that
monocytic Ly6G2 cells are indeed MDSCs. Recruitment of
MDSCs to the heart could be potentiated by granulocytic Ly6G+
cells through S100A8 and S100A9 protein expression. T cell
suppression in vitro by those CD11b+Ly6G2 cells is mostly me-
diated by NO, and the in vivo high level of expression of arginase I
by MDSCs produces systemic depletion of L-arginine that may
contribute to systemic immunosuppression in the acute phase of
infection.
We found that isolated CD11b+ cells from the hearts of infected
mice expressed both arginase I and iNOS but not arginase II.
In addition, gene expression of several type 1 chemokines and
cytokines was found to be selectively upregulated by CD11b+ HI
cells. Notably, the regulatory cytokine Il10 was also highly in-
duced, as well as markers of M2 populations. We focused our
studies in the BALB/c model, which presented higher infiltration
of those cells; however, similar qualitative results were obtained in
the C57BL/6 model (data not shown). The expression of M1 and
M2 genes could be the result of heterogeneity of the CD11b+
isolated population. Nonetheless, it is accepted that coexpression
of M1/M2 genes is characteristic of MDSCs (26). Moreover, a
striking similar profiling of M1/M2 genes (Il10, Ccl2, and Ccl5,
IFN-inducible chemokines Cxcl9 and Cxcl10) has been described
in MDSCs infiltrating tumors (27, 28). Giemsa staining of the
isolated CD11b+Ly6G2 HI cells revealed a monocytic phenotype.
Therefore, the monocytic CD11b+Ly6G2 isolated subpopulation
expressing both iNOS and arginase I could be considered as bona
fide MDSCs accumulating in the hearts of T. cruzi-infected mice.
The Ly6G+ sorted population was more heterogeneous and
showed a predominant granulocytic phenotype that was devoid of
iNOS and arginase I expression. In a different model, the exis-
tence of a Ly6C+ granulocytic population has been described in
the injured myocardium, which is recruited via CCR2 and thought
to digest damaged tissue (29). In addition, CD11b+Gr-1+F4/80+
populations that presented mixed M2/MDSCs phenotype have
been described infiltrating the heart during Coxsackie virus B3
(CVB3) viral myocarditis (9). Neither iNOS expression nor sup-
pressor activity had been reported in the injured heart or in CVB3
myocarditis. It is worth mentioning that CD11b+ HI cells were
F4/802 but CD68+, being both mature macrophage markers. Our
FIGURE 7. Plasma L-arginine depletion in mice
infected with T. cruzi. BALB/c and C57BL/6 mice
were infected i.p. with 23 103 blood trypomastigotes
of the Y strain. Plasma was isolated at indicated
days postinfection and L-arginine concentration de-
termined. A, Values for C57BL/6 mice. B, Values for
BALB/c mice. C, T. cruzi parasite load determined
by quantitative PCR in mice with or without dietary
L-arginine supplement. Data are representative of at
least two independent experiments. Statistically sig-
nificant difference with respect to noninfected mice
(A, B) and untreated infected mice (C) is shown:
*p , 0.05, **p , 0.01, ***p , 0.001.
FIGURE 6. S100A8/S100A9 expression in hearts from T. cruzi-infected BALB/c mice and in hearts isolated cells after Ly6G and CD11b magnetic
sorting. Groups of 5–15 BALB/c mice were infected i.p. with 2 3 103 blood trypomastigotes of the Y strain. Mice were sacrificed at 0, 7, 14, and 21 dpi. A,
mRNA was extracted from hearts, and S100a8 and S100a9 expression was analyzed by quantitative RT-PCR. B, Protein extracts were isolated from heart
tissue from BALB/c mice at different days postinfection; 20 mg loaded in 15% SDS-PAGE gels and subjected to Western blot analysis with anti S100A8
and S100A9 Abs. A representative Ponceau-stained band is shown as loading control. Data are representative of at least two independent experiments. C,
Hearts were mechanically and enzymatically digested. Cells were purified with Ly6G microbeads, and the resulting Ly6G2 cells were subsequently purified
with CD11b microbeads. Protein content was quantified by BCA method; 20 mg loaded in 15% SDS-PAGE gels and subjected to Western blot with Abs
against S100A8 and S100A9. A representative Ponceau-stained band is shown as loading control. Data are representative of at least two independent
experiments.
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results indicate that T. cruzi infection induces the recruitment of
a particular phenotype of cells different from the ones described in
CVB3 myocarditis.
It is known that MDSCs express arginase I that can cause
suppression of T cell proliferation by extracellular L-arginine
depletion. We observed that during acute T. cruzi infection, there
is plasma L-arginine depletion at day 14 postinfection in less
susceptible C57BL/6 mice and at days 14 and 21 postinfection in
more susceptible BALB/c mice. These results suggest that fast
recovery from L-arginine plasma depletion in C57BL/6 mice is
linked to their low susceptibility to infection. In addition, L-argi-
nine plasma depletion nicely correlated with the kinetics of argi-
nase I expression in isolated blood and heart CD11b+ cells (19)
and with systemic immunosuppression (5). The mechanism of
T cell suppression in vitro in T. cruzi-infected mice by CD11b+
Ly6G2 cells is mediated by NO, and in vivo systemic depletion of
L-arginine, likely mediated by high level of expression of arginase
I by those cells, may contribute to systemic immunosuppression in
the acute phase of infection. Thus, according to markers, pheno-
type, and suppressive function, these cells are in fact bona fide
MDSCs.
CD11b+ BI cells did not express iNOS compared with CD11b+
HI cells. Thus, induction of arginase I and iNOS in CD11b+ cells
could occur after their recruitment from periphery to heart tissue,
similar to what happens in tumor infiltration by myeloid cells (10,
28). In this regard, we found that only the Ly6G+ cells isolated
from heart tissue of infected mice expressed S100A8 and S100A9
proteins. Those molecules have been described to regulate the ac-
cumulation of MDSCs (24). Thus, a plausible explanation is that
Ly6G+ infiltrated in heart tissue could be triggering recruitment of
Ly6G2 cells through expression of S100A8 and S100A9 proteins,
which also prevent further differentiation of MDSCs to macro-
phages and dendritic cells. Nonetheless, we cannot discard the
involvement of other chemokines as CCL2 in this recruitment. In
contrast, it could be possible that blood cells expressing arginase I
(but no iNOS) are M2 macrophages, a possibility that has not been
addressed in this study. Alternatively, MDSCs in heart may result
from expansion of resident tissue macrophages, but this is un-
likely, as they do not express the mature macrophage marker F4/
80. Also, the spleen has been described to function as a source of
monocytes that have further ability to infiltrate the heart (30),
therefore it could be that CD11b+ HI cells are originated and
mobilized from the spleen. In this regard, we have found that
spleens of T. cruzi-infected animals in the same days postinfection
contain a CD11b+Gr1+ population that inhibits T cell proliferation
via NO (5).
The goal of immune regulation is to avoid excessive production
of immune mediators that could be detrimental to the host and even
cause its death, as it seems to be in T. cruzi myocarditis (3). Thus,
CD11b+ HI MDSCs may regulate the excessive T cell-dependent
inflammation in the heart at the onset of infection, which could
much later determine the severity of cardiomyopathy. Among the
genes expressed by CD11b+ HI cells are the chemokines Ccl2,
Ccl5, Cxcl9, and Cxcl10 that were previously shown to be
expressed in the hearts of T. cruzi-infected mice during the acute
phase, and they play a protective role in T. cruzi infection but not
in association with the heart inflammatory phenotype (23, 25).
This indirectly would suggest a protective role of CD11b+ HI cells
in T. cruzi-induced myocarditis. On the contrary, in susceptible
mice, expression of iNOS and arginase I by MDSCs is higher and
more prolonged in time than in nonsusceptible C57BL/6 mice,
suggesting an association between MDSCs, iNOS/arginase I ex-
pression, and higher parasite burden followed by worst outcome of
the disease.
A formal demonstration of the exact role of MSDCs in T. cruzi
infection is difficult because there are no conclusive markers of
those cells to allow their selective elimination in infected animals.
To evaluate the relevance of MDSCs, we followed an alternative
approach: we inhibited iNOS with L-NAME treatment of infected
mice resulting in a dramatic increase in parasitemia, mortality,
and parasite load in heart tissue with respect to untreated mice,
showing that iNOS, and by extension NO-producing MDSCs, are
necessary to control the T. cruzi infection (31–34). In addition, L-
arginine supplementation reduced parasite burden in heart tissue,
indicating that restoration of L-arginine levels is beneficial for the
host. Because L-arginine is one of the rate-limiting factors in NO
production (35), it is possible that L-arginine supplementation
increases NO production in infected mice, which would end in
a more efficient control of the infection. Therefore, L-arginine
supplementation can have two different effects: 1) it could fuel
iNOS-derived NO production, thus reducing parasite replication
that is evidenced by a reduction in heart parasite load; 2) it can
revert immunosuppression, thus allowing a more efficient control
of infection by the immune system. Moreover, there is a strong
correlation between the appearance of those cells and severity of
the disease. More importantly, antagonizing or preventing the
effect of arginase I and iNOS, enzymes that best define their
function, modulates parasite load in heart tissue and mortality.
Our results support the hypothesis that iNOS- and arginase I-
expressing MDSCs are beneficial in T. cruzi infection when L-
arginine is available but detrimental for the host when they cause
persistent L-arginine depletion.
In summary, we describe in this study for the first time to our
knowledge that monocytic MDSCs that express iNOS and argi-
nase I are present in heart tissue in the acute phase of T. cruzi
infection, where they have the potential to suppress T lymphocytes
present in the infiltrate. This is the first description of MDSCs
found infiltrating the heart during T. cruzi infection and, to our
knowledge, in the context of cardiac inflammation. The presence
of MDSCs correlates with depletion of L-arginine from plasma
that can have a systemic suppressor effect on T cell function
extending to other inflamed organs and tissues. MDSC iNOS ac-
tivity may be required for efficient control of parasite load in the
heart that leads to survival of infected mice, but iNOS in combi-
nation with arginase I also could be detrimental for the host when
iNOS/arginase I expression is persistent through the acute phase
of infection causing plasma L-arginine depletion. Cardiac and
systemic effects of MDSCs are transient, and the outcome of
disease may depend as well on components of the innate, adaptive,
and regulatory immune responses.
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Abstract
Background: Leishmania major cutaneous leishmaniasis is an infectious zoonotic disease. It is produced by a digenetic
parasite, which resides in the phagolysosomal compartment of different mammalian macrophage populations. There is an
urgent need to develop new therapies (drugs) against this neglected disease that hits developing countries. The main goal
of this work is to establish an easier and cheaper tool of choice for real-time monitoring of the establishment and
progression of this pathology either in BALB/c mice or in vitro assays. To validate this new technique we vaccinated mice
with an attenuated Dhsp70-II strain of Leishmania to assess protection against this disease.
Methodology: We engineered a transgenic L. major strain expressing the mCherry red-fluorescent protein for real-time
monitoring of the parasitic load. This is achieved via measurement of fluorescence emission, allowing a weekly record of the
footpads over eight weeks after the inoculation of BALB/c mice.
Results: In vitro results show a linear correlation between the number of parasites and fluorescence emission over a range of
four logs. The minimum number of parasites (amastigote isolated from lesion) detected by their fluorescent phenotype was
10,000. The effect of antileishmanial drugs against mCherry+L. major infecting peritoneal macrophages were evaluated by
direct assay of fluorescence emission, with IC50 values of 0.12, 0.56 and 9.20 mM for amphotericin B, miltefosine and
paromomycin, respectively. An experimental vaccination trial based on the protection conferred by an attenuated Dhsp70-II
mutant of Leishmania was used to validate the suitability of this technique in vivo.
Conclusions: A Leishmania major strain expressing mCherry red-fluorescent protein enables the monitoring of parasitic load
via measurement of fluorescence emission. This approach allows a simpler, faster, non-invasive and cost-effective technique
to assess the clinical progression of the infection after drug or vaccine therapy.
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Introduction
Leishmania major is the main cause of cutaneous leishmaniasis
(CL) in the Old World. Parasites are transmitted by Phlebotominae
sandflies whilst blood feeding on infected mammalian hosts. CL is
widely spread in the developing world, affecting people in 88
countries with 1.5 million new cases reported each year. CL
usually produces ulcers on the exposed parts of the body that often
leave disfiguring scars, which in turn, can cause serious social
prejudice [1].
Conventional in vivo animal models for the study of parasite-host
relationships involve large number of animals. These animals are
required to be slaughtered at different time points in order to
identify both anatomical distribution and parasite numbers in
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Role of Trypanosoma cruzi
Autoreactive T Cells in the Generation
of Cardiac Pathology
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ABSTRACT: Chagas disease, caused byTrypanosoma cruzi, affects several
million people in Central and South America. About 30% of chronic pa-
tients develop cardiomyopathy probably caused by parasite persistence
and/or autoimmunity. While several cross-reactive antibodies generated
during mammal T. cruzi infection have been described, very few cross-
reactive T cells have been identified. We performed adoptive transfer ex-
periments of T cells isolated from chronically infected mice. The results
showed the generation of cardiac pathology in the absence of parasites.
We also transferred cross-reactive SAPA-specific T cells and observed
unspecific alterations in heart repolarization, cardiac inflammatory in-
filtration, and tissue damage.
KEYWORDS: T. cruzi; autoreactive T cells; autoimmunity;Chagas disease
INTRODUCTION
Chagas disease is a debilitating multisystemic disorder that affects sev-
eral million people (approximately 18 million individuals are infected with
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